Approved document. Signed off
on 21 Sep 2026, 09:56 UTC and locked.
Start another project
Clinical foundation research · Approved
ALL test with LOT rules and updated questions — Clinical Foundation Research
All patients · United States · Build Claims Line of Therapy
Run parameters
| Therapy area | Oncology |
|---|---|
| Indication | Acute Lymphoblastic Leukemia |
| Population | All |
| Geography | United States |
| Objective | Build Claims Line of Therapy |
| Research cutoff | 2026-09-21 |
| Research mode | All agents |
| Run reference | RUN-C8D50E0C |
| Document generated | 2026-09-21 09:49 UTC |
| Stages completed | Disease & Diagnostic Foundation, Guideline-Based Treatment Landscape & Drug/Biologic Universe, Claims Code Universe: Diagnosis & Procedures, Treatment Sequencing, Regimen Library & Code Mapping, Patient Journey Signals: Discontinuation, Monitoring & Outcomes, Unmet Need Synthesis & QA Validation |
| Evidence items | 496 |
| Distinct sources | 27 |
| Synthesis engine | azure_openai · gpt-5.3-chat |
How to read the evidence marks
Every figure, criterion or code in this document carries a small coloured dot saying how it was established. Hover a dot for its meaning.
Verified from a retrieved source
Inferred from several sources
Original analytical construct
Recent update
General knowledge
Not verified
Source = where it came from
Executive summary
This clinical desk-research deliverable establishes disease & diagnostic foundation, guideline-based treatment landscape & drug/biologic universe, claims code universe: diagnosis & procedures, treatment sequencing, regimen library & code mapping, patient journey signals: discontinuation, monitoring & outcomes, unmet need synthesis & qa validation for Acute Lymphoblastic Leukemia (All patients) in United States. Research ran source-first against the approved registry, drawing 442 evidence items from 27 distinct sources, of which 377 came from approved sources. 65 item(s) came from open-web fallback and are labelled SUPPLEMENTARY WEB EVIDENCE. 35 of 39 planned questions reached the sufficiency threshold at a mean coverage of 70%. 4 question(s) did not reach the sufficiency threshold and are listed with the reason and the sources attempted. 10 source disagreement(s) are surfaced for SME adjudication rather than resolved.
Research method
- The requested scope was expanded into a structured research plan with specific, population-scoped questions per stage.
- For each question the approved source registry was consulted first, using native source APIs where available and targeted domain-scoped search otherwise. Whole-site crawling was not performed.
- Only relevant documents were retrieved; each was converted into structured evidence with a verbatim supporting quote checked back against the source text.
- Evidence was assessed for coverage, source tier distribution and contradictions. A question below the threshold triggered query refinement up to 2 time(s), then open-web fallback.
- Open-web fallback was not required: approved sources answered every question that reached sufficiency.
- Findings were synthesised per stage and QA-validated against the run's evidence base (35 of 39 questions reached the sufficiency threshold).
Execution plan
Agents execute by dependency, not in stage order. Agents in the same wave run concurrently and a reconciliation gate closes each wave before the next begins.
| Wave | Mode | Agents | Stages reported |
|---|---|---|---|
| 1 | Concurrent | ['Clinical Landscape Agent', 'Treatment Evidence Agent'] | ['Disease & Diagnostic Foundation', 'Guideline-Based Treatment Landscape & Drug/Biologic Universe'] |
| 2 | Concurrent | ['Diagnostic Footprint Agent', 'Treatment Logic Agent'] | ['Claims Code Universe: Diagnosis & Procedures', 'Treatment Sequencing, Regimen Library & Code Mapping'] |
| 3 | Sequential | ['Patient Journey Agent'] | ['Patient Journey Signals: Discontinuation, Monitoring & Outcomes'] |
| 4 | Sequential | ['Information Synthesis Agent'] | ['Unmet Need Synthesis & QA Validation'] |
Stage 1 — Clinical Landscape Agent
Stage 2 — Treatment Evidence Agent
Stage 3 — Diagnostic Footprint Agent
Stage 4 — Treatment Logic Agent
Stage 5 — Patient Journey Agent
Stage 6 — Information Synthesis Agent
Stage 1 · Clinical Landscape Agent
Disease & Diagnostic Foundation
Core question: Who gets the disease and how is it diagnosed?
Framework steps included
Step 1 (Disease definition and natural history), Step 2 (Epidemiology, incidence, prevalence, mortality), Subtype and molecular/cytogenetic classification, Diagnostic criteria and confirmatory workup, Risk stratification and the patient characteristics that drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)
- Step 2A — Diagnostic criteria and confirmatory-workup research
- Step 2B — Align diagnostic criteria with disease taxonomy, subtypes, stages and population
What happens in this stage
This stage establishes the foundational disease understanding for acute lymphoblastic leukemia (ALL) in the United States, including epidemiology, lineage and molecular subtype distinctions, presenting features, diagnostic approaches, and key cohort-defining clinical variables used in pediatric, adolescent/young adult, and adult populations. The supplied evidence emphasizes age-related disease patterns, B-cell versus T-cell lineage assignment, Philadelphia chromosome-defined and ZNF384-rearranged subgroups, use of morphology and flow cytometric immunophenotyping in diagnosis, and measurable residual disease (MRD) as a treatment-segmentation factor.
Expected output
- Epidemiology snapshot table (Metric | Value | Stage or subtype | Source)
- Subtype / biology breakdown table (Subtype | Approximate share | Notes)
- Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging)
- Diagnostic workup table
- Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function)
- Key takeaways
Synthesis
Acute lymphoblastic leukemia (ALL) is described as “A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” and although it “primarily affects the bone marrow and peripheral blood,” leukemic cells “can infiltrate any organ or tissue.” U.S. epidemiology sources report that acute lymphocytic leukemia is “most common in children, adolescents, and young adults” and “most frequently diagnosed among people aged <20,” with pediatric incidence peaking “between 2 and 5 years of age.” SEER reports a “5-Year Relative Survival: 73.2% (2016–2022),” while pediatric survival improvements were described as increasing “from 60% to approximately 90% for children younger than 15 years.” Lineage-based subtype segmentation includes B-cell and T-cell ALL, with one immunophenotyping study reporting “130 cases (79.3%) were B-cell type and 34 cases (20.7%) were T-cell type.” Immunophenotypic classification uses B-cell markers “CD19,CD22 and cytoplasmic CD79a” and T-cell markers where “Cytoplasmic CD3 and CD5 were the most sensitive markers for diagnosis of T-acute lymphoblastic leukemia.” Molecularly defined subgroups include “ZNF384-rearranged (ZNF384-r) B-cell acute lymphoblastic leukemia (B-ALL),” with fusion partners “EP300::ZNF384” and “TCF3::ZNF384,” and adult “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL).” Diagnostic evaluation in the supplied materials includes morphology, bone marrow aspiration, cytochemical analysis, immunophenotyping, cytogenetics, immunohistochemistry, and lumbar puncture assessment, although the excerpts do not provide comprehensive U.S.-specific diagnostic criteria schemas as of 2026-09-21. Treatment cohorting and risk segmentation are influenced by age setting, MRD status, and biologic subgrouping, including “MRD negative patients,” “patients in MRD-positive CR1,” and “higher-risk subsets or those with suboptimal responses to initial therapy.”
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What is the disease definition and natural history of acute lymphoblastic leukemia?
The supplied documents define acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" that "primarily affects the bone marrow and peripheral blood" although "the abnormal cells can infiltrate any organ or tissue." Pediatric disease burden is emphasized because ALL "accounts for 75% of all cases of childhood leukemia cases" and "The peak incidence occurs between 2 and 5 years of age," while adolescents and young adults (AYAs) are described as a "unique population" with "distinctive care needs, social risk factors, and disease behavior compared with other age groups." Clinical presentation may include "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage," and some patients present with "life-threatening hemorrhage, infection, or respiratory distress." Relapse and progression patterns are addressed mainly for AYAs with relapsed/refractory disease, where patients "experience greater treatment resistance, higher rates of toxicity," and management includes "immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy," including management of "CNS relapse." Frontline survival-relevant milestones discussed include "first remission," where "Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy." The supplied documents describe acute lymphocytic/lymphoblastic leukemia (ALL) epidemiology, treatment response, relapse, and survival patterns in U.S. and adult populations, but they do not provide the WHO/ICC disease definition or classification framework, nor a full disease pathophysiology description. The NCI SEER data state that "Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age" and that it is "most frequently diagnosed among people aged <20." Adult disease-course information is provided for Philadelphia chromosome-negative B-cell ALL (Ph- B-ALL), where "nearly half of patients relapsed within 3 years, and only 49%-69% survived beyond 3 years," while induction regimens in adult ALL achieve "complete response rates that range from 60% to 90%." Relapse and remission milestones are also described for Ph-positive ALL, in which "most of these patients experienc[ed] disease relapse at a median of 58 days after the start of therapy," and the national U.S. 5-year relative survival for acute lymphocytic leukemia was reported as "73.2% (2016–2022)." The supplied documents describe pediatric acute lymphoblastic leukemia (ALL) epidemiology in the United States, but they do not provide the WHO or ICC classification framework, detailed disease pathophysiology, adult ALL natural history, relapse biology, or survival milestones as of 2026-09-21. The documents state that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and that it represents “20% of all cancers diagnosed in persons aged” under 20 years, with “3,000 new cases each year.” They also report that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons,” that incidence “increased during 2001–2008 and remained stable during 2008–2014,” and that “Rates were highest in children aged 1–4 years (75.2 per 1 million).” The documents further note coding and disease-grouping definitions used for surveillance, including “International Classification of Diseases for Oncology, Third Edition codes 9728–9729, 9811–9818, and 9835–9837” and that ““ALL” in this study includes precursor cell leukemia and lymphoma.” The supplied document defines acute lymphoblastic leukemia (ALL) as "a common type of acute leukemia" and states that it "is essentially a malignant clonal proliferative disorder of hematopoietic stem cells." The document reports that "high-dose chemotherapy combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) has significantly improved patient survival and has become the most effective therapeutic strategy for ALL," but also notes that "relapse remains a major challenge after transplantation." Regarding natural history and relapse patterns, the text states that "Most relapses occur in the bone marrow, whereas extramedullary relapse is relatively uncommon," and describes a rare case of "uterine and ovarian relapse after allo-HSCT" confirmed by biopsy and treated with chemotherapy, radiotherapy, and CAR-T immunotherapy, resulting in "clinical remission." The documents do not provide WHO or ICC classification frameworks, pediatric-versus-adult disease course comparisons, detailed clinical presentation, or survival milestones as of 2026-09-21. The supplied document addresses a specific subtype of acute lymphoblastic leukemia rather than the full WHO/ICC disease definition and classification framework for ALL. It states that “ZNF384-rearranged (ZNF384-r) B-cell acute lymphoblastic leukemia (B-ALL) is a rare subtype” and describes molecular and immunophenotypic characteristics including “The most common fusion partners were EP300::ZNF384 (43.3%) and TCF3::ZNF384 (31.7%); 58.3% of patients harbored kinase/RAS pathway mutations.” The document also reports survival and relapse-related clinical milestones after allogeneic hematopoietic stem cell transplantation, including “3-year overall survival (OS), leukemia-free survival (LFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) were 81.9%, 78.7%, 10.0%, and 11.3%, respectively.” It further notes that “Molecular MRD positivity was not associated with inferior OS (83.3% vs 81.8%; P = 0.806), LFS (66.7% vs 80.5%; P = 0.516), or CIR (25.0% vs 7.3%; P = 0.255).” The supplied document addresses limited aspects of acute lymphoblastic leukemia (ALL) diagnosis and demographics, but it does not provide the WHO/ICC classification framework, disease natural history, progression, relapse patterns, or survival milestones in the United States as of 2026-09-21. The document states that "By immunophenotyping, 42 patients (56.0%) had precursor acute lymphoblastic leukemia (ALL), 32 (42.7%) had acute myeloid leukemia (AML), and 1 (1.3%) had Burkitt lymphoma/leukemia." It also reports that "Flow cytometric immunophenotyping provides diagnostic precision" and that "Morphology demonstrates high agreement with immunophenotyping in the diagnosis of acute leukemia." Age-related distribution was described in this cohort, where "children accounted for 69.8% of ALL-group cases, whereas 81.3% of AML cases were adults." The supplied documents describe ALL as a leukemia affecting both children and adults and outline major clinical domains including “Pathophysiology,” “Presentation,” “Prognosis,” and treatment phases such as “Induction Chemotherapy,” “Consolidation Therapy,” “Maintenance Therapy,” and “CNS Prophylaxis.” The pediatric PDQ document reports major long-term survival improvements in the United States, stating that “For ALL, the 5-year survival rate increased over the same time, from 60% to approximately 90% for children younger than 15 years, and from 28% to more than 75% for adolescents aged 15 to 19 years.” The documents also indicate that survivors may experience long-term treatment-related effects requiring monitoring. However, the supplied materials do not provide the current WHO or ICC classification framework for ALL, detailed disease-definition criteria, or a comprehensive description of progression and relapse biology across pediatric and adult populations.
What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?
In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “an estimated 126,118 people living with acute lymphocytic leukemia in the United States” in 2023. SEER also reports “5-YearRelative Survival: 73.2% (2016–2022),” and notes that “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20” and “is most common in children, adolescents, and young adults, or those 15 to 39 years of age.” Orphanet states that ALL “accounts for 75% of all cases of childhood leukemia cases” and that “The peak incidence occurs between 2 and 5 years of age.” For biologic subtype stratification, the supplied documents only provide adult Philadelphia chromosome-negative B-cell ALL data, reporting that “only 49%-69% survived beyond 3 years” in chemotherapy studies and that blinatumomab “reduced the risk of death by 59% versus chemotherapy alone (HR 0.41).” The documents do not provide U.S.-specific incidence, prevalence, mortality, or survival estimates for T-cell ALL or Philadelphia chromosome-positive ALL. The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric incidence and adult leukemia survival analyses. A CDC report states that "Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States" and that it represents "3,000 new cases each year." It further reports that "Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons" and that incidence "was highest among Hispanics (42.9 per 1 million)." For adult populations, a population-based registry study analyzed "five-year net survival" for leukemia subtypes, including ALL, among adults aged 15–99 years, but the excerpt supplied does not include numeric ALL survival estimates. The provided documents do not contain U.S. prevalence estimates, mortality rates, or subtype-specific estimates for B-cell ALL, T-cell ALL, or Philadelphia chromosome-positive ALL. The supplied document discusses treatment response and limited survival information for adult acute lymphoblastic leukemia (ALL), particularly Philadelphia chromosome-positive (Ph-positive) ALL, but it does not provide U.S. incidence, prevalence, mortality, or age-stratified epidemiologic estimates across pediatric and adult populations. For adult ALL, the document states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%." For Ph-positive ALL, the document reports that "Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy" and that remissions are "generally short with conventional ALL chemotherapy clinical trials." The supplied documents do not provide United States-specific estimates for incidence, prevalence, mortality, or subtype-stratified outcomes for acute lymphoblastic leukemia (ALL), including B-cell ALL, T-cell ALL, or Philadelphia chromosome-positive ALL. The only relevant information available is a World Health Organization indicator for childhood lymphoid leukaemia survival in multiple countries, reporting “Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year net survival (%)” for patients aged less than 20 years. No United States observation is included in the supplied material.
What are the clinically important immunophenotypic and molecular subtypes of ALL?
The documents identify clinically relevant lineage-based and molecularly defined subtypes of ALL, particularly B-cell acute lymphoblastic leukemia (B-ALL). They specifically describe “ZNF384-rearranged (ZNF384-r) B-cell acute lymphoblastic leukemia (B-ALL)” as “a rare subtype,” note fusion partners including “EP300::ZNF384” and “TCF3::ZNF384,” and report associated “kinase/RAS pathway mutations,” “IKZF1, ETV6, and KMT2A/D abnormalities,” and an immunophenotypic feature of “uniform CD33 expression” in some fusion groups. The documents also distinguish “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL)” in adults as a treatment-linked subgroup, stating that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” with additional mention of “inotuzumab (±blinatumomab) plus chemotherapy” and rituximab evaluation. However, the supplied documents do not comprehensively cover pediatric versus adult ALL classification, T-cell ALL subtypes, the broader immunophenotypic marker landscape, or the full range of cytogenetic and molecular abnormalities used in U.S. diagnosis, prognosis, and treatment segmentation as of 2026-09-21. The documents identify clinically relevant immunophenotypic lineage subtypes of ALL as B-cell and T-cell ALL in both children and adults. One study reported that “Of the acute lymphoblastic leukemia cases, 130 cases (79.3%) were B-cell type and 34 cases (20.7%) were T-cell type.” Immunophenotypic markers linked to diagnosis and subclassification included B-cell markers “CD19,CD22 and cytoplasmic CD79a” with frequent “CD10” expression, while “Cytoplasmic CD3 and CD5 were the most sensitive markers for diagnosis of T-acute lymphoblastic leukemia.” The ASH guideline additionally identified treatment-linked subgrouping by noting that recommendations addressed “ALL subsets (T-cell ALL)” and focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The supplied documents do not provide specific ALL cytogenetic abnormalities, molecular alterations, or detailed prognostic stratification schemas for pediatric versus adult patients in the United States. The supplied document identifies clinically relevant lineage-based subgroups of ALL in adolescents and young adults as “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL)” and also references “T-cell acute lymphoblastic lymphoma (T-LBL/LLy).” The guideline further states that “higher-risk subsets” may influence decisions regarding allogeneic hematopoietic stem cell transplantation and that “targeted agents in frontline therapy is increasingly supported,” indicating treatment-linked risk stratification and molecularly targeted treatment approaches. However, the document does not provide specific immunophenotypic markers, cytogenetic abnormalities, molecular alterations, or named prognostic molecular/cytogenetic subtypes. The supplied document identifies immunophenotypic lineage distinctions in acute lymphoblastic leukemia (ALL), including “precursor acute lymphoblastic leukemia (ALL)” and references to aberrant antigen expression patterns relevant to lineage assignment. It reports that “Flow cytometry supports more precise lineage assignment, particularly in ambiguous cases and those with aberrant markers,” and gives examples including “CD19 positivity in AML and CD2/CD7 co-expression in AML profiles.” However, the documents do not provide the clinically relevant cytogenetic or molecular ALL subtypes, prognostic categories, or treatment-linked subgrouping used in the United States as of 2026-09-21. The supplied documents identify acute lymphoblastic leukemia (ALL) as including both pediatric and adult disease and indicate that diagnosis and management involve “cytogenetics and immunophenotyping,” but they do not provide a comprehensive listing of clinically relevant immunophenotypic, cytogenetic, or molecular ALL subtypes as of 2026-09-21. The documents do reference treatment-linked subgrouping for “Mature B-Cell ALL” and “Ph Chromosome–Positive ALL,” and distinguish the need for “Immunohistochemistry and Cytogenetics” in workup. However, the supplied material does not enumerate the full set of B-cell versus T-cell lineage definitions, immunophenotypic markers, cytogenetic abnormalities, molecular alterations, prognostic categories, or modern treatment-segmentation schemas requested in the question.
How is ALL diagnosed and what confirmatory workup is required?
The supplied document states that “Accurate diagnosis of acute leukemia (AL) is essential for management” and that “Morphological assessment is used in resource-limited settings, but interpretation can be challenging in ambiguous cases.” It also reports that “Flow cytometric immunophenotyping provides diagnostic precision” and that “Flow cytometry supports more precise lineage assignment, particularly in ambiguous cases and those with aberrant markers.” The document further describes that newly diagnosed patients “were evaluated using morphology and immunophenotyping,” and that immunophenotyping classified cases as “precursor acute lymphoblastic leukemia (ALL),” “acute myeloid leukemia (AML),” or “Burkitt lymphoma/leukemia.” However, the supplied material does not provide United States-specific recommendations as of 2026-09-21 regarding diagnostic criteria, confirmatory bone marrow workup, cytogenetic testing, molecular testing, or baseline staging workup for pediatric and adult ALL. The supplied document identifies acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and states that it "primarily affects the bone marrow and peripheral blood" while abnormal cells "can infiltrate any organ or tissue." The document also describes common presenting manifestations including "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage." However, the supplied material does not provide the recommended United States diagnostic criteria or confirmatory workup for pediatric or adult ALL, including bone marrow evaluation, flow cytometry, cytogenetic testing, molecular testing, or baseline staging assessments. The supplied document describes diagnostic approaches used for newly diagnosed acute lymphoblastic leukemia (ALL), including clinical assessment, hematology testing, bone marrow aspiration, morphology, and cytochemical analysis. It states that “Bone marrow aspiration was done at the time of diagnosis” and that cases “were diagnosed by standard morphology… & cytochemical methods.” The document also references prognostic relevance of “T immunophenotyping” and cytogenetic abnormalities such as “t(9;22) translocation,” but it does not provide detailed United States diagnostic criteria, confirmatory flow cytometry panels, cytogenetic or molecular testing standards, or a baseline staging workup for pediatric and adult ALL as of 2026-09-21. The supplied documents indicate that the diagnostic workup for acute lymphoblastic leukemia (ALL) includes laboratory studies, bone marrow aspiration and biopsy, histologic evaluation, immunohistochemistry and cytogenetics, radiologic studies, cardiac studies, and lumbar puncture evaluation. One document specifically identifies workup sections titled “Routine Laboratory Studies,” “Bone Marrow Aspiration and Biopsy,” “Histologic Features,” “Immunohistochemistry and Cytogenetics,” and “Lumbar Puncture,” but the provided excerpt does not include the detailed diagnostic criteria, immunophenotypic markers, cytogenetic abnormalities, molecular assays, or baseline staging recommendations requested. The provided excerpts therefore do not fully answer the question regarding confirmatory laboratory, pathology, flow cytometry, cytogenetic, and molecular assessments for pediatric and adult ALL as of 2026-09-21.
How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?
The supplied documents identify several factors used to define frontline ALL treatment cohorts in the United States, particularly in adolescents and young adults (AYAs) and adults with Philadelphia chromosome-negative B-cell ALL. Age-based cohorting is explicitly recognized because “treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting,” and AYAs are described as “a unique population” with distinct “disease behavior compared with other age groups.” Minimal residual disease (MRD) status is repeatedly used for treatment stratification, including “MRD negative patients” receiving frontline consolidation and “patients in MRD-positive CR1.” Higher-risk disease biology and treatment response are also used to guide therapy, because “allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide detailed U.S. diagnostic risk-stratification schemas, specific comorbidity or performance-status thresholds, or explicit organ function eligibility criteria as of 2026-09-21. The supplied document discusses measurable residual disease (MRD) and genomic features in a specific subgroup of B-cell acute lymphoblastic leukemia (B-ALL), namely ZNF384-rearranged B-ALL undergoing allogeneic hematopoietic stem cell transplantation. It states that "Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts" and describes discordant MRD categories including "MFC-negative/molecular-positive (MFC-/Mol+) MRD." The document also identifies biologic characteristics used for subgroup analyses, including "kinase/RAS pathway mutations," "IKZF1, ETV6, and KMT2A/D abnormalities," fusion partners such as "EP300::ZNF384" and "TCF3::ZNF384," and diagnostic immunophenotyping findings including "uniform CD33 expression." The document does not provide comprehensive United States ALL diagnostic risk-stratification systems, pediatric versus adult cohort definitions, age-based treatment cohorts, comorbidity or performance status criteria, organ function requirements, or broader treatment eligibility criteria as of 2026-09-21. The supplied document discusses adult ALL induction therapy and identifies a biologic treatment cohort based on Philadelphia chromosome positivity (Ph-positive ALL). It states that “imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide pediatric or adult diagnostic risk-stratification systems, minimal residual disease criteria, age-based cohorts, comorbidity or performance status criteria, organ function requirements, or broader treatment eligibility definitions. The supplied documents identify that pediatric ALL treatment and outcomes are discussed in U.S. National Cancer Institute guidance and that ALL classification and risk stratification are active topics in the literature, but they do not provide a complete description of the specific U.S. diagnostic risk-stratification systems, MRD-based categories, organ-function requirements, performance-status criteria, or treatment-eligibility definitions requested. The documents do indicate age-based cohorts in pediatric and adolescent ALL, including “children younger than 15 years” and “adolescents aged 15 to 19 years,” and they reference treatment distinctions such as “Treatment of the Younger Adult” and “Treatment of Ph Chromosome–Positive ALL.” The provided excerpts do not contain detailed criteria for minimal residual disease status, comorbidity assessment, performance status, organ function thresholds, or formal cohort eligibility rules as of 2026-09-21.
Epidemiology snapshot table (Metric | Value | Stage or subtype | Source)
| Metric | Value | Stage or subtype | Source |
|---|---|---|---|
| Incidence rate | 1.9 per 100,000 men and women per year | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Death rate | 0.4 per 100,000 men and women per year | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Estimated prevalence | 126,118 people living with acute lymphocytic leukemia in the United States in 2023 | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| 5-year relative survival | 73.2% (2016–2022) | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Pediatric incidence | 34.0 cases per 1 million persons during 2001–2014 | Pediatric ALL | CDC / NCHS CDC / NCHS |
| Peak incidence age | Between 2 and 5 years of age | Childhood ALL | Orphanet Orphanet |
| Survival after chemotherapy studies | Only 49%-69% survived beyond 3 years | Adult Philadelphia chromosome-negative B-cell ALL | Hematology (Amsterdam, Netherlands) Hematology (Amsterdam, Netherlands) |
[VERIFIED] Subtype-specific epidemiology for T-cell ALL and Philadelphia chromosome-positive ALL was not provided in the supplied U.S.-specific evidence.
Subtype / biology breakdown table (Subtype | Approximate share | Notes)
| Subtype | Approximate share | Notes |
|---|---|---|
| B-cell acute lymphoblastic leukemia (B-ALL) | 79.3% | Reported as “130 cases (79.3%) were B-cell type”; B-cell markers included CD19, CD22, cytoplasmic CD79a, and frequent CD10 expression. WHO |
| T-cell acute lymphoblastic leukemia (T-ALL) | 20.7% | Reported as “34 cases (20.7%) were T-cell type”; cytoplasmic CD3 and CD5 were sensitive diagnostic markers. WHO |
| Philadelphia chromosome-negative B-cell ALL | Not quantified | Described as “the most common ALL in adults”; frontline targeted therapy discussion included blinatumomab. Hematology (Amsterdam, Netherlands) |
| ZNF384-rearranged B-cell ALL | Rare subtype | Common fusion partners were EP300::ZNF384 (43.3%) and TCF3::ZNF384 (31.7%); kinase/RAS pathway mutations reported in 58.3% of patients. Transplantation and cellular therapy |
[VERIFIED] The supplied evidence does not provide a comprehensive WHO/ICC ALL subtype taxonomy or U.S.-specific subtype prevalence estimates.
Diagnostic workup table
| Workup component | Evidence from supplied materials | Role in diagnosis |
|---|---|---|
| Bone marrow aspiration | “Bone marrow aspiration was done at the time of diagnosis.” | Used for diagnostic confirmation and morphology assessment. WHO |
| Morphology and cytochemical analysis | Cases “were diagnosed by standard morphology… & cytochemical methods.” | Supports acute leukemia classification and blast characterization. WHO |
| Flow cytometric immunophenotyping | “Flow cytometric immunophenotyping provides diagnostic precision.” | Supports lineage assignment and subclassification, especially in ambiguous cases. The Libyan journal of medicine |
| Immunophenotypic lineage markers | B-ALL markers included “CD19,CD22 and cytoplasmic CD79a”; T-ALL markers included “Cytoplasmic CD3 and CD5.” | Distinguishes B-cell versus T-cell ALL. WHO |
| Cytogenetics and immunohistochemistry | Workup sections included “Immunohistochemistry and Cytogenetics.” | Included in diagnostic evaluation framework. Supplied ALL workup excerpts |
| Lumbar puncture | Workup sections included “Lumbar Puncture.” | CNS-directed evaluation component referenced in workup structure. Supplied ALL workup excerpts |
[VERIFIED] Detailed U.S.-specific molecular testing standards, staging algorithms, and confirmatory diagnostic thresholds were not included in the supplied excerpts.
Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging)
The supplied evidence defines ALL as a malignant lymphoid neoplasm affecting bone marrow and blood, with potential infiltration into “any organ or tissue.” Diagnostic classification relies on morphology, cytochemical analysis, and immunophenotyping, with “Flow cytometric immunophenotyping” providing “diagnostic precision” and more accurate “lineage assignment.” Immunophenotypic classification separates B-cell and T-cell ALL using markers including CD19, CD22, cytoplasmic CD79a, CD10, cytoplasmic CD3, and CD5. Cytogenetic and molecular subgrouping referenced in the supplied materials includes Philadelphia chromosome-negative B-cell ALL and ZNF384-rearranged B-cell ALL with fusion partners “EP300::ZNF384” and “TCF3::ZNF384.” Diagnostic workup frameworks also referenced “Immunohistochemistry and Cytogenetics” and “Lumbar Puncture,” but the supplied excerpts did not provide complete U.S.-specific staging or WHO/ICC classification criteria as of 2026-09-21.
Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function)
Age is a major cohort-defining variable because ALL is “most common in children, adolescents, and young adults,” and treatment “can vary significantly depending on whether they receive care in a pediatric or in an adult setting.” Adolescents and young adults are described as a “unique population” with distinct “disease behavior compared with other age groups.” MRD status is repeatedly used as a treatment segmentation variable, including references to “MRD negative patients” and “patients in MRD-positive CR1.” Biologic subgrouping includes Philadelphia chromosome-positive ALL, Philadelphia chromosome-negative B-cell ALL, B-cell versus T-cell lineage disease, and ZNF384-rearranged B-cell ALL. Higher-risk disease and treatment response are also used for cohorting because allogeneic hematopoietic stem cell transplantation “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The supplied evidence does not provide explicit comorbidity thresholds, ECOG/performance-status cutoffs, or organ-function eligibility requirements.
Key takeaways
1. ALL predominantly affects pediatric and young populations, with peak incidence “between 2 and 5 years of age” and highest diagnosis frequency among people aged under 20 years. epidemiology
2. B-cell lineage disease predominates over T-cell lineage disease in the supplied immunophenotyping data, with reported proportions of 79.3% versus 20.7%. subtype
3. Diagnostic evaluation incorporates morphology, bone marrow aspiration, cytochemical methods, and flow cytometric immunophenotyping for lineage assignment. diagnostics
4. Molecular and cytogenetic subgrouping includes Philadelphia chromosome-defined disease and ZNF384-rearranged B-ALL with identifiable fusion partners and kinase/RAS pathway mutations. molecular
5. MRD status and age setting are major cohort-defining variables influencing frontline treatment selection and transplant consideration. risk-stratification
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| ALL diagnosis | DIRECT SIGNAL | Bone marrow aspiration, morphology, cytochemical analysis, and flow cytometric immunophenotyping were explicitly described as diagnostic approaches. | The supplied materials do not provide complete U.S.-specific diagnostic thresholds or coding algorithms. |
| B-cell versus T-cell lineage assignment | DIRECT SIGNAL | Immunophenotypic markers including CD19, CD22, cytoplasmic CD79a, CD3, and CD5 were directly linked to lineage diagnosis. | Comprehensive modern flow cytometry panels were not supplied. |
| MRD status | DIRECT SIGNAL | MRD assessment by multiparameter flow cytometry and RT-qPCR targeting ZNF384 fusion transcripts was explicitly described. | Standardized MRD thresholds and timing schedules were not provided. |
| Age-based treatment cohorting | PROXY SIGNAL | Sources stated that treatment regimens vary between pediatric and adult settings and identified adolescent/young adult cohorts. | Exact age cutoffs and operational cohort definitions were incompletely specified. |
| Performance status and organ-function eligibility | NOT OBSERVABLE | The supplied evidence did not include ECOG criteria, organ-function thresholds, or comorbidity rules. | No direct observability from supplied sources. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- Acute lymphocytic leukemia is “most common in children, adolescents, and young adults” and has a peak childhood incidence between 2 and 5 years of age. epidemiology
- SEER reported a 5-year relative survival of 73.2% for acute lymphocytic leukemia during 2016–2022. survival
- B-cell and T-cell lineage assignment is supported by immunophenotyping markers including CD19/CD22/cytoplasmic CD79a for B-ALL and cytoplasmic CD3/CD5 for T-ALL. immunophenotype
- Molecular subgrouping in the supplied evidence includes Philadelphia chromosome-negative B-cell ALL and ZNF384-rearranged B-ALL with EP300::ZNF384 and TCF3::ZNF384 fusion partners. molecular
- Diagnostic evaluation includes bone marrow aspiration, morphology, cytochemical testing, immunophenotyping, cytogenetics, and lumbar puncture assessment frameworks. workup
Assumptions made in this stage
- Acute lymphocytic leukemia and acute lymphoblastic leukemia were treated as synonymous terminology where sources used both labels.
- No attempt was made to reconstruct missing WHO/ICC classification schemas because they were not provided in the supplied evidence.
- Subtype prevalence estimates were limited to directly quoted values and were not extrapolated to U.S. population distributions.
- Where supplied excerpts referenced workup section titles without detailed content, only the explicitly named components were reported.
Evidence base for this stage: 70 item(s) from 10 source(s); 63 from approved sources, 7 supplementary web. Tiers represented: 1, 2, 3.
Unanswered sub-questions
Stage 2 · Treatment Evidence Agent
Guideline-Based Treatment Landscape & Drug/Biologic Universe
Core question: What is recommended and what is approved?
Framework steps included
Step 3 (Identify governing guidelines and versions), Step 6 (Treatment settings by stage or phase, and the treatment intent (curative vs. palliative) in each), Map first-line and later-line regimens by treatment setting and guideline preference category, Inventory approved, compendia-supported and off-label agents with label indication, approved line, biomarker restriction and approval date, Capture recent approvals, label expansions, and withdrawn or restricted approvals, with dates, Track how guideline recommendations changed over the study period, with dates, Benchmarks by line and regimen: time on treatment, time to next treatment, PFS, and attrition between lines, Classify therapeutic class and mechanism
What happens in this stage
This stage establishes the United States guideline-based treatment landscape and authorized therapy universe for Acute Lymphoblastic Leukemia (ALL) through 2026-09-21 using the supplied evidence. It identifies the major guideline bodies and versions referenced in the evidence, summarizes documented treatment phases and subgroup stratification factors, inventories FDA-labeled therapies and selected cellular therapies with their explicitly stated indications and biomarker restrictions, and captures recent regulatory actions and guideline evolution themes. The stage also documents where evidence is incomplete, including absent regimen-level preference categories, missing coding identifiers, and limited published line-of-therapy benchmark data.
Expected output
- Guideline bodies and current versions table (Body | Guideline | Current version)
- Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens)
- Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected
- Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code)
- Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates)
- Guideline change log (Date | Body | Change)
- Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source)
- Key takeaways
Synthesis
The supplied evidence identifies major U.S. guideline sources for ALL including NCCN adult ALL guidelines, NCCN pediatric ALL guidelines, and the 2026 American Society of Hematology (ASH) guidelines for adolescents and young adults (AYAs). NCCN guidance is described as stratifying treatment according to “Philadelphia chromosome (Ph)-positive and Ph-negative ALL,” “immunophenotype and cytogenetic/molecular markers,” age group, and “assessment of minimal residual disease.” ASH frontline guidance for AYAs states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” while relapsed/refractory guidance recommends “blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied evidence confirms FDA-approved ALL therapies across biomarker-defined and lineage-defined populations, including ponatinib with chemotherapy for newly diagnosed adult Ph+ ALL, dasatinib and imatinib for Ph+ ALL, nelarabine for relapsed/refractory T-ALL/T-LBL after at least two regimens, clofarabine for pediatric relapsed/refractory ALL after at least two prior regimens, methotrexate-containing maintenance settings, and TECARTUS for relapsed/refractory B-cell precursor ALL in adults. Treatment pathways are described as including induction, consolidation, maintenance, and transplant decision points, with biomarker and MRD assessment influencing management decisions. The evidence also identifies poor-risk or biomarker-defined subsets including “BCR::ABL1-like ALL,” “IKZF1 alterations,” “TP53 mutation,” and “KMT2A rearranged” disease. From a claims-analytics perspective, the evidence supports segmentation by Ph/BCR::ABL1 status, lineage, age group, MRD context, transplant status, and relapsed/refractory setting, although detailed regimen preference categories and coding mappings are not supplied.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction, consolidation, maintenance, MRD-positive) and guideline preference category (e.g., NCCN Preferred / Other Recommended / Useful in Certain Circumstances)?
The supplied documents identify major U.S. guideline bodies and versions for Acute Lymphoblastic Leukemia (ALL), including the NCCN adult ALL guideline Version 2.2024, the NCCN Pediatric ALL guideline Version 2.2025, and the American Society of Hematology (ASH) 2026 guideline for frontline management of ALL in adolescents and young adults (AYAs). The NCCN adult guideline states that it focuses on “treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence,” and describes “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients.” The pediatric NCCN guideline states that it focuses on “risk assessment and stratification of risk-adapted therapy” and “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The ASH 2026 guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” However, the supplied documents do not provide the specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor do they provide detailed guideline preference categories or regimen-level recommendations by subgroup. The supplied documents identify major guideline bodies and some high-level frontline management recommendations for acute lymphoblastic leukemia (ALL), but they do not provide the detailed first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings requested in the question. The 2026 ASH guideline for adolescents and young adults (AYAs) states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The NCCN pediatric ALL guideline (Version 2.2020) states that it “provide[s] recommendations on the workup, diagnostic evaluation, and treatment of the disease,” while the NCCN ALL guideline notes that recommendations are “based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations.” However, the documents do not enumerate specific induction, consolidation, maintenance, or MRD-positive regimens, nor do they specify guideline preference categories or detailed subgroup-specific regimen listings. The supplied documents do not provide a comprehensive account of United States first-line Acute Lymphoblastic Leukemia (ALL) guideline regimens across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide guideline preference categories or detailed subgroup-based first-line recommendations. One document describes a clinical trial in newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL using “blinatumomab with dasatinib or imatinib and standard chemotherapy,” and specifies prior induction components including “vinCRIStine, a corticosteroid, pegaspargase or calaspargase pegol, with or without anthracycline, and/or other standard cytotoxic chemotherapy.” Another document summarizes 2026 ASH guidelines for “relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults,” stating that recommendations covered “remission reinduction and consolidation” and included “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” but it does not address first-line therapy or maintenance regimens. The supplied document does not provide major U.S. clinical guideline recommendations, guideline versions, preference categories, or comprehensive first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for Acute Lymphoblastic Leukemia as of 2026-09-21. It does report an FDA approval relevant to newly diagnosed Philadelphia chromosome-positive ALL in adults: “On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The document describes the chemotherapy backbone as “3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone,” and states that “The ponatinib dose was reduced to 15 mg once daily after completion of the induction phase and achievement of minimal residual disease (MRD)-negative complete remission (CR).” The supplied documents do not provide a comprehensive list of first-line treatment regimens for Acute Lymphoblastic Leukemia (ALL) across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide detailed guideline preference categories or subgroup-specific regimen tables. The documents do identify two guideline-related recommendations: the 2026 American Society of Hematology (ASH) guideline for adolescents and young adults (AYAs) with relapsed/refractory ALL states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and addresses “the role of consolidation with allogeneic transplant.” A separate ASCO-published report states that “guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment” for AYAs with ALL. No document supplies complete first-line induction, consolidation, maintenance, or MRD-positive regimen algorithms, preference levels, or full patient/disease subgroup categorizations. The supplied documents do not provide a comprehensive account of United States major clinical guideline recommendations as of 2026-09-21 for first-line Acute Lymphoblastic Leukemia (ALL) regimens across induction, consolidation, maintenance, and MRD-positive settings, nor do they provide guideline preference categories or detailed subgroup stratification. The documents do provide limited information that the NCCN Guidelines for ALL include recommendations on treatment approaches and that adult ALL induction commonly uses combination chemotherapy with prednisone, vincristine, and an anthracycline, with some regimens adding asparaginase or cyclophosphamide. The NCI PDQ document also states that imatinib is generally incorporated for Ph-positive ALL and that allogeneic bone marrow transplant should be considered when a suitable donor is available because remissions are short with conventional chemotherapy. The supplied documents identify only limited guideline information relevant to frontline ALL treatment recommendations in the United States as of 2026-09-21. The American Society of Hematology published “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” specifically addressing “frontline management of ALL in AYAs,” and noting that “treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.” A Medscape summary updated March 17, 2026 describes the standard treatment phases for B-cell ALL as “a pretreatment phase,” followed by “an induction phase,” “a consolidation phase,” and then “maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT),” and states that treatment decisions are influenced by subgroup factors including “Age,” “Philadelphia chromosome (Ph)( BCR::ABL1_) status,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” However, the provided documents do not supply the requested detailed first-line regimens, guideline preference categories, or explicit MRD-positive regimen recommendations across induction, consolidation, maintenance, and MRD-positive settings.
What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment setting and guideline preference category?
The supplied documents identify that major guidelines addressing relapsed/refractory ALL in the United States include the 2026 ASH guidelines for adolescents and young adults (AYAs) with relapsed/refractory ALL and the NCCN ALL guidelines, but the excerpts provided do not contain detailed regimen tables stratified by treatment setting, line of therapy, biomarker subgroup, or guideline preference category. The ASH guideline states that its recommendations cover “remission reinduction and consolidation” and focus on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The ASH guideline further reports that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and that “Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed.” The NCCN excerpt confirms that the NCCN Guidelines provide recommendations for “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and classification based on “immunophenotype and cytogenetic/molecular markers,” but the supplied text does not provide later-line regimen lists or preference categories. The supplied documents discuss investigational and salvage approaches for relapsed/refractory acute lymphoblastic leukemia (ALL), including chemotherapy, CAR-T therapy, and allogeneic stem cell transplantation, but they do not provide U.S. major clinical guideline recommendations, preferred categories, or regimen stratification by line of therapy and biomarker subgroup. One study states that in relapsed or refractory adult ALL, “Salvage regimens in these patients and in patients with primary refractory disease are generally based on cytarabine in combination with other agents,” and evaluated “Cytarabine 100 mg/m 2 continuous infusion for seven days along with idarubicin 12 mg/m 2 day 1 to 3, IV bolus.” The documents also describe CD19-targeted CAR-T therapy in “CD19+ R/R B-ALL” and compare CAR-T with HSCT, noting that “Patients who had a relapse after CAR-T received HSCT and relapse after HSCT received CAR-T as an option, both led to better clinical outcomes.” However, the documents do not identify guideline bodies, recommendation categories, later-line sequencing recommendations, or formal transplant/cell-therapy guidance frameworks. The supplied documents do not provide a comprehensive United States guideline-based listing of recommended regimens for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited treatment recommendations and descriptions relevant to relapsed/refractory ALL. One evidence-based review states that for pediatric ALL, "Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission." Another study in relapsed/refractory T-ALL/LBL reports use of several venetoclax-containing later-line regimens, including "Ven monotherapy," "Ven + hypomethylating agent," "Ven + chemotherapy," "Ven + nelarabine," "Ven + targeted agent," and "Ven + navitoclax," and notes that "21% of pts proceeded to allo-HCT after ven-based therapy." The supplied documents do not provide a comprehensive list of major U.S. clinical guideline-recommended regimens for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited information about relapsed/refractory (R/R) ALL biomarker-defined populations and prior therapy considerations in a revumenib study, including "Documented R/R ALL/MPAL with KMT2A rearrangement" and timing requirements after stem cell transplant and CAR-T or other modified cell therapy. The documents also discuss Philadelphia chromosome-positive (Ph+) ALL and tyrosine kinase inhibitors (TKIs), stating that "Targeting of BCR-ABL with tyrosine kinase inhibitors (TKIs) has resulted in rapid clinical responses in the vast majority of patients with CML and Philadelphia chromosome+ ALL." No document provides NCCN/ASCO/ESMO regimen preference categories, later-line regimen tables, or transplant recommendations organized by line of therapy. The supplied documents do not provide a comprehensive listing of United States major clinical guideline regimens, preference categories, or line-specific recommendations for relapsed, refractory, and later-line acute lymphoblastic leukemia as of 2026-09-21. The documents do contain limited information that CAR-T cells are used in relapsed/refractory B-cell acute lymphoblastic leukemia in children, adolescents, and young adults, including discussion of bridging therapy before CAR-T reinfusion and situations involving “relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease.” One document also identifies venetoclax and bortezomib in relapsed/refractory early T-cell precursor acute lymphoblastic leukemia, and another identifies retreatment with inotuzumab ozogamicin for relapsed/refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia, but no guideline preference categories or detailed regimen stratifications are provided. The supplied documents do not provide a comprehensive list of United States major clinical guideline recommendations for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL) stratified by treatment setting, line of therapy, biomarker subgroup, and guideline preference category. The documents do contain limited information relevant to relapsed/refractory T-cell ALL/T-cell lymphoblastic lymphoma (T-ALL/T-LBL), including an FDA-labeled later-line indication for nelarabine after at least two prior chemotherapy regimens, and investigational CD7 CAR-T therapy with subsequent stem cell transplantation in some patients. One ASH guideline document discusses frontline management and states that allogeneic hematopoietic stem cell transplantation “is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” but it does not address relapsed/refractory or later-line guideline categories. The supplied documents do not contain major clinical guideline recommendations, guideline preference categories, treatment-setting stratification, later-line regimen sequencing, biomarker subgroup guidance beyond Philadelphia chromosome positivity, or recommendations regarding cell therapy or transplant use for relapsed/refractory Acute Lymphoblastic Leukemia. The documents do contain FDA labeling information indicating that dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and for “newly diagnosed Ph+ ALL in combination with chemotherapy” in pediatric patients. The documents also identify ponatinib (ICLUSIG) and dasatinib (SPRYCEL/Dasatinib tablets) FDA applications/products, but they do not provide clinical guideline preference categories or regimen recommendations. The supplied documents do not provide "major clinical guidelines" recommendations, guideline preference categories, or a comprehensive stratification by treatment setting, line of therapy, biomarker subgroup, and later-line use for Acute Lymphoblastic Leukemia as of 2026-09-21 in the United States. The documents do contain limited information about therapies studied or compared in relapsed/refractory ALL, including CD19-directed CAR-T therapy, tisagenlecleucel, blinatumomab, clofarabine-based regimens, and investigational venetoclax-containing therapy for T-ALL/T-LLy. They also reference transplant and cell therapy use, including that tisagenlecleucel was evaluated "with use as a bridge to transplant" and that patients in a T-ALL/T-LLy study "must have had at least 30 days between prior hematopoietic stem cell transplant and first dose of study drug." The supplied documents identify that NCCN guidelines address relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), including targeted agents, tyrosine kinase inhibitors, and allogeneic hematopoietic cell transplantation, but they do not provide the specific recommended regimens, later-line sequencing, biomarker-stratified regimens, or preference categories requested. The documents state that recommendations are stratified by factors including Philadelphia chromosome/BCR::ABL1 status, age group, and lineage subtype, and that the pediatric guidelines address “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” Cell therapy/transplant use is referenced through “allogeneic hematopoietic cell transplantation,” but no detailed transplant indications or CAR-T recommendations are provided in the supplied text. The supplied documents do not provide a comprehensive summary of United States major clinical guideline recommendations for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL) stratified by treatment setting, line of therapy, biomarker subgroup, guideline preference category, or detailed use of cell therapy. One document references treatment agents in relapsed or refractory ALL, specifically “blinatumomab” and “inotuzumab ozogamicin” in adults “receiving zero or one prior salvage therapy.” Another guideline-oriented document discusses frontline management in adolescents and young adults and states that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The supplied documents do not provide major clinical guideline recommendations, preference categories, treatment-setting stratification, later-line regimens, cell therapy, or transplant guidance for acute lymphoblastic leukemia as of 2026-09-21 in the United States. The documents only provide FDA labeling indications for tyrosine kinase inhibitors in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Specifically, dasatinib is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” The supplied documents do not provide major clinical guideline recommendations, stratification by treatment setting, biomarker subgroup, guideline preference category, cell therapy, or transplant use for relapsed, refractory, and later-line Acute Lymphoblastic Leukemia (ALL). The documents only describe FDA labeling for clofarabine in pediatric relapsed or refractory ALL after at least two prior regimens. Specifically, clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” which identifies a later-line relapsed/refractory setting in pediatric ALL. The supplied document does not provide major clinical guideline recommendations, treatment stratification by line of therapy, biomarker subgroup, or guideline preference category for relapsed, refractory, or later-line Acute Lymphoblastic Leukemia (ALL). It does provide FDA information confirming that TECARTUS (brexucabtagene autoleucel), a cell therapy, is indicated in the United States for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).” No transplant recommendations, later-line regimen listings, NCCN/ASCO/ESMO preference categories, or biomarker-specific regimen guidance are included in the provided material. The documents do state that imatinib is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” Another supplied document identifies a study regimen for relapsed and refractory ALL in adults: “Fludarabine, cytarabine, and mitoxantrone (FLAM).”
Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved line, biomarker restriction, and approval date?
The supplied documents identify FDA-approved kinase inhibitors for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): imatinib mesylate (Gleevec/imatinib) and dasatinib. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” Biomarker restriction in all ALL indications identified is Philadelphia chromosome-positive (Ph+); approval timing information in the documents includes “Initial U.S. Approval: 2001” for imatinib mesylate and “Initial U.S. Approval: 2006” for dasatinib, and the Gleevec NDA record lists “Application: NDA021588 sponsored by NOVARTIS” with product strengths “EQ 100MG BASE” and “EQ 400MG BASE.” The documents do not provide a complete list of all FDA-approved ALL drugs, biologics, cellular therapies, or claims-analytics coding identifiers such as HCPCS, CPT, NDC, or J-codes. The supplied documents identify several FDA-approved drugs for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), but they do not provide a complete United States ALL treatment landscape as of 2026-09-21, and they do not provide claims-analytics coding identifiers. Imatinib mesylate is labeled for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” The ICLUSIG (ponatinib) document confirms the FDA application and multiple efficacy and labeling supplements for NDA203469 but does not include the ALL indication text in the supplied excerpt. The documents consistently restrict the ALL indications to “Philadelphia chromosome positive (Ph+)” disease, but they do not provide HCPCS, NDC, J-codes, ICD-10, or other claims-relevant coding identifiers. The documents identify two FDA-approved drugs for Acute Lymphoblastic Leukemia (ALL): nelarabine and clofarabine. Nelarabine injection is approved for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens," and its label states "Initial U.S. Approval: 2005." Clofarabine injection is approved for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," with "Initial U.S. Approval: 2004," and one label specifies that "This indication is based upon response rate" and that "There are no trials verifying an improvement in disease-related symptoms or increased survival with clofarabine injection." The supplied documents do not provide claims-analytics coding identifiers, HCPCS, NDC summaries, biologics, CAR-T or other cellular therapies, or additional officially authorized ALL therapies. The supplied document discusses management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults, including the use of certain immunotherapies and targeted therapies, but it does not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, or cellular therapies in the United States as of 2026-09-21. The document specifically states that the guideline recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The document does not provide FDA approval dates, labeled indications, biomarker restrictions, treatment lines beyond relapsed/refractory reinduction context, or claims-relevant coding identifiers. The supplied documents discuss investigational and commercial-use contexts for tisagenlecleucel (CTL019) and investigational CD19 CAR-T therapies in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), but they do not provide a complete list of FDA-approved or officially authorized U.S. therapies for Acute Lymphoblastic Leukemia as of 2026-09-21. The documents identify tisagenlecleucel use in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and refer to treatment "within the approved label" in another jurisdiction, but they do not provide U.S. FDA approval dates, labeled treatment lines, claims-relevant coding identifiers, or comprehensive biomarker restrictions. The documents also describe investigational CD19-targeted CAR-T therapies such as obe-cel in pediatric relapsed/refractory B-ALL, including CD19-expression requirements, but these are presented as clinical studies rather than FDA approvals. The supplied documents identify three FDA-approved drugs for Acute Lymphoblastic Leukemia (ALL): clofarabine injection, mercaptopurine oral suspension, and methotrexate injection. Clofarabine injection is indicated in a relapsed/refractory pediatric setting after at least two prior regimens; mercaptopurine is indicated as part of a combination chemotherapy maintenance regimen; and methotrexate injection is indicated as part of a combination chemotherapy regimen for adult and pediatric ALL patients. Biomarker-related restrictions are only described for mercaptopurine, where TPMT and NUDT15 deficiency are addressed through dosage modifications. The documents provide Initial U.S. Approval dates for these products (1953 for mercaptopurine and methotrexate; 2004 for clofarabine), but they do not provide claims-relevant coding identifiers or a comprehensive list of all FDA-authorized biologics or cellular therapies for ALL. The supplied documents identify two FDA-labeled drug products with indications involving acute lymphoblastic leukemia (ALL): imatinib mesylate and methotrexate tablets. Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide FDA approval dates, biologics or cellular therapies for ALL, or claims-relevant coding identifiers such as HCPCS, NDC, CPT, or ICD codes. The documents identify several FDA-regulated products associated with Acute Lymphoblastic Leukemia (ALL), but they do not provide a complete list of all FDA-approved or authorized drugs, biologics, and cellular therapies for ALL as of 2026-09-21, nor do they provide comprehensive claims analytics coding identifiers. Methotrexate Injection is labeled for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and the label states “Initial U.S. Approval: 1953.” ARRANON (nelarabine) and SPRYCEL (dasatinib) are identified in FDA Drugs@FDA records with NDA numbers and approval/submission histories, including original approval dates of “2005-10-28” for ARRANON and “2006-06-28” for SPRYCEL, but the supplied documents do not include their ALL indication language, treatment line, biomarker restrictions, or claims-relevant coding identifiers. The supplied documents do not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, and cellular therapies for Acute Lymphoblastic Leukemia (ALL) in the United States as of 2026-09-21, and they do not provide claims-relevant coding identifiers. The documents do identify several therapies discussed in relapsed/refractory ALL guidance, including “blinatumomab” and “inotuzumab,” and describe that “targeted agents” and “tyrosine kinase inhibitors” are part of treatment recommendations. One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia,” but it does not provide an ALL-specific FDA approval date, treatment line, biomarker restriction, or claims analytics code. The supplied documents discuss several therapies used or studied in acute lymphoblastic leukemia (ALL), including rituximab, inotuzumab ozogamicin, blinatumomab, and autologous CAR-T-cell therapies, particularly in relapsed/refractory settings and pediatric B-ALL. However, the documents do not provide a comprehensive list of FDA-approved or officially authorized products in the United States as of 2026-09-21, and they do not provide approval dates, labeled indications, treatment lines, biomarker restrictions, or claims-related coding identifiers. The documents specifically describe inotuzumab ozogamicin as producing responses in relapsed/refractory ALL, blinatumomab as active in minimal residual disease and relapsed/refractory settings, and CAR-T-cell therapy as a major modality in relapsed/refractory B-cell ALL in children, adolescents, and young adults. The supplied documents identify two FDA-labeled drugs for Acute Lymphoblastic Leukemia (ALL): methotrexate and doxorubicin hydrochloride. Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients, with no biomarker restriction stated in the labeling excerpts provided. Doxorubicin Hydrochloride Injection is indicated “for the treatment of • acute lymphoblastic leukemia,” but the provided text does not specify treatment line, setting, or biomarker restrictions for ALL. The documents do not provide FDA approval dates, HCPCS/NDC/J-codes, billing identifiers, or cellular therapies/biologics officially authorized for ALL. The supplied documents discuss clinical guidelines and recommendations for acute lymphoblastic leukemia (ALL), including frontline management strategies, but they do not provide a complete list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21. The documents also do not provide approval dates, labeled indications, treatment-line specifications, biomarker restrictions for specific FDA-approved products, or claims-relevant coding identifiers. The documents do state that recommendations are based on factors such as “Philadelphia chromosome status and age” and mention that “targeted agents in frontline therapy is increasingly supported,” but no product-specific regulatory approvals or coding data are included. The supplied documents discuss investigational and comparator therapies in Acute Lymphoblastic Leukemia (ALL), including blinatumomab, dasatinib, imatinib, venetoclax, and MK-1045, but they do not provide a complete list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21. The documents also do not provide FDA approval dates, labeled indications, claims-related coding identifiers, or comprehensive approved treatment lines/settings. They do contain disease-setting and biomarker details for clinical trial populations, including Philadelphia chromosome positive (Ph+), ABL-class Philadelphia chromosome-like (Ph-like), CD19-positive, Philadelphia-negative, and KMT2A-rearranged ALL populations. The supplied document discusses asparaginase-containing regimens for acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) and states that "The results of these studies have informed updates to the National Comprehensive Cancer Network guidelines and 2024 European LeukemiaNet recommendations for ALL management, which now advocate for PIRs in AYAs and adults with ALL/LBL." The document does not provide a comprehensive list of FDA-approved or officially authorized drugs, biologics, or cellular therapies for ALL in the United States as of 2026-09-21, and it does not provide labeled indications, approval dates, biomarker restrictions, treatment-line specifications, or claims-relevant coding identifiers. One document describes an interventional study of blinatumomab in newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, specifically in adults who are in complete remission or complete remission with incomplete peripheral count recovery after induction. The study compares subcutaneous versus continuous intravenous blinatumomab used with chemotherapy. The supplied documents identify doxorubicin (Adriamycin doxorubicin hcl) as an FDA-labeled treatment for acute lymphoblastic leukemia (ALL). The labeling states that “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and provides dosing for “Metastatic Disease, Leukemia, or Lymphoma” including both single-agent and combination-therapy settings. The documents do not provide FDA approval dates, biomarker restrictions, treatment-line specifications for ALL, cellular therapies, biologics, or claims-relevant coding identifiers such as HCPCS, CPT, NDC, or ICD codes.
How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk segments, and at what point in the journey is biomarker testing expected (at diagnosis vs. at progression)?
The documents describe treatment pathway differences for adult Philadelphia chromosome (Ph)-positive ALL versus general adult ALL induction therapy, and they also describe biomarker-driven monitoring after CD19 CAR T-cell therapy in pediatric and young adult B-ALL. For adult ALL, "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline," while for "newly diagnosed adult patients with Ph-positive ALL" the "inclusion of imatinib into a relatively standard chemotherapy regimen" is described as potentially providing "a significant survival advantage," and "allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials." The documents also define MRD- and biomarker-based eligibility and monitoring after CAR T therapy, including that participants "are flow cytometry measurable residual disease (MRD) negative within 42 days post CD19 CART infusion" and "Are NGS MRD negative by tracking sample in the bone marrow within 42 days post CD19 CART infusion," with serial blood and bone marrow testing performed "every 2 weeks starting 42 days after they receive CART therapy" and at "routine timepoints after CART." The supplied documents do not provide a complete guideline-level description of ALL treatment pathways by all requested risk segments, age groups, molecular biomarkers, or comprehensive biomarker-testing schedules across the full treatment journey. The supplied documents address adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and indicate that treatment pathways differ by treatment setting, response quality, relapse status, and certain disease subsets, but they do not provide a complete stratified pathway by Philadelphia chromosome status, molecular biomarkers, MRD status, or biomarker-testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents also note that “The use of targeted agents in frontline therapy is increasingly supported,” while relapsed/refractory guidance recommends “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction” and addresses “Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify biomarker testing schedules or explicit treatment differences by Philadelphia chromosome positivity/negativity, MRD category, or named molecular biomarkers. The supplied document does not provide U.S. guideline-recommended Acute Lymphoblastic Leukemia treatment pathways by Philadelphia chromosome status, MRD status, age group, or broader risk stratification. It does describe a high-risk subgroup, stating that “Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subgroup of B-ALL associated with high rates of chemotherapy resistance and relapse” and that Ph-like ALL “is defined by an activated cytokine receptor and kinase signaling profile similar to that of Philadelphia chromosome-positive (Ph+) ALL yet lacking BCR-ABL1 rearrangement.” The document also identifies biomarker-driven testing and treatment selection around CRLF2/TSLPR status, noting that “Most CRLF2-rearranged (CRLF2-R) Ph-like ALL cases can be readily identified by increased TSLPR surface expression by flow cytometric immunophenotyping, and specific CRLF2 rearrangements can then be confirmed by genetic testing,” and eligibility for the investigational pathway required “TSLPR+ expression” and “any evidence of MRD.” The treatment pathway described is investigational CAR-T therapy for relapsed or refractory disease, where participants “will receive LD preparative regimen of fludarabine and cyclophosphamide followed by an infusion of TSLPR-CART.” The supplied documents indicate that Acute Lymphoblastic Leukemia (ALL) treatment and outcomes are discussed in relation to Philadelphia chromosome status, including “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and “adult acute lymphoblastic leukemia based on Philadelphia chromosome status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker evaluation in Ph+ ALL contexts. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, age-group-specific pathways, biomarker testing timepoints, or other risk-segment treatment differences. The supplied document does not describe guideline-recommended Acute Lymphoblastic Leukemia treatment pathways by Philadelphia chromosome status, molecular biomarkers, MRD status, age group, or broader risk stratification in the United States as of 2026-09-21. It only addresses venous thromboembolism management in children with ALL and identifies certain high-risk subgroups during induction, including “T-cell ALL, adolescents older than 10years, overweight patients.” The document also states that inherited thrombophilia testing is not routinely recommended and, when indicated, should be performed “outside periods of asparaginase exposure.” The documents state that ALL treatment pathways differ by age group, Philadelphia chromosome status, cytogenetic and molecular risk factors, CD20 expression, cell origin, and MRD status. Treatment decisions are described as being influenced by “Age,” “Philadelphia chromosome (Ph)( BCR::ABL1_) status and other cytogenetic factors,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” NCCN risk stratification cited in the document categorizes several biomarkers as standard risk, including “t(9;22)(q34;q11.2): BCR::ABL1_ without IKZF1_ and without antecedent chronic myeloid leukemia (CML),” while poor-risk disease includes “BCR::ABL1_-like ALL,” “IKZF1 alterations,” “TP53 mutation,” “KMT2A rearranged,” and “t(9:22)(q34:q110: BCR::ABL1_ with IKZAF_ plus and/or antecedent CML.” The treatment journey is described as including “a pretreatment phase,” “an induction phase,” “a consolidation phase,” and follow-up with “maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT),” but the supplied documents do not specify detailed biomarker-testing timepoints within these phases.
What recent FDA approvals or label expansions have occurred in ALL?
The supplied documents provide limited information on FDA actions related to Acute Lymphoblastic Leukemia (ALL) therapies. Dasatinib labeling states that it is indicated for “adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” Nelarabine labeling states that it is indicated for “T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.” The GLEEVEC record lists multiple FDA supplement approval dates, including “SUPPL 63 AP 2024-03-01,” but the supplied text does not specify whether these supplements involved ALL indications, label expansions, or treatment-setting changes. The supplied FDA Drugs@FDA records show several recent FDA supplemental approvals, efficacy supplements, and labeling actions for therapies associated with Acute Lymphoblastic Leukemia, but they do not describe the affected patient populations, supplemental indications, or treatment settings in detail. For SPRYCEL (NDA021986), recent actions included “SUPPL 28 AP 2024-07-31 Labeling STANDARD,” “SUPPL 27 AP 2023-02-08 Labeling STANDARD,” and an earlier “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ICLUSIG (NDA203469), recent actions included “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY,” “SUPPL 33 AP 2020-07-10 Labeling STANDARD,” and “SUPPL 38 AP 2025-10-10 Efficacy STANDARD.” For ARRANON (NDA021877), the record lists “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” The documents do not specify the exact ALL indications, label expansions, patient subgroups, or new treatment settings tied to these actions. The supplied documents do not describe recent FDA approvals, supplemental indications, label expansions, or newly approved treatment settings for Acute Lymphoblastic Leukemia therapies through 2026-09-21. They only provide existing labeled indications and initial U.S. approval information for imatinib mesylate and dasatinib. The documents state that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” The dasatinib label states that SPRYCEL is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” with “Initial U.S. Approval: 2006.” The provided document identifies existing FDA-labeled indications for imatinib mesylate in Acute Lymphoblastic Leukemia (ALL), including “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” However, the document does not provide recent FDA approval dates, supplemental indication dates, label expansion dates, or new treatment-setting approvals through 2026-09-21. The supplied document reports an FDA approval related to IMKELDI. It states that NDA219097 for "IMKELDI SOLUTION ORAL strength EQ 80MG BASE/ML" received an approval on "2024-11-22" as a "Type 3 - New Dosage Form STANDARD" application sponsored by SHORLA ONCOLOGY. The document does not state that this therapy is for Acute Lymphoblastic Leukemia, and it does not provide any affected patient population, supplemental indication, label expansion, or treatment setting information.
Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval withdrawals), and on what dates?
The supplied documents do not identify any Acute Lymphoblastic Leukemia drug or biologic approvals or indications that were explicitly withdrawn, restricted, suspended, or materially revised. One document lists regulatory submission and approval dates for ICLUSIG (ponatinib), including labeling and efficacy supplements through 2025, but it does not describe the scope of any withdrawn or restricted ALL indication. Another document describes clofarabine’s indication for relapsed or refractory ALL and states that the indication is "based upon response rate" with "no trials verifying an improvement in disease-related symptoms or increased survival," but it does not state that any approval or indication was withdrawn or revised. The supplied document identifies the FDA approval history for ARRANON (nelarabine), an Acute Lymphoblastic Leukemia therapy, including the original approval and later supplements, but it does not describe any withdrawn indications, restricted approvals, suspended approvals, or accelerated approval withdrawals or revisions. The document shows that ARRANON NDA021877 received its original FDA approval on 2005-10-28 and includes later labeling and efficacy supplements through 2025-03-11.
Which products are used off-label or are compendia-supported for ALL, by line of therapy, and what codes represent each?
The documents describe therapies used in adult and pediatric acute lymphoblastic leukemia (ALL) across induction, maintenance, and Philadelphia chromosome positive (Ph+ ALL) settings, but they do not provide billing codes, HCPCS/NDC product codes, or explicit major drug compendia listings. For remission induction in adult ALL, the NCI PDQ states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline," and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." The same source states that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials," including in "newly diagnosed adult patients with Ph-positive ALL." FDA labeling documents show that methotrexate is indicated for "acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen," while imatinib is labeled for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The documents describe investigational or off-label use of several therapies in Acute Lymphoblastic Leukemia (ALL), including venetoclax, blinatumomab, and daratumumab-hyaluronidase, but they do not provide major drug compendia support status, billing codes, HCPCS/J-codes, NDCs, or other product codes for claims-based analysis. In the newly diagnosed infant ALL setting, a phase II trial evaluated “the addition of venetoclax and/or blinatumomab to usual chemotherapy” in “infants with newly diagnosed acute lymphoblastic leukemia (ALL)” including KMT2A-rearranged and KMT2A-germline disease, with venetoclax used during induction and blinatumomab used in a “BLINATUMOMAB BLOCK 1.” In a relapsed or refractory minimal residual disease setting, daratumumab-hyaluronidase was studied for “persistent or recurrent MRD following treatment with chemotherapy” in T-cell ALL patients who were “in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy.” The supplied documents do not identify lines of therapy using standardized commercial terminology, do not mention treatment-setting reimbursement classifications, and do not include any billing or product coding information. The supplied documents provide guideline-supported treatment recommendations and settings for acute lymphoblastic leukemia (ALL), including newly diagnosed adult Ph-negative ALL, pediatric ALL, and relapsed/refractory ALL in adolescents and young adults (AYAs). The NCCN adult ALL guideline "focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence," while the pediatric NCCN guideline focuses on "treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL." The ASH 2026 guideline for relapsed/refractory AYA ALL states that key recommendations "include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction" and that recommendations addressed "immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy." The documents do not provide billing codes, HCPCS/J-codes, NDCs, product codes, explicit off-label designations, or detailed claims-analysis coding information by line of therapy. The supplied documents identify some labeled therapies and mention NCCN guideline coverage for pediatric acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide billing codes, product codes, or a comprehensive list of off-label or compendia-supported therapies by line of therapy and treatment setting. Imatinib mesylate is labeled for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” Mercaptopurine is labeled “for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The NCCN pediatric ALL guideline document states that it “focuses on the frontline and relapsed/refractory management of pediatric ALL,” but the excerpt does not enumerate therapies, lines of therapy, compendia support categories, or claims-analysis coding information. The supplied documents describe some therapies and treatment settings for acute lymphoblastic leukemia (ALL), including frontline and resistant/intolerant Philadelphia chromosome-positive (Ph+) ALL settings, but they do not provide billing codes, HCPCS/CPT codes, NDCs, or other claims-analysis product codes. The ASH 2026 guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” The dasatinib label states that dasatinib is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.” The NCCN guideline excerpt states that recommendations include “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults).” The documents identify therapies used in relapsed/refractory acute lymphoblastic leukemia (ALL) settings and specify prior-line requirements for some products, but they do not provide billing codes, HCPCS codes, NDCs, or other claims-analysis product codes. Nelarabine is indicated in the relapsed/refractory setting for “T-cell acute lymphoblastic leukemia (T-ALL)” after “at least two chemotherapy regimens,” and clofarabine is indicated for pediatric relapsed/refractory ALL after “at least two prior regimens.” An ASH guideline for adolescents and young adults with relapsed/refractory ALL states that recommendations “include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and that the guideline addresses “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The supplied documents do not explicitly identify therapies as “off-label” or “supported by major drug compendia,” and they do not include treatment billing or product coding information. The supplied documents identify several therapies used in Acute Lymphoblastic Leukemia (ALL), including Philadelphia chromosome-positive ALL and relapsed/refractory ALL, but they do not provide major drug compendia support details or any billing/product codes for claims-based analysis. Dasatinib (SPRYCEL) is described for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” indicating a relapsed/refractory treatment setting after prior therapy. Blinatumomab was studied in pediatric “relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)” including patients with “refractory, ≥ 2 relapses or relapse after transplant hct,” corresponding to later-line/high-risk treatment settings. ICLUSIG (ponatinib) product information is listed, but the supplied text does not state ALL indications, line of therapy, treatment setting, compendia support, or billing/product codes. The supplied documents identify therapies and treatment settings for Acute Lymphoblastic Leukemia (ALL), but they do not provide billing codes, HCPCS/J-codes, NDC product codes, or explicit claims-analysis coding guidance. Imatinib mesylate is described for ALL in specific settings: “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The NCCN Guidelines Insights document discusses treatment recommendations and settings for ALL, including “relapsed or refractory (R/R) ALL,” and notes use of “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,” but it does not identify billing codes or explicitly label therapies as off-label or compendia-supported. The supplied documents discuss several therapies used in Acute Lymphoblastic Leukemia (ALL), including CD19 CAR therapy and asparaginase-based regimens, but they do not provide major drug compendia listings, explicit off-label classifications, line-of-therapy categorizations, treatment-setting mappings, or billing/product codes for claims-based analysis. One document states that “CD19 CAR therapy” has shown “remarkable clinical outcomes in adults and children with ALL” and may “become part of the armamentarium for B cell-ALL,” indicating use in B-cell ALL across heavily pretreated populations. Another document describes “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute lymphoblastic leukemia/lymphoblastic lymphoma,” but without coding or reimbursement information. The supplied documents identify clofarabine as an FDA-labeled therapy for a relapsed/refractory acute lymphoblastic leukemia setting in pediatric patients after at least two prior regimens, which corresponds to a later-line therapy setting rather than frontline use. The documents also include ASH 2026 frontline management guidance for adolescents and young adults with ALL, stating that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” However, the documents do not provide specific off-label therapies, compendia-supported uses, billing codes, HCPCS/CPT/J-codes, NDCs, or other product codes for claims-based analysis. The supplied documents identify methotrexate as a therapy used for Acute Lymphoblastic Leukemia (ALL) in a defined treatment context: "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents also identify ARRANON as an FDA-listed injectable intravenous product, but they do not state its ALL indication, line of therapy, treatment setting, compendia-supported use, off-label use, or any billing or claims-analysis codes. None of the supplied documents provide information about major drug compendia support, off-label ALL therapies, treatment-line categorization, treatment settings beyond maintenance regimen language, or billing/product codes such as HCPCS, CPT, NDC mappings, or revenue codes. The supplied documents identify FDA-labeled therapies for Acute Lymphoblastic Leukemia (ALL), but they do not provide information on off-label therapies, compendia-supported uses, line of therapy, treatment settings, or billing/product codes for claims-based analysis. Methotrexate Injection is described as indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and the dosage section states that “Methotrexate Injection is used as part of a multi-drug regimen.” The SPRYCEL document lists oral tablet product strengths and regulatory submission history, but it does not describe ALL treatment lines, settings, compendia support, off-label use, or claims codes. The supplied document provides treatment regimens and treatment phases for adult acute lymphoblastic leukemia (ALL), including induction, consolidation/post-remission, and maintenance therapy, but it does not identify United States-specific off-label uses, major drug compendia support, or billing/product codes for claims-based analysis. The document describes induction regimens such as VDP, VIP, VD(C)LP, Hyper-CVAD, CD20 monoclonal antibody combinations, and post-remission use of CD19/CD3 bispecific antibody therapy (blinatumomab), including settings such as younger adults, older adults, MRD-positive disease, consolidation, and transplant bridging. No HCPCS, NDC, CPT, revenue, billing, or product codes are provided. The supplied documents identify doxorubicin (including Adriamycin formulations) as a therapy indicated for Acute Lymphoblastic Leukemia (ALL). The documents state that “Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia” and similarly that “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia.” However, the documents do not provide information about off-label use, compendia-supported use, line of therapy, treatment settings, or billing/product codes for claims-based analysis. Therefore, only the existence of an FDA-labeled ALL indication for doxorubicin can be confirmed from the supplied evidence. The documents identify several therapies used or studied in Acute Lymphoblastic Leukemia (ALL), including rituximab, inotuzumab ozogamicin, blinatumomab, and autologous chimeric antigen receptor cells. The treatment settings explicitly described include relapsed/refractory ALL, minimal residual disease, and newly diagnosed ALL, but the documents do not provide explicit line-of-therapy categorizations, compendia-supported indications, or U.S. billing/product codes for claims-based analysis. One document discusses the broader topic of off-label oncology drug use and drug compendia, but it does not provide ALL-specific therapies or coding details in the supplied text.
How have guideline recommendations for ALL changed over the study period, and on what dates?
The supplied documents describe 2026 American Society of Hematology (ASH) guideline recommendations for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory management, but they do not provide a longitudinal chronology of guideline evolution, regimen removals, or reclassification history across multiple years. The 2026 frontline guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “The use of targeted agents in frontline therapy is increasingly supported.” The 2026 relapsed/refractory guideline highlights biomarker- and immunotherapy-oriented treatment changes, including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” with focus on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” The documents indicate that the evidence reviews supporting these recommendations included “systematic evidence reviews up to November 2023,” but they do not specify additional effective dates, regimen removals, or preference-category reclassifications. The supplied document describes contemporaneous treatment approaches for adult Acute Lymphoblastic Leukemia (ALL) but does not provide a chronology of guideline evolution, update dates, regimen removals, or reclassification history through 2026-09-21. It states that "Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline" and that some regimens "also add other drugs, such as asparaginase or cyclophosphamide." The document also describes a biomarker-driven change for Philadelphia chromosome–positive (Ph-positive) ALL, noting that "inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage" and that "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials." The supplied documents describe guideline and treatment recommendation updates for ALL through 2026, but they do not provide a complete longitudinal chronology of additions, removals, or regimen preference reclassifications across all major U.S. guidelines. In February 2026, ASH published new clinical practice guidelines for adolescents and young adults with ALL, including recommendations favoring “Pediatric-inspired regimens over traditional adult-inspired protocols,” emphasizing “Asparaginase as a cornerstone of therapy,” and calling for “Re-evaluation of allogeneic transplant in first remission given insufficient evidence to support its routine use.” The same ASH release stated that relapsed/refractory recommendations included “Immunotherapy over traditional chemotherapy approaches,” support for “Allogeneic transplant in patients who achieve remission but with individualized assessment,” and “Intrathecal chemotherapy for isolated central nervous system relapse.” A March 17, 2026 Medscape summary citing NCCN-described risk factors documented biomarker-driven stratification including “_BCR::ABL1_ without _IKZF1_” as standard risk and “_BCR::ABL1_-like ALL,” “_IKZF1_ alterations,” and other molecular abnormalities as poor risk, while also stating that “BCR-ABL TKIs are the backbone of care in Ph-positive B-cell ALL” and that second- or third-generation TKIs are preferred over “the first-generation TKI imatinib.”
What are the published benchmarks for time on treatment, time to next treatment, and PFS (progression-free survival) in ALL by line and key regimen?
The supplied literature is a 2026 ASH guideline for frontline management of acute lymphoblastic leukemia in adolescents and young adults (AYAs), and it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or other line-specific survival metrics by regimen or subgroup. The document does identify frontline treatment approaches and subgroup context, stating that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The guideline also specifies that it applies to “AYAs with B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy) receiving frontline therapy.” The supplied literature provides only limited benchmark-style outcome data for adult and relapsed/refractory acute lymphoblastic leukemia (ALL). In newly diagnosed adult ALL, the NCI PDQ states that “Current multiagent induction regimens result in complete response rates that range from 60% to 90%,” and for Philadelphia chromosome–positive (Ph-positive) ALL treated with imatinib-containing approaches, “most of these patients experiencing disease relapse at a median of 58 days after the start of therapy” with “a median duration of 2.2 months.” The ASH 2026 guideline for adolescents and young adults (AYAs) with relapsed/refractory ALL discusses treatment approaches by subgroup and modality, including “blinatumomab and/or inotuzumab over chemotherapy for reinduction,” but the provided text does not report numerical benchmarks for time on treatment, time to next treatment, progression-free survival, or line-specific survival outcomes. The supplied literature does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or line-specific outcomes by regimen and subgroup in Acute Lymphoblastic Leukemia. The document instead describes a biomarker-guided post-CAR-T monitoring study in pediatric and young adult relapsed B-ALL, and reports only limited remission-related outcome context. Specifically, it states that after CAR-T therapy, remission “may cure up to 50% of people who receive this therapy,” while also noting “dismal outcomes for patients who experience a relapse following CD19 CART.” The study focus is on “improving overall survival” and “improve LFS post CD19 CART” through biomarker-guided monitoring and potential transplant consolidation, but no numerical benchmarks for progression-free survival, time on treatment, or time to next treatment are reported. The document instead describes eligibility, follow-up duration, and general response observations for a first-in-human CAR T-cell trial in recurrent or refractory CRLF2/TSLPR-overexpressing B-ALL. It notes that CD19-directed CAR T-cell therapies produced “dramatic responses in >70% of patients with relapsed/refractory B-ALL,” and that “up to 50% of those who achieve remission will subsequently relapse,” but no formal progression-free survival, treatment duration, or time-to-next-treatment benchmarks are reported by line of therapy, regimen, or subgroup.
What proportion of ALL patients advance from 1L to 2L, 3L, and beyond, and what drives attrition between lines?
The supplied document discusses relapsed B-cell acute lymphoblastic leukemia (B-ALL) populations receiving CD19 CAR T-cell therapy and subsequent consideration of hematopoietic cell transplantation (HCT), but it does not report quantitative line-of-therapy advancement rates or proportions of patients moving from first-line to later-line therapy. The document does identify relapse after CAR T-cell therapy as a major driver for subsequent treatment escalation, stating that “for people who relapse after CART, it can be hard to achieve remission again” and that “In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure.” Mortality and outcome concerns are also described as attrition-related factors, including “the dismal outcomes for patients who experience a relapse following CD19 CART” and the need “to improve overall survival.” Clinical and treatment-related factors affecting continuation or transition of therapy include measurable residual disease (MRD), persistence of B-cell aplasia, relapse risk, eligibility for HCT, comorbidities precluding transplant, and uncontrolled illness or social situations that could limit compliance with treatment. The supplied document discusses relapsed/refractory acute lymphoblastic leukemia (ALL) management in adolescents and young adults (AYAs), but it does not report United States population-level proportions advancing from first-line to subsequent lines of therapy, nor quantitative line-to-line attrition rates through 2026-09-21. The document does identify factors associated with relapse/refractory disease and treatment progression, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of toxicity.” It also discusses treatment sequencing considerations and consolidation decisions after relapse, including use of “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “allo-HSCT,” with treatment choice based on “individual patient assessment, burden of disease, and candidacy for future consolidative therapy.” Mortality-related attrition, demographic drivers beyond the AYA population, discontinuation patterns, and quantitative transition rates between therapy lines are not provided in the document. The supplied document reports induction treatment response and relapse information for adult acute lymphoblastic leukemia (ALL), but it does not provide explicit proportions of patients advancing from first-line to second-line or later lines of therapy through 2026-09-21 in United States populations. The document states that "Current multiagent induction regimens result in complete response rates that range from 60% to 90%" and also notes that "Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy." Treatment-related and disease-related attrition factors described include relapse after therapy, short remission duration, and consideration of allogeneic bone marrow transplant because "remissions are generally short with conventional ALL chemotherapy clinical trials." No demographic drivers, mortality-related attrition proportions, or treatment discontinuation transition rates between therapy lines are reported in the provided material. The supplied document discusses management of relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), but it does not report proportions of U.S. ALL patients advancing from first-line to later lines of therapy, nor quantitative line-to-line attrition rates through 2026-09-21. The document does describe factors associated with treatment challenges and decision-making in later-line therapy, stating that AYAs with relapsed/refractory ALL “experience greater treatment resistance” and “higher rates of toxicity,” and that treatment selection should consider “individual patient assessment, burden of disease, and candidacy for future consolidative therapy including allo-HSCT.” Mortality-related attrition, treatment discontinuation patterns, and demographic predictors of transition between therapy lines are not reported in the supplied evidence. The supplied documents do not report proportions of United States acute lymphoblastic leukemia patients who advance from first-line to second-line or later therapies, nor do they quantify attrition between lines of therapy. The documents do mention factors associated with outcomes and treatment decisions, including that survival rates “can vary depending on age, disease subtype, genetic features, and response to treatment,” and that newer adult ALL approaches are “less chemotherapy-intensive” with attention to “MRD risk stratification and transplant decision-making.” Mortality-related information is limited to population survival estimates, including a reported “5-year relative survival of 72.6%” in the United States and lower survival in adults compared with children.
Guideline bodies and current versions table (Body | Guideline | Current version)
| Body | Guideline | Current version |
|---|---|---|
| NCCN | NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (adult ALL) | Version 2.2024 Journal of the National Comprehensive Cancer Network : JNCCN |
| NCCN | NCCN Pediatric Acute Lymphoblastic Leukemia guideline | Version 2.2025 established_answer synthesis |
| American Society of Hematology | American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults | 2026 Blood advances |
| American Society of Hematology | American Society of Hematology 2026 guidelines for relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults | 2026 Blood advances |
[VERIFIED] The supplied evidence references NCCN adult and pediatric ALL guidelines and 2026 ASH guideline publications but does not provide a comprehensive cross-guideline version inventory.
Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens)
| Setting | Intent | Guideline-preferred regimens |
|---|---|---|
| Frontline AYA ALL | Initial remission induction/frontline management | Pediatric-inspired regimens containing asparaginase compared with traditional adult-inspired protocols Blood advances |
| Adult ALL induction | Remission induction | Combination chemotherapy with prednisone, vincristine, and an anthracycline; some regimens add asparaginase or cyclophosphamide National Cancer Institute |
| Newly diagnosed adult Ph+ ALL | Frontline Ph+ disease management | Ponatinib with chemotherapy including vincristine/dexamethasone induction, methotrexate/cytarabine consolidation, and vincristine/prednisone maintenance FDA |
| Relapsed/refractory AYA ALL reinduction | Reinduction therapy | Blinatumomab and/or inotuzumab over chemotherapy for reinduction Blood advances |
| First remission higher-risk subsets | Consolidation/transplant consideration | Allogeneic hematopoietic stem cell transplantation may be indicated for higher-risk subsets or suboptimal responses to initial therapy American Society of Hematology |
[VERIFIED] The supplied evidence does not provide NCCN or ASH regimen preference categories beyond the explicitly quoted recommendations.
Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code)
| Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code |
|---|---|---|---|---|---|---|
| Ponatinib (ICLUSIG) | Tyrosine kinase inhibitor | approved | Newly diagnosed adult Ph+ ALL with chemotherapy | Philadelphia chromosome-positive ALL | 2024-03-19 accelerated approval FDA | |
| Dasatinib (SPRYCEL) | Tyrosine kinase inhibitor | approved | Adults with Ph+ ALL with resistance or intolerance to prior therapy; pediatric patients 1 year and older with newly diagnosed Ph+ ALL in combination with chemotherapy | Philadelphia chromosome-positive ALL | Initial U.S. Approval: 2006 BRISTOL MYERS SQUIBB | |
| Imatinib mesylate (Gleevec/imatinib) | Tyrosine kinase inhibitor | approved | Adult relapsed/refractory Ph+ ALL; pediatric newly diagnosed Ph+ ALL in combination with chemotherapy | Philadelphia chromosome-positive ALL | Initial U.S. Approval: 2001 established_answer synthesis | NDA021588 established_answer synthesis |
| Nelarabine (ARRANON) | Purine nucleoside analog | approved | Relapsed/refractory after at least two chemotherapy regimens | T-ALL/T-LBL | Initial U.S. Approval: 2005 Alembic Pharmaceuticals Limited | NDA021877 SANDOZ |
| Clofarabine injection | Purine nucleoside analog | approved | Pediatric relapsed/refractory ALL after at least two prior regimens | Pediatric patients 1 to 21 years old | Initial U.S. Approval: 2004 Amneal Pharmaceuticals LLC | |
| Methotrexate Injection | Antimetabolite | approved | Combination chemotherapy regimen or maintenance regimen for adult and pediatric ALL | No biomarker restriction stated | Initial U.S. Approval: 1953 Hospira, Inc. | |
| TECARTUS (brexucabtagene autoleucel) | CAR-T cellular therapy | approved | Adult relapsed or refractory B-cell precursor ALL | B-cell precursor ALL |
[VERIFIED] The supplied evidence does not provide HCPCS, CPT, J-codes, NDC mappings, or comprehensive coding identifiers for ALL therapies.
Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates)
| Date | Regulatory event | Affected population or scope |
|---|---|---|
| 2024-03-19 | FDA accelerated approval of ponatinib with chemotherapy | Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) FDA |
| 2024-07-31 | SPRYCEL SUPPL 28 labeling action | Specific ALL population/scope not provided in supplied evidence BRISTOL MYERS SQUIBB |
| 2025-03-11 | ARRANON SUPPL 14 labeling action | Specific ALL population/scope not provided in supplied evidence SANDOZ |
| 2025-10-10 | ICLUSIG SUPPL 38 efficacy supplement | Specific ALL population/scope not provided in supplied evidence TAKEDA PHARMS USA |
| No explicit withdrawn or suspended ALL indication identified | Evidence reviewed did not identify explicit ALL approval withdrawal | Clofarabine indication described as based upon response rate without verified survival improvement US Food and Drug Administration |
[VERIFIED] The supplied evidence contains regulatory supplement histories but often does not specify the indication-level scope of the action.
Guideline change log (Date | Body | Change)
| Date | Body | Change |
|---|---|---|
| 2026 | American Society of Hematology | Pediatric-inspired asparaginase-containing regimens recommended over traditional adult-inspired protocols for frontline AYA ALL American Society of Hematology |
| 2026 | American Society of Hematology | Blinatumomab and/or inotuzumab recommended over chemotherapy for reinduction in relapsed/refractory AYA ALL American Society of Hematology |
| 2026 | American Society of Hematology | Allogeneic hematopoietic stem cell transplantation not routinely recommended in first remission but may be indicated for higher-risk subsets or suboptimal responders American Society of Hematology |
| Contemporary NCCN guidance referenced through 2024 | NCCN | Risk-stratified treatment approaches based on Philadelphia chromosome status, age, MRD assessment, and cytogenetic/molecular markers Journal of the National Comprehensive Cancer Network : JNCCN |
[VERIFIED] The supplied evidence does not provide a complete longitudinal chronology of regimen additions, removals, or preference-category reclassifications.
Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source)
| Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source |
|---|---|---|---|---|---|---|
| Newly diagnosed adult ALL induction | Multiagent induction regimens | Complete response rates range from 60% to 90% | National Cancer Institute | |||
| Ph+ ALL treated with imatinib-containing therapy | Median relapse at 58 days after therapy start | Median duration 2.2 months | National Cancer Institute | |||
| Post-CD19 CAR-T remission context | CD19 CAR-T therapy | May cure up to 50% of people who receive this therapy | National Cancer Institute (NCI) |
[VERIFIED] The supplied evidence does not provide comprehensive time-on-treatment, TTNT, or PFS benchmarks by regimen and line of therapy.
Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected
The supplied evidence describes ALL treatment as proceeding through “a pretreatment phase,” “an induction phase,” “a consolidation phase,” and “maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).” NCCN guidance is described as using “Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations” to guide treatment selection. Adult induction therapy commonly includes “prednisone, vincristine, and an anthracycline,” while Ph+ ALL may incorporate imatinib or ponatinib-containing approaches. ASH frontline guidance for AYAs recommends pediatric-inspired asparaginase-containing regimens. Relapsed/refractory guidance recommends “blinatumomab and/or inotuzumab over chemotherapy for reinduction” and addresses “T-cell ALL,” “CNS relapse,” and transplant consolidation decisions. Biomarker and risk segmentation factors identified in the evidence include BCR::ABL1/Ph status, BCR::ABL1-like ALL, IKZF1 alterations, TP53 mutation, KMT2A rearrangement, CD20 expression, lineage subtype, and MRD status. MRD assessment is referenced during frontline management and in post-CAR-T monitoring, including flow cytometry MRD-negative and NGS MRD-negative assessments within 42 days after CD19 CAR-T infusion. Biomarker testing is therefore observable around diagnosis/risk stratification, during MRD response assessment after induction or CAR-T therapy, and before targeted therapy selection in Ph+ or molecularly defined disease subsets.
Key takeaways
ALL management in the supplied evidence is strongly stratified by Philadelphia chromosome/BCR::ABL1 status, age group, lineage subtype, and MRD context. The clearest frontline recommendation in the evidence is the ASH 2026 recommendation favoring pediatric-inspired asparaginase-containing regimens for AYA frontline ALL. Relapsed/refractory AYA guidance favors blinatumomab and/or inotuzumab over chemotherapy for reinduction. FDA-labeled ALL therapies in the supplied evidence include TKIs for Ph+ ALL, lineage-specific agents such as nelarabine for T-ALL/T-LBL, pediatric relapsed/refractory clofarabine, methotrexate-containing maintenance settings, and CAR-T therapy for relapsed/refractory B-cell precursor ALL. The evidence base remains incomplete for detailed regimen preference categories, coding identifiers, and comprehensive line-of-therapy benchmarks. Claims-based cohort logic should prioritize biomarker segmentation, relapsed/refractory status, transplant exposure, CAR-T exposure, and age-group stratification.
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| Philadelphia chromosome-positive ALL | DIRECT SIGNAL | FDA labels and guideline excerpts explicitly reference Ph+ ALL populations. | The supplied evidence does not include ICD or biomarker billing-code mappings. |
| Relapsed/refractory setting | DIRECT SIGNAL | Multiple labels specify relapsed/refractory disease after prior regimens. | Exact line-number attribution may not always be observable in claims alone. |
| MRD assessment | PROXY SIGNAL | Evidence references MRD-negative assessments and MRD-guided management. | MRD laboratory results are typically absent from administrative claims. |
| CAR-T therapy exposure | DIRECT SIGNAL | TECARTUS and CD19 CAR-T therapy are explicitly identified. | Product-specific coding identifiers were not supplied in the evidence. |
| Transplant consolidation | PROXY SIGNAL | Allogeneic transplant is discussed as a treatment pathway branch point. | Clinical intent and remission status may not be fully distinguishable in claims data alone. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- NCCN and ASH guidance stratify ALL management by Philadelphia chromosome/BCR::ABL1 status, lineage, age group, and MRD context. guidelines
- ASH 2026 frontline guidance for AYAs recommends pediatric-inspired asparaginase-containing regimens over traditional adult-inspired protocols. frontline
- Relapsed/refractory AYA guidance recommends blinatumomab and/or inotuzumab over chemotherapy for reinduction. r/r
- FDA-approved therapies identified in the evidence include ponatinib, dasatinib, imatinib, nelarabine, clofarabine, methotrexate-containing ALL regimens, and TECARTUS. approvals
- Published evidence supplied for this stage lacks comprehensive HCPCS/J-code/NDC mappings and detailed regimen-level preference categories. claims_limitation
Assumptions made in this stage
- When exact guideline version numbers were not directly quoted in evidence excerpts, the established_answer wording was used without extending beyond it.
- Cells marked indicate information requested by the framework but not directly supported by supplied evidence.
- Biomarker testing timepoints were inferred from described diagnostic stratification, MRD monitoring, and targeted-therapy selection contexts.
Evidence base for this stage: 133 item(s) from 9 source(s); 120 from approved sources, 13 supplementary web. Tiers represented: 1, 2, 3.
Unanswered sub-questions
Stage 3 · Diagnostic Footprint Agent
Claims Code Universe: Diagnosis & Procedures
Core question: How would the clinical concepts appear in claims?
Framework steps included
Step 4 (Diagnosis code universe (ICD-10-CM, ICD-9-CM, ICD-11)), Step 5 (Procedure, test and encounter codes: diagnostic evidence, non-drug treatment (surgery, radiation, transplant, CAR-T), drug administration, clinical-trial participation), Laboratory and molecular testing codes (LOINC, CPT), Disease-state coding conventions: suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history, Observability limitations
What happens in this stage
This stage establishes the observable diagnosis, laboratory, and procedure-code universe for Acute Lymphoblastic Leukemia (ALL) in United States claims data through 2026-09-21 using the supplied evidence. The stage identifies ICD-9-CM and ICD-10-CM leukemia diagnosis concepts tied to active disease, remission, and relapse states; summarizes available HCPCS, CPT, and LOINC procedure and laboratory concepts associated with bone marrow evaluation, flow cytometry, and FISH testing; and documents where the evidence set does not provide ICD-11 extensions, clinical-trial indicators, or comprehensive treatment-administration coding.
Expected output
- Three-system diagnosis code crosswalk (ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates)
- Disease-state code variants (suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history Z85)
- ICD-11 extension codes for molecular subtypes, layered onto the disease stem
- Diagnostic test, procedure and non-drug treatment code universe (Category | Example codes | Purpose)
- Drug administration and clinical-trial participation codes (Code | Use | Note)
- Monitoring signal table
- Observability limitations
Synthesis
The supplied CMS ICD-10-CM release files identify the ALL diagnosis family "C910 — Acute lymphoblastic leukemia all" with remission-state subcodes including "C9100 — Acute lymphoblastic leukemia not having achieved remission," "C9101 — Acute lymphoblastic leukemia, in remission," and "C9102 — Acute lymphoblastic leukemia, in relapse." The NLM Clinical Tables additionally define ICD-10-CM codes C91.00, C91.01, and C91.02 with the same remission-state terminology for active disease, remission, and relapse. Legacy ICD-9-CM leukemia concepts identified in the supplied evidence include 20400 "Acute lymphoid leukemia, without mention of having achieved remission," 20401 "Acute lymphoid leukemia, in remission," and 20402 "Acute lymphoid leukemia, in relapse." The evidence also includes ICD-9-CM code V1061 defined as "Personal history of lymphoid leukemia," while the supplied materials do not provide ICD-10-CM personal-history Z85 mappings, secondary malignancy codes, or suspected-versus-confirmed coding conventions. Procedure and laboratory observability in the supplied materials includes HCPCS G0364 for combined bone marrow aspiration and biopsy, HCPCS C1830 for a powered bone marrow biopsy needle, and multiple LOINC concepts related to flow cytometry, bone marrow pathology reports, and blast-cell assessment. Cytogenetic and genomic-testing evidence in the supplied documents includes FISH-associated CPT codes 88237, 88275, and 88271 and references genomic targets including "t(9;22) (BCR/ABL1), 11q23.3 (KMT2A, formerly MLL), t(12;21) (ETV6/RUNX1)," CRLF2, ABL1, ABL2, PDGFRB, PBX1;TCF3, and CDKN2A. The supplied documents do not provide ICD-11 stem or extension codes for molecular ALL subtypes, comprehensive non-drug treatment procedure coding, drug-administration procedure coding, or clinical-trial participation modifiers such as Q0 or Q1.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What ICD-10-CM diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., Z85) variants?
The supplied documents identify ICD-10-CM codes for Acute lymphoblastic leukemia (ALL) and remission/relapse states. The CMS ICD-10-CM release files list "C9100 — Acute lymphoblastic leukemia not having achieved remission," "C9101 — Acute lymphoblastic leukemia, in remission," and "C9102 — Acute lymphoblastic leukemia, in relapse" under "C910 — Acute lymphoblastic leukemia all." The NLM Clinical Tables additionally define ICD-10-CM code C91.01 as "Acute lymphoblastic leukemia, in remission" and ICD-10-CM code C91.02 as "Acute lymphoblastic leukemia, in relapse." The documents do not provide codes or conventions for refractory disease, secondary malignancy involvement, personal-history Z85 codes, or suspected versus confirmed diagnosis coding. The supplied documents identify ICD-9-CM acute lymphoid leukemia diagnosis codes for three disease-status categories: active disease without remission, remission, and relapse. Specifically, code 20400 is defined as "Acute lymphoid leukemia, without mention of having achieved remission," code 20401 as "Acute lymphoid leukemia, in remission," and code 20402 as "Acute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents identify ICD-9-CM leukemia codes for subacute lymphoid leukemia with distinct disease-status modifiers relevant to claims classification. Specifically, code 20420 is defined as "Subacute lymphoid leukemia, without mention of having achieved remission," code 20421 as "Subacute lymphoid leukemia, in remission," and code 20422 as "Subacute lymphoid leukemia, in relapse." The documents do not provide ICD-10-CM diagnosis codes, refractory disease codes, secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents only identify ICD-9-CM lymphoid leukemia remission and relapse codes, not ICD-10-CM Acute Lymphoblastic Leukemia coding through 2026-09-21. The documents include code 20481 for “Other lymphoid leukemia, in remission,” code 20482 for “Other lymphoid leukemia, in relapse,” and code 20492 for “Unspecified lymphoid leukemia, in relapse.” The documents do not provide ICD-10-CM active disease codes, remission variants for ALL, refractory disease coding, secondary malignancy involvement codes, personal-history Z85 codes, or suspected-versus-confirmed diagnosis coding conventions. The supplied documents identify one ICD-10-CM code for active Acute Lymphoblastic Leukemia and one historical leukemia code from ICD-9-CM. ICD-10-CM code C91.00 is defined as "Acute lymphoblastic leukemia not having achieved remission." The documents also include ICD-9-CM code V1061, defined as "Personal history of lymphoid leukemia." The documents do not provide ICD-10-CM remission variants beyond not having achieved remission, relapse or refractory codes, secondary malignancy codes, ICD-10-CM personal-history Z85 codes, or coding conventions for suspected versus confirmed diagnoses. The supplied documents do not provide United States ICD-10-CM diagnosis codes, remission variants, relapse or refractory codes, secondary malignancy codes, personal-history Z85 codes, or suspected-versus-confirmed coding conventions for Acute Lymphoblastic Leukemia. The only coding information provided is an ICD-9-CM entry stating that code 20491 is defined as "Unspecified lymphoid leukemia, in remission." The supplied documents identify the primary ICD-10-CM Acute Lymphoblastic Leukemia (ALL) code family as C91.0 and provide specific 2026 billable diagnosis codes for active disease, remission, and relapse states: C91.00 "Acute lymphoblastic leukemia not having achieved remission," C91.01 "Acute lymphoblastic leukemia, in remission," and C91.02 "Acute lymphoblastic leukemia, in relapse." The documents also state that C91.00 is applicable to "Acute lymphoblastic leukemia with failed remission" and "Acute lymphoblastic leukemia NOS," which addresses refractory/failed-remission disease terminology within claims coding. The supplied materials do not provide specific ICD-10-CM secondary malignancy involvement codes, personal-history Z85 codes, or coding conventions distinguishing suspected versus confirmed ALL diagnoses.
What CPT and HCPCS codes cover bone marrow biopsy, aspiration and flow cytometry in ALL?
The supplied documents identify one HCPCS code for a combined bone marrow aspiration and biopsy procedure, one HCPCS code for a powered bone marrow biopsy needle device, and one LOINC code for a flow cytometry study. Specifically, HCPCS code G0364 is defined as "Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service." HCPCS code C1830 is defined as "Powered bone marrow biopsy needle." The documents also include LOINC code 33719-6 for a "Flow cytometry study." The documents do not provide CPT codes, additional bone marrow biopsy or aspiration procedure codes, hematopathology service codes, or information specific to monitoring procedure use in Acute Lymphoblastic Leukemia. The supplied documents identify LOINC entries related to bone marrow biopsy, bone marrow aspiration, and flow cytometry review, but they do not provide CPT or HCPCS procedure codes. The documents include LOINC 33721-2 for a "Bone marrow Pathology biopsy report," LOINC 48807-2 for a "Bone marrow aspiration report," and LOINC 69052-9 for "Flow cytometry specialist review of results." No documents describe hematopathology CPT/HCPCS services or monitoring procedure-use coding for Acute Lymphoblastic Leukemia claims data. The supplied document does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, flow cytometry, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia claims data. It only identifies a LOINC entry related to bone marrow aspiration guidance: LOINC code 87008-9, defined as "Guidance for fluid aspiration of Bone marrow." The supplied document only identifies a LOINC laboratory concept related to flow cytometry and does not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The document states that LOINC code 61126-9 is defined as "Blasts/cells in Specimen by Flow cytometry (FC)." The supplied documents do not provide CPT or HCPCS procedure codes for bone marrow biopsy, bone marrow aspiration, hematopathology services, or monitoring procedures in Acute Lymphoblastic Leukemia. The only procedure-related coding information provided is a LOINC entry for flow cytometry: LOINC code 107079-6, defined as "Blasts/Cells in Blood by Flow cytometry (FC)." It only identifies a flow cytometry-related laboratory concept: LOINC code 54226-6, defined as "Lymphoma panel - Specimen by Flow cytometry (FC)."
What CPT and LOINC codes cover cytogenetic and molecular testing relevant to ALL?
The supplied documents identify three LOINC laboratory codes relevant to flow cytometry testing that may be used in hematologic malignancy evaluation and monitoring. The documents provide LOINC code 61126-9 for "Blasts/cells in Specimen by Flow cytometry (FC)", LOINC code 69052-9 for "Flow cytometry specialist review of results", and LOINC code 54226-6 for "Lymphoma panel - Specimen by Flow cytometry (FC)". The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or ALL-specific monitoring assay coding beyond these LOINC entries. The supplied documents identify several LOINC laboratory mappings relevant to hematologic evaluation and monitoring. LOINC code 61123-6 is defined as "Lymphocytes/Leukocytes in Specimen by Flow cytometry (FC)." Additional LOINC mappings include 33721-2 for a "Bone marrow Pathology biopsy report" and 48807-2 for a "Bone marrow aspiration report." The documents do not provide CPT codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay CPT mappings for Acute Lymphoblastic Leukemia classification or risk stratification. The supplied documents identify three LOINC laboratory codes relevant to flow cytometry and leukemia-related laboratory assessment. LOINC 30912-0 is defined as "DNA index in Specimen by Flow cytometry (FC)." LOINC 33719-6 is defined as "Flow cytometry study," and LOINC 107079-6 is defined as "Blasts/Cells in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay CPT mappings for Acute Lymphoblastic Leukemia. The supplied documents identify two LOINC laboratory codes potentially relevant to Acute Lymphoblastic Leukemia evaluation and monitoring. LOINC 66119-9 is defined as "Bone marrow Pathology biopsy report Narrative," and LOINC 30364-4 is defined as "Lymphocytes [#/volume] in Blood by Flow cytometry (FC)." The documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or specific monitoring assay code sets for ALL classification or risk stratification. The supplied documents only identify one LOINC laboratory mapping relevant to flow cytometry testing. LOINC code 101147-7 is defined as "Monocytes/Leukocytes in Blood by Flow cytometry (FC)." No CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes specific to Acute Lymphoblastic Leukemia classification, risk stratification, or monitoring are provided in the documents. The supplied documents only identify one LOINC laboratory code related to flow cytometry and do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay mappings for Acute Lymphoblastic Leukemia. The available document states that LOINC code 104548-3 corresponds to "Monocytes [#/volume] in Blood by Flow cytometry (FC)." The supplied documents do not provide CPT codes, cytogenetic testing codes, FISH assay codes, molecular pathology codes, genomic biomarker tests, or monitoring assay codes relevant to Acute Lymphoblastic Leukemia. The only laboratory mapping identified is the LOINC code 26028-1, defined as "HLA-B27 presence by Flow cytometry (FC)." The documents identify several CPT codes for fluorescence in situ hybridization (FISH) testing relevant to Acute Lymphoblastic Leukemia (ALL): "CPT Code(s): 88237, 88275 (x per analyses), 88271 (x per probe)." The FISH panels include genomic targets used for ALL classification, prognostic assessment, and monitoring, including "t(9;22) (BCR/ABL1), 11q23.3 (KMT2A, formerly MLL), t(12;21) (ETV6/RUNX1)," as well as CRLF2, ABL1, ABL2, PDGFRB, PBX1;TCF3, and CDKN2A. The documents also state that "FISH is useful to identify chromosome abnormalities in patients with pediatric or adult acute lymphoblastic leukemia (ALL) for diagnostic and prognostic purposes as well as for follow-up to evaluate patient response to therapy" and that "Companion testing with chromosome analysis is recommended." No LOINC codes, specific cytogenetic chromosome analysis CPT codes beyond the listed FISH-related CPTs, or broader molecular pathology/genomic laboratory billing codes are provided in the supplied documents.
How are ICD-9-CM and ICD-11 leukemia codes crosswalked to ICD-10-CM, and what are each code's effective and retirement dates across annual code-set updates?
The supplied documents identify ICD-9-CM legacy Acute Lymphoid Leukemia diagnosis codes and one ICD-10-CM Acute Lymphoblastic Leukemia concept. ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission," and ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse." The CMS ICD-10-CM release file excerpt lists ICD-10-CM concept C910 "Acute lymphoblastic leukemia all" with subcode C9100 "Acute lymphoblastic leukemia not having achieved remission." The documents do not provide ICD-9-CM to ICD-10-CM crosswalk mappings, ICD-11 stem or extension codes, linkage rules, or effective, revision, and retirement dates across annual coding updates. The supplied documents identify two ICD-10-CM concepts for Acute Lymphoblastic Leukemia. ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission," and ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse." The documents do not provide ICD-9-CM legacy leukemia mappings, ICD-11 stem or extension code mappings, linkage information, or any effective, revision, or retirement dates across annual coding updates. The supplied documents identify ICD-10-CM concepts for Acute Lymphoblastic Leukemia (ALL) and provide some annual update and effective-date information, but they do not provide ICD-9-CM legacy leukemia code mappings, ICD-11 stem-code mappings, ICD-11 extension-code linkage, or retirement-date histories. The documents state that “The ICD-10 code for acute lymphoblastic leukemia is C91.0, with specific codes for remission status,” and list the ICD-10-CM remission-status concepts “C91.00,” “C91.01,” and “C91.02.” The 2026 ICD-10-CM update documentation states that “The 2026 edition of ICD-10-CM C91.00 became effective on October 1, 2025,” and displays annual code-set continuity for “20162017201820192020202120222023202420252026.” No supplied document contains ICD-9-CM to ICD-10-CM crosswalks, ICD-11 mappings, revision histories beyond the cited annual editions, or retirement dates.
Which ICD-11 extension codes express ALL molecular subtypes on the disease stem?
Not answered. evidence was retrieved but no source answered the question
What procedure codes identify non-drug anti-cancer treatments for ALL, such as radiation, stem cell transplant, and CAR-T?
The supplied documents identify Acute Lymphoblastic Leukemia diagnosis coding, including ICD-10-CM code C91.0 and related remission-status codes C91.00, C91.01, and C91.02. The documents also mention that ALL treatment can include “radiation therapy” and “stem cell transplant,” but they do not provide CPT, HCPCS, ICD-10-PCS, leukapheresis, cellular collection, conditioning regimen, CAR-T administration, or specific procedure codes requested in the question.
Which drug administration codes (e.g., the CPT 96413 chemotherapy administration series) provide treatment evidence in ALL when the drug code is missing or unspecified?
Not answered. evidence was retrieved but no source answered the question
Which codes identify clinical trial participation in ALL (e.g., Z00.6, Q0/Q1 modifiers)?
The supplied documents identify ICD-10-CM diagnosis codes for Acute Lymphoblastic Leukemia (ALL), including remission and relapse status codes. However, the documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers such as Q0 or Q1, investigational service indicators, routine clinical trial care billing indicators, or revenue code markers for claims-based line-of-therapy analyses. The supplied documents only identify one Acute Lymphoblastic Leukemia diagnosis code: ICD-10-CM code C91.02, defined as “Acute lymphoblastic leukemia, in relapse.” The documents do not provide any information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing markers, or revenue code indicators for claims-based line-of-therapy analyses. The supplied documents identify one Acute Lymphoblastic Leukemia diagnosis code relevant to claims-based analyses: ICD-10-CM code C91.00, defined as “Acute lymphoblastic leukemia not having achieved remission.” The documents do not provide information on clinical trial diagnosis codes, HCPCS modifiers Q0 or Q1, investigational service indicators, routine trial care billing, or revenue code markers. The supplied documents do not provide the requested diagnosis codes, HCPCS modifiers such as Q0 and Q1, revenue codes, investigational service indicators, or routine clinical trial billing markers specific to claims-based line-of-therapy analyses in Acute Lymphoblastic Leukemia patients. The documents only establish that HCPCS includes categories related to “Administrative, Miscellaneous and Investigational” services and that CMS maintains annually updated CPT/HCPCS code lists through 2026. No document in the set identifies specific clinical trial participation diagnosis codes, Q0/Q1 modifier definitions, or revenue code indicators for investigational or routine trial-related care.
Three-system diagnosis code crosswalk (ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates)
| ICD-9-CM legacy | ICD-10-CM current | ICD-11 stem + extension | Description | Effective and retirement dates |
|---|---|---|---|---|
| 20400 | C91.00 | Not provided | Acute lymphoid/leukoblastic leukemia not having achieved remission or without mention of remission U.S. National Library of Medicine | "The 2026 edition of ICD-10-CM C91.00 became effective on October 1, 2025"; retirement dates not provided Open web |
| 20401 | C91.01 | Not provided | Acute lymphoid/leukoblastic leukemia, in remission U.S. National Library of Medicine | Effective and retirement dates not provided U.S. National Library of Medicine |
| 20402 | C91.02 | Not provided | Acute lymphoid/leukoblastic leukemia, in relapse U.S. National Library of Medicine | Effective and retirement dates not provided U.S. National Library of Medicine |
| V1061 | Not provided | Not provided | Personal history of lymphoid leukemia U.S. National Library of Medicine | Effective and retirement dates not provided U.S. National Library of Medicine |
[VERIFIED] The supplied documents do not provide ICD-11 mappings, ICD-9-to-ICD-10 linkage rules, or retirement-date histories beyond the cited ICD-10-CM effective-date statement.
Disease-state code variants (suspected / rule-out, confirmed, active, remission, relapse, secondary or metastatic, personal history Z85)
| Disease-state category | Code system | Code | Description | Claims interpretation |
|---|---|---|---|---|
| Suspected / rule-out | Not provided | Not provided | Not provided | The supplied documents do not provide coding conventions distinguishing suspected versus confirmed ALL diagnoses CMS ICD-10-CM Release Files |
| Active disease | ICD-10-CM | C91.00 | Acute lymphoblastic leukemia not having achieved remission U.S. National Library of Medicine | C91.00 is applicable to "Acute lymphoblastic leukemia with failed remission" and "Acute lymphoblastic leukemia NOS" Open web |
| Remission | ICD-10-CM | C91.01 | Acute lymphoblastic leukemia, in remission U.S. National Library of Medicine | Remission-state ALL diagnosis concept CMS ICD-10-CM Release Files |
| Relapse | ICD-10-CM | C91.02 | Acute lymphoblastic leukemia, in relapse U.S. National Library of Medicine | Relapse-state ALL diagnosis concept CMS ICD-10-CM Release Files |
| Secondary or metastatic involvement | Not provided | Not provided | Not provided | The supplied materials do not provide specific ICD-10-CM secondary malignancy involvement codes CMS ICD-10-CM Release Files |
| Personal history | ICD-9-CM | V1061 | Personal history of lymphoid leukemia U.S. National Library of Medicine | ICD-10-CM personal-history Z85 mappings were not provided U.S. National Library of Medicine |
[VERIFIED] The evidence set identifies remission-state coding but does not provide refractory-specific ICD-10-CM codes beyond failed-remission terminology attached to C91.00.
ICD-11 extension codes for molecular subtypes, layered onto the disease stem
| ICD-11 stem code | ICD-11 extension code | Subtype represented | Evidence status |
|---|---|---|---|
| Not provided | Not provided | Molecular, cytogenetic, immunophenotypic, or lineage-specific ALL subtype | The supplied documents do not provide ICD-11 extension codes for ALL subtypes CMS ICD-10-CM Release Files |
[VERIFIED] No ICD-11 stem or extension-code mappings were identified in the supplied evidence.
Diagnostic test, procedure and non-drug treatment code universe (Category | Example codes | Purpose)
| Category | Example codes | Purpose |
|---|---|---|
| Bone marrow aspiration and biopsy | HCPCS G0364 | "Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service" U.S. National Library of Medicine |
| Bone marrow biopsy device | HCPCS C1830 | "Powered bone marrow biopsy needle" U.S. National Library of Medicine |
| Bone marrow pathology reporting | LOINC 33721-2; LOINC 66119-9; LOINC 48807-2 | Bone marrow pathology biopsy report and bone marrow aspiration report concepts U.S. National Library of Medicine |
| Flow cytometry laboratory assessment | LOINC 33719-6; 61126-9; 107079-6; 61123-6; 30364-4; 101147-7; 104548-3; 54226-6; 69052-9 | Flow cytometry study, blast-cell assessment, lymphocyte/leukocyte quantification, lymphoma panel, and specialist review concepts U.S. National Library of Medicine |
| FISH cytogenetic testing | CPT 88237; 88275; 88271 | FISH testing used "for diagnostic and prognostic purposes as well as for follow-up to evaluate patient response to therapy" in pediatric or adult ALL Open web |
| Radiation therapy and stem cell transplant | Specific procedure codes not provided | ALL treatment may include "radiation therapy" and "stem cell transplant" Open web |
[VERIFIED] The supplied evidence does not provide ICD-10-PCS, leukapheresis, cellular collection, conditioning regimen, CAR-T administration, or comprehensive hematopathology CPT coding.
Drug administration and clinical-trial participation codes (Code | Use | Note)
| Code | Use | Note |
|---|---|---|
| Q0 | Investigational clinical service modifier | The supplied documents do not provide Q0 modifier definitions or usage Open web |
| Q1 | Routine clinical trial service modifier | The supplied documents do not provide Q1 modifier definitions or usage Open web |
| Drug administration CPT/HCPCS codes | Evidence of systemic anti-cancer treatment exposure | The supplied documents do not provide CPT and HCPCS drug-administration procedure codes for ALL CMS ICD-10-CM Release Files |
[VERIFIED] Evidence was not supplied for chemotherapy administration procedure coding, investigational billing indicators, or routine trial-care markers.
Monitoring signal table
| Monitoring concept | Potential signal | Supporting code(s) | Interpretive note |
|---|---|---|---|
| Active ALL disease | Diagnosis claim | C91.00 | Active disease or failed-remission terminology associated with ALL U.S. National Library of Medicine |
| Remission monitoring | Diagnosis status transition | C91.01 | Remission-state diagnosis coding identified in ICD-10-CM U.S. National Library of Medicine |
| Relapse monitoring | Diagnosis status transition | C91.02 | Relapse-state diagnosis coding identified in ICD-10-CM U.S. National Library of Medicine |
| Bone marrow reassessment | Procedure utilization | G0364; C1830 | Bone marrow aspiration/biopsy and biopsy-device coding may indicate diagnostic or monitoring encounters U.S. National Library of Medicine |
| Flow cytometry reassessment | Laboratory observation | LOINC 33719-6; 61126-9; 107079-6 | Flow cytometry concepts include blasts/cells and blood assessment U.S. National Library of Medicine |
| Cytogenetic follow-up | FISH testing utilization | CPT 88237; 88275; 88271 | FISH may be used for follow-up to evaluate patient response to therapy Open web |
[INFERENCE] Monitoring interpretations are based on repeated appearance of diagnosis, procedure, and laboratory concepts over time in longitudinal claims or linked laboratory data.
Observability limitations
The supplied evidence does not provide ICD-11 stem or extension codes for molecular or lineage-specific ALL subtype representation. The supplied documents do not provide coding conventions for suspected-versus-confirmed diagnoses, secondary malignancy involvement, or ICD-10-CM personal-history Z85 mappings. Procedure-code coverage is incomplete because the evidence set does not include comprehensive CPT, HCPCS, or ICD-10-PCS coding for leukapheresis, stem-cell transplantation workflows, conditioning regimens, CAR-T administration, radiation delivery, or chemotherapy administration. Clinical-trial participation indicators, including HCPCS modifiers Q0 and Q1, investigational service indicators, and revenue-code markers, were not identified in the supplied materials. Many monitoring signals in ALL claims analytics may therefore require proxy inference from diagnosis-state transitions, laboratory utilization, or repeated bone marrow and flow-cytometry testing rather than direct treatment-intent coding.
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| Active ALL disease | DIRECT SIGNAL | ICD-10-CM code C91.00 is defined as "Acute lymphoblastic leukemia not having achieved remission." | The supplied documents do not provide suspected-versus-confirmed coding conventions. |
| ALL remission state | DIRECT SIGNAL | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission." | Remission coding alone does not establish treatment exposure or minimal residual disease status. |
| ALL relapse state | DIRECT SIGNAL | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse." | Refractory-specific diagnosis codes were not separately identified in the supplied materials. |
| Bone marrow reassessment | PROXY SIGNAL | HCPCS G0364 identifies combined bone marrow aspiration and biopsy procedures. | Procedure occurrence does not independently distinguish diagnosis from surveillance or relapse evaluation. |
| Flow-cytometry monitoring | PROXY SIGNAL | Multiple LOINC entries describe flow cytometry studies, blast-cell measurements, and lymphoma panels. | LOINC observability may depend on linked laboratory data availability rather than adjudicated medical claims alone. |
| Molecular subtype capture with ICD-11 extensions | NOT OBSERVABLE | The supplied evidence does not provide ICD-11 extension codes for ALL molecular or lineage-specific subtypes. | No ICD-11 layering schema was identified in the supplied documents. |
| Clinical-trial participation | NOT OBSERVABLE | No Q0/Q1 modifiers, investigational indicators, or trial-related revenue codes were identified in the supplied evidence. | Trial participation may be under-detected without external registry linkage or payer-specific indicators. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
| Topic | Source A | Source A says | Source B | Source B says | Possible reason |
|---|---|---|---|---|---|
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim describes an in-remission leukemia code while the other describes not having achieved remission, which are incompatible disease-status definitions. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | One claim defines an in-remission code whereas the other defines a not-in-remission code, so they assert different remission statuses for the same disease category. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim defines a relapse-state leukemia code while the other describes disease not having achieved remission, which are distinct and conflicting statuses. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim specifies acute lymphoblastic leukemia in remission while the other specifies not having achieved remission, which are contradictory statuses. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | The first claim defines an in-remission code and the second defines a not-in-remission code, creating a direct status conflict. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim defines relapse disease status while the other defines not having achieved remission, which are different and incompatible statuses. |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | The first claim identifies a relapse code whereas the second identifies a not-in-remission code, so they conflict on disease status. |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims assign different remission statuses within ICD-10-CM acute lymphoblastic leukemia coding: C91.01 is in remission whereas C91.00 is not having achieved remission. |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims describe different disease-status concepts for acute lymphoblastic/lymphoid leukemia: relapse versus not having achieved remission. |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims refer to different ICD-10-CM remission-status concepts: C91.02 is in relapse whereas C91.00 is not having achieved remission. |
Disagreements are surfaced, not resolved. SME adjudication required.
Key takeaways from this stage
- ICD-10-CM ALL diagnosis coding in the supplied evidence is centered on the C91.0 family with explicit active, remission, and relapse states (C91.00, C91.01, C91.02).
- Legacy ICD-9-CM leukemia status coding includes active disease, remission, relapse, and personal-history concepts such as V1061.
- HCPCS G0364 and C1830 plus multiple LOINC flow-cytometry and bone-marrow concepts provide observable diagnostic-workup signals in claims-linked datasets.
- FISH-associated CPT codes 88237, 88275, and 88271 were identified with ALL-relevant genomic targets including BCR/ABL1, KMT2A, and ETV6/RUNX1.
- The supplied evidence does not provide ICD-11 subtype extensions, comprehensive non-drug treatment procedure coding, or chemotherapy-administration coding.
- Longitudinal ALL line-of-therapy analytics may require combining diagnosis-state transitions with laboratory and procedure utilization because direct treatment-intent coding is incompletely represented in the evidence set.
Assumptions made in this stage
- ICD-9-CM and ICD-10-CM concepts were aligned by identical remission-state wording when presented together in the supplied evidence.
- LOINC laboratory concepts were included because the supplied questions explicitly requested claims-oriented coding references and monitoring signals.
- Open-web references were retained only where directly cited in the established answers and not expanded beyond quoted content.
Evidence base for this stage: 62 item(s) from 6 source(s); 39 from approved sources, 23 supplementary web. Tiers represented: 1, 3.
Unanswered sub-questions
Question:
In United States claims-oriented coding references through 2026-09-21, which ICD-11 extension codes can be layered onto Acute Lymphoblastic Leukemia stem codes to represent molecular, cytogenetic, immunophenotypic, or lineage-specific ALL subtypes for all patients?
Reason:
evidence was retrieved but no source answered the question
Sources Attempted:
cms_gems, cms_hcpcs, cms_icd10, loinc, nlm_hcpcs, nlm_icd10cm, nlm_icd9cm, nlm_loinc
Question:
In United States claims data through 2026-09-21, which CPT and HCPCS drug administration procedure codes provide evidence of systemic anti-cancer treatment exposure for Acute Lymphoblastic Leukemia among all patients when specific drug product codes are absent, nonspecific, or missing in claims?
Reason:
evidence was retrieved but no source answered the question
Sources Attempted:
cms_gems, cms_hcpcs, cms_icd10, loinc, nlm_hcpcs, nlm_icd10cm, nlm_icd9cm, nlm_loinc
Stage 4 · Treatment Logic Agent
Treatment Sequencing, Regimen Library & Code Mapping
Core question: How does treatment sequence appear in real-world data?
Framework steps included
Step 7 (Define line-of-therapy (LOT) rules), Step 8 (Build the regimen library by line and phase), Step 9 (Map regimen components to HCPCS/J-codes and NDC), Step 10 (Separate pharmacy from medical benefit claims), Define supportive-care exclusions and ambiguity rules
- Step 8A — Collect guideline, trial and real-world regimen evidence
- Step 8B — Finalize regimen library by line, segment, setting and evidence source
- Step 10A — Collect preliminary supportive-care and non-therapeutic candidates
- Step 10B — Classify therapeutic components versus supportive or contextual medications
- Step 10C — Finalize supportive-care exclusions and contextual exceptions
What happens in this stage
This stage establishes the evidence-supported building blocks needed for Acute Lymphoblastic Leukemia treatment-sequencing analyses in U.S. claims data, including limited operational cycle logic, identifiable regimen components, HCPCS/J-code mappings, representative NDC examples, administration and dosing references, and observed areas where claims-based line construction remains underdefined. The supplied evidence supports therapy-specific scheduling and administration rules for selected ALL agents such as blinatumomab, inotuzumab ozogamicin, nelarabine, CAR-T products, methotrexate, mercaptopurine, dasatinib, ponatinib, and clofarabine, but does not provide a comprehensive claims algorithm for line advancement, maintenance handling, relapse episode creation, transplant episode grouping, or standardized regimen aliasing.
Expected output
- Line-of-therapy trigger rules (Trigger | Interpretation)
- Regimen library (Regimen | Setting | Components)
- Component and HCPCS/J-code mapping (Component drug | HCPCS code | Biosimilar / NDC considerations)
- NDC universe (Agent | Representative NDCs | Labeler | Coverage note) with a method note for an exhaustive pull
- Dosing and administration reference (Agent | Standard adult dosing | Route / schedule | Key administration notes)
- Supportive-care and non-therapeutic exclusion list
- Ambiguity rules (pharmacy vs medical benefit, same-drug different-intent)
Synthesis
The supplied evidence provides therapy-level cycle timing and interruption rules for BLINCYTO and BESPONSA rather than a complete U.S. claims-based line-of-therapy algorithm for ALL. BLINCYTO induction or consolidation is described as "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval," while continued therapy uses a "56-day treatment-free interval," and interruptions longer than 7 days require starting "a new cycle." BESPONSA cycle guidance includes dosing on Days 1, 8, and 15, with Cycle 1 potentially extended to 28 days and HSCT-directed treatment commonly limited to 2 cycles for patients proceeding to transplant. The evidence identifies multiple ALL-related therapies and subpopulation-specific indications, including relapsed/refractory CD22-positive B-cell precursor ALL for inotuzumab ozogamicin, relapsed/refractory Ph+ ALL for dasatinib and imatinib, and relapsed/refractory T-ALL/T-LBL after at least two prior regimens for nelarabine. CMS HCPCS evidence supports direct code mapping for multiple injectable and cellular therapies including blinatumomab (J9039), inotuzumab ozogamicin (J9229), rituximab (J9312), tisagenlecleucel (Q2042), and brexucabtagene autoleucel (Q2053). FDA Purple Book evidence additionally identifies rituximab biosimilars including Truxima (rituximab-abbs), Ruxience (rituximab-pvvr), and Riabni (rituximab-arrx). Oral therapies including dasatinib, ponatinib, mercaptopurine, methotrexate tablets, and imatinib formulations are identified through NDC/package listings, while infused therapies and CAR-T products are represented through HCPCS-coded medical-claim constructs. Because the supplied evidence lacks standardized regimen aliases, maintenance grouping logic, pharmacy-versus-medical routing conventions, and comprehensive exclusion lists, claims-based sequencing frameworks will require analyst-defined governance rules beyond the supplied source material.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
How are lines of therapy defined for ALL in real-world claims research?
The supplied document contains treatment-cycle and interruption rules for BESPONSA in relapsed or refractory acute lymphoblastic leukemia, including cycle start timing, dose scheduling, interruption thresholds, and hematopoietic stem cell transplant (HSCT) considerations. It states that "Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity," and that subsequent cycles are "4 weeks in duration." The document also specifies interruption and discontinuation logic, including that clinicians should "interrupt the next cycle of treatment until recovery" for specified hematologic toxicities and that "Greater than 28 days" of interruption may require to "Consider permanent discontinuation of treatment." For HSCT handling, it states that "For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles," with a possible third cycle under defined response conditions. The document does not provide United States claims-data operational algorithms for constructing lines of therapy, including regimen-level line advancement triggers, treatment-gap definitions in claims data, maintenance handling, relapse/re-treatment episode construction, or claims-based transplant episode logic. The supplied document does not describe United States claims-data algorithms for constructing lines of therapy in Acute Lymphoblastic Leukemia, including regimen start/stop logic, line advancement triggers, treatment gaps, maintenance handling, stem-cell transplant episode handling, or relapse/retreatment operational rules. It only provides BLINCYTO treatment-cycle schedules and interruption rules that mention induction, consolidation, continued therapy, treatment-free intervals, and restarting cycles after interruptions. Specifically, the document states that induction and consolidation cycles are "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval," while "continued therapy consists of 28 days of continuous intravenous infusion followed by a 56-day treatment-free interval." It also states that "If the interruption after an adverse reaction is no longer than 7 days, continue the same cycle," but "If an interruption due to an adverse reaction is longer than 7 days, start a new cycle."
What are the standard multi-agent induction, consolidation and maintenance regimens for ALL?
The supplied documents do not provide a comprehensive United States claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or detailed multi-agent regimen sequencing groupings and aliases. The documents do identify several ALL-related therapeutic agents and cellular therapies that may appear in regimen libraries, including “rituximab,” “blinatumomab,” “inotuzumab ozogamicin,” “vincristine sulfate,” “doxorubicin hydrochloride,” “cyclophosphamide,” “methotrexate sodium,” “cytarabine,” “daunorubicin hydrochloride,” “Tisagenlecleucel CAR-T,” and “Brexucabtagene autoleucel CAR-T.” The transplantation-related document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission,” and also notes that “chemotherapy + imatinib” had outcomes “comparable for allogeneic SCT.” No document supplies standardized regimen aliases, naming conventions, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a comprehensive United States clinical practice or claims-based regimen library for Acute Lymphoblastic Leukemia (ALL), and they do not enumerate induction, consolidation, intensification, maintenance, or treatment-sequencing regimen groupings and aliases. The documents do identify several therapies used in relapsed or refractory ALL and transplant-related settings, including "blinatumumab," "inotuzumab," and "CAR-T cells," and they discuss "bridging therapy prior to reinjection of autologous CAR-T cells" in relapsed/refractory B-ALL. The FDA Purple Book document lists product and generic names relevant for alias grouping, including "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and rituximab biosimilars such as "Truxima rituximab-abbs," "Ruxience rituximab-pvvr," and "Riabni rituximab-arrx." The transplant-focused guideline also states that "post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended" for Philadelphia chromosome positive ALL, but no specific multi-agent maintenance regimen compositions or sequencing rules are provided. The supplied documents identify only limited Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive U.S. clinical practice or claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, and transplant-related settings through 2026-09-21. For relapsed or refractory Ph+ ALL, dasatinib (SPRYCEL) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and imatinib is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also note a pediatric Ph+ ALL combination approach where “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy” may receive imatinib, but no specific chemotherapy backbone, induction, consolidation, maintenance, intensification, transplant-related regimen definitions, aliases, or component-grouping rules are provided. The supplied documents describe broad United States clinical practice guidance for ALL but do not provide the detailed claims-based regimen library, regimen-component grouping rules, aliases, or exhaustive multi-agent regimen names requested for sequencing analyses. The documents state that ALL management includes “risk-stratified treatment approaches,” “more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,” and that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols.” The relapsed or refractory setting is specifically referenced, with NCCN updates that “summarize treatment recommendations for R/R ALL.” Transplant-related management is also referenced, including that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do identify several treatment settings and regimen elements: relapsed/refractory management recommendations include “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” with discussion of “consolidation with allogeneic transplant” and “CNS-directed therapy.” The documents also describe “asparaginase-containing regimens” and “pediatric/pediatric-inspired regimens incorporating asparaginase” used in AYA and adult ALL populations. Maintenance therapy is described as “the last phase of treatment for acute lymphoblastic leukemia in children and adolescents,” but no specific multi-agent maintenance regimen components, aliases, or grouping conventions are supplied. The supplied documents only partially address Acute Lymphoblastic Leukemia regimens and do not provide a comprehensive United States claims-based regimen library across induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related settings, or regimen alias grouping rules. The documents identify methotrexate as being used "as part of a combination chemotherapy maintenance regimen" for ALL, clofarabine for "relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens," and imatinib mesylate for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." No induction, consolidation, intensification, transplant-conditioning regimens, sequencing logic, component grouping methodology, or regimen aliases are described in the supplied documents. The supplied documents do not provide a United States claims-based ALL regimen library, treatment-sequencing grouping rules, or comprehensive induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias mappings. The only explicit relapsed/refractory regimen-related information is that nelarabine is indicated for "T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)" in patients "whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens." The documents also describe a nelarabine administration schedule in relapsed/refractory T-ALL/T-LBL clinical trials: "1,500 mg/m 2 of Nelarabine Injection Administered Intravenously Over 2 Hours on Days 1, 3, and 5 Repeated Every 21 Days." No source text defines how regimen components or aliases should be grouped for sequencing analyses. The supplied documents only identify limited Acute Lymphoblastic Leukemia (ALL) treatment settings and do not provide a comprehensive U.S. claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, BESPONSA (inotuzumab ozogamicin) is indicated for "relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older." For maintenance therapy, methotrexate tablets are indicated for the "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not describe induction regimens, consolidation regimens, intensification regimens, transplant-conditioning regimens, regimen component grouping rules, or regimen aliases/naming conventions for treatment sequencing analyses. The supplied documents identify only limited Acute Lymphoblastic Leukemia (ALL) regimen information. Methotrexate labeling states that it is used for ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia," but no induction, consolidation, intensification, maintenance, transplant-related, or sequencing regimen library definitions are provided. Imatinib and dasatinib labeling identify Philadelphia chromosome-positive ALL settings, including "relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)," "newly diagnosed Ph+ ALL in combination with chemotherapy," and "Ph+ ALL with resistance or intolerance to prior therapy," but the documents do not define multi-agent regimen names, aliases, component grouping rules, or claims-based sequencing conventions. The supplied documents identify that NCCN ALL guidelines address treatment strategies and management settings for adult and pediatric acute lymphoblastic leukemia, including “risk-adapted therapy,” “frontline and relapsed/refractory management,” “hematopoietic stem cell transplantation,” and management of “BCR::ABL1-positive” and “BCR::ABL1-negative” disease. However, the documents provided do not enumerate specific multi-agent induction, consolidation, intensification, maintenance, relapsed/refractory, or transplant-related regimens, nor do they provide claims-based regimen library conventions, component grouping rules, aliases, or treatment-sequencing nomenclature. Therefore, the requested regimen lists, aliases, and grouping logic for sequencing analyses cannot be fully derived from the supplied text. The supplied documents only identify two Acute Lymphoblastic Leukemia treatment contexts and do not provide a comprehensive United States claims-based regimen library through 2026-09-21. For relapsed or refractory ALL, clofarabine is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." For maintenance therapy, mercaptopurine is indicated "for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The documents do not list specific induction, consolidation, intensification, transplant-related multi-agent regimens, regimen aliases, or component-grouping rules for treatment sequencing analyses. The supplied documents do not provide a United States ALL regimen library through 2026-09-21 and do not enumerate induction, consolidation, intensification, maintenance, transplant-related, or regimen-alias grouping frameworks for treatment sequencing analyses. The documents only identify selected agents and limited usage context in ALL, including that methotrexate is used in ALL "as part of a combination chemotherapy regimen" and for "prophylaxis and treatment of meningeal leukemia." The documents also identify FDA products relevant to ALL care, including ICLUSIG (ponatinib) and ARRANON (nelarabine), but they do not describe multi-agent regimens, regimen naming conventions, or component-grouping logic. The supplied document only states that doxorubicin hydrochloride is indicated for treatment of "acute lymphoblastic leukemia" and that it may be used "in combination with other chemotherapy drugs." It does not provide United States ALL regimen libraries, induction, consolidation, intensification, maintenance, relapsed/refractory, transplant-related regimens, or guidance on regimen component grouping, aliases, or treatment sequencing analyses. Therefore, the requested regimen-level details are not available in the provided materials. The supplied documents identify the major treatment phases for Acute Lymphoblastic Leukemia (ALL), including induction chemotherapy, consolidation therapy, maintenance therapy, CNS prophylaxis, treatment of mature B-cell ALL, treatment of Philadelphia chromosome–positive ALL, and treatment of younger adults, but they do not provide a complete claims-oriented regimen library or detailed multi-agent regimen component mappings and aliases for sequencing analyses. The documents also do not enumerate specific regimen names, standardized aliases, component-grouping rules, transplant-conditioning regimens, or relapsed/refractory regimen taxonomies. Therefore, the available material only partially addresses the requested scope.
What HCPCS J-codes and NDC identifiers map to ALL regimen components?
The supplied documents identify several Acute Lymphoblastic Leukemia regimen component drugs and branded products, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mappings. Clofarabine injection is described as "indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." Imatinib mesylate is described for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The Drugs@FDA record identifies the branded product SPRYCEL with multiple tablet strengths, but no claims-code mappings or administration linkages are provided. The supplied documents provide HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia regimen component drugs used in treatment sequencing analyses, including rituximab (J9312), blinatumomab (J9039), inotuzumab ozogamicin (J9229), vincristine sulfate (J9370), doxorubicin hydrochloride (J9000), cyclophosphamide (J9070), methotrexate sodium (J9250 and J9260), cytarabine (J9100), daunorubicin hydrochloride (J9150), tisagenlecleucel (Q2042), and brexucabtagene autoleucel (Q2053). The documents also specifically confirm that HCPCS code J9039 corresponds to “Injection, blinatumomab, 1 microgram” and HCPCS code J9229 corresponds to “Injection, inotuzumab ozogamicin, 0.1 mg.” However, the supplied documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings beyond the named generic ingredients, or CPT drug-administration code linkage. The documents identify imatinib mesylate tablets for "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and for "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." They also identify clofarabine injection "for intravenous use" for pediatric relapsed/refractory ALL and methotrexate injection "for intravenous, intramuscular, subcutaneous, or intrathecal use" for ALL as part of combination chemotherapy regimens. The supplied documents identify regimen component drugs used in Acute Lymphoblastic Leukemia (ALL) treatment contexts, specifically methotrexate and clofarabine, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic mapping tables. Methotrexate labeling states it is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." Clofarabine labeling states it is indicated for "pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." No claims-code linkage or administration-code mapping information is present in the documents. The supplied documents identify several Acute Lymphoblastic Leukemia regimen component products and some HCPCS mappings, including branded products and rituximab biosimilars. The FDA Purple Book rows list "Rituxan rituximab," "Blincyto blinatumomab," "Besponsa inotuzumab ozogamicin," "Kymriah tisagenlecleucel," "Tecartus brexucabtagene autoleucel," "Aucatzyl obecabtagene autoleucel," and biosimilars "Truxima rituximab-abbs (biosimilar to Rituxan)," "Ruxience rituximab-pvvr (biosimilar to Rituxan)," and "Riabni rituximab-arrx (biosimilar to Rituxan)." The HCPCS tables map tisagenlecleucel to HCPCS codes Q2040 and Q2042 with detailed code descriptions. The documents do not provide NDC mappings, J-codes, CPT drug-administration codes, or multi-source generic mappings. The documents state that SPRYCEL (dasatinib) is indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” They also identify branded products relevant to leukemia treatment sequencing analyses, including “ICLUSIG TABLET ORAL” in multiple strengths and “ARRANON INJECTABLE INTRAVENOUS strength 250MG/50ML (5MG/ML).” No administration code linkage or claims-code crosswalks are provided in the supplied material. The supplied documents identify several regimen component drugs and treatment contexts for Acute Lymphoblastic Leukemia (ALL), including BESPONSA (inotuzumab ozogamicin), BLINCYTO (blinatumomab), KYMRIAH (tisagenlecleucel), and comparator chemotherapy regimens containing fludarabine, cytarabine, mitoxantrone, granulocyte colony-stimulating factor, and high-dose cytarabine. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multisource generic mappings. The documents also describe administration modality for BLINCYTO and KYMRIAH, including intravenous infusion and continuous IV infusion schedules, but no billing-code linkage is provided. The supplied documents identify regimen component drugs used for Acute Lymphoblastic Leukemia treatment analyses, including doxorubicin hydrochloride and methotrexate sodium formulations, and include branded and multi-source generic injectable product descriptions. However, the documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or NDC mappings. The documents do provide evidence that doxorubicin hydrochloride is indicated for “acute lymphoblastic leukemia” and list multiple methotrexate injectable product variants and preservative-free formulations that could correspond to generic product mapping exercises in claims-based sequencing analyses. The supplied documents provide limited NDC mapping information for dasatinib products relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. Documented products include Biocon Pharma Inc. ANDA dasatinib tablet products with NDC package identifiers "70377-087-11" and "70377-088-11" for 100 mg and 140 mg strengths, respectively, and a Prasco Laboratories "NDA AUTHORIZED GENERIC" dasatinib 20 mg tablet product with package identifier "66993-233-60." The documents identify these as generic or authorized generic oral products, but they do not provide HCPCS codes, J-codes, CPT drug-administration linkage, biosimilar mappings, or broader multi-source generic mappings. The supplied documents provide limited HCPCS/J-code mappings for several Acute Lymphoblastic Leukemia treatment components. Documented mappings include HCPCS code C9449 for blinatumomab defined as "Injection, blinatumomab, 1 mcg," HCPCS code C9028 for inotuzumab ozogamicin defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code Q2053 for brexucabtagene autoleucel defined as "up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The documents do not provide NDC mappings, biosimilar mappings, multi-source generic mappings, or CPT drug-administration code linkages. The supplied documents identify doxorubicin (Adriamycin/DOXOrubicin HCl) as a regimen component drug used for treatment of acute lymphoblastic leukemia and describe intravenous administration details, but they do not provide HCPCS codes, J-codes, CPT drug-administration codes, NDC mappings, biosimilar mappings, or multi-source generic coding crosswalks. The labels state that "Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia" and describe administration "as an intravenous injection" and dosing in "combination with other chemotherapy drugs." No claims-data coding mappings or administration billing code linkages are present in the documents. The documents do establish branded/generic drug identities and ALL-related treatment use cases: nelarabine injection for relapsed or refractory T-ALL/T-LBL, dasatinib tablets for Ph+ ALL, and mercaptopurine oral suspension for ALL maintenance therapy. No administration-code linkage or claims-code crosswalks are present in the supplied materials. The supplied documents provide limited NDC mappings for branded oral ALL therapies, specifically SPRYCEL (dasatinib) and Iclusig (ponatinib hydrochloride). Document 0 identifies SPRYCEL with package NDC "0003-0524-11" and active ingredient "DASATINIB 70 mg/1," while Document 1 identifies SPRYCEL with package NDC "0003-0857-22" and active ingredient "DASATINIB 140 mg/1." Document 2 identifies Iclusig with package NDC "63020-533-30" and active ingredient "PONATINIB HYDROCHLORIDE 30 mg/1." The documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, generic product mappings, or treatment sequencing linkage information. The documents provide limited NDC mappings for several Acute Lymphoblastic Leukemia regimen component drugs, including branded and generic products, but they do not provide HCPCS, J-code, CPT drug-administration, biosimilar linkage, or treatment sequencing analysis mappings. Documented NDC products include Clofarabine injection marketed as an ANDA generic with package code 43598-309-20, Arranon (nelarabine) intravenous injection with package code 66758-165-94, and Dasatinib oral tablets with package code 70377-085-11. The supplied records identify product names, active ingredients, dosage forms, package identifiers, and marketing categories only. The supplied documents provide limited mappings for regimen component drugs relevant to Acute Lymphoblastic Leukemia claims analyses. HCPCS mapping is available for imatinib: HCPCS code S0088 is defined as “Imatinib 100 mg — Imatinib, 100 mg.” NDC mappings are provided for branded and generic kinase inhibitors, including IMKELDI (imatinib oral solution) with NDC 81927-201-01 and an authorized generic dasatinib product with NDC 66993-234-60. The documents do not provide CPT drug-administration code linkage, biosimilar mappings, or broader multisource generic mapping tables beyond the specific examples shown. The supplied documents provide limited mappings relevant to Acute Lymphoblastic Leukemia treatment sequencing analyses. HCPCS mappings are provided for obecabtagene autoleucel under codes C9301 and Q2058, including descriptions of the leukapheresis and infusion-related therapeutic dose definitions. An NDC mapping is provided for Arranon (nelarabine) intravenous injection under NDC 0078-0683-61 with active ingredient nelarabine 5 mg/mL. The documents do not provide broader HCPCS/J-code mappings, CPT drug-administration linkage, biosimilar mappings, or multi-source generic mappings beyond these examples. The supplied documents only provide partial NDC mapping information for dasatinib generic products and do not provide HCPCS, J-code, CPT drug-administration, biosimilar, or treatment-sequencing linkage information. The documents identify Biocon Pharma Inc. oral dasatinib tablet products with NDC package identifiers 70377-083-11 (20 mg), 70377-084-11 (50 mg), and 70377-086-11 (80 mg), each with marketing category "ANDA," indicating generic products. No branded-product mappings, biosimilar mappings, HCPCS/J-codes, or administration code linkages are present in the supplied material. The documents provide NDC mappings for the branded product Iclusig (ponatinib hydrochloride), including multiple strengths and package configurations. Specifically, NDC 63020-534 corresponds to 45 mg tablets, NDC 63020-536 corresponds to 10 mg tablets, and NDC 63020-535 corresponds to 15 mg tablets with both 30-count and 60-count bottle presentations. The supplied documents do not provide HCPCS codes, J-codes, CPT drug-administration codes, biosimilar mappings, or multi-source generic mappings for treatment sequencing analyses. A HCPCS mapping is provided for brexucabtagene autoleucel under code C9073, and NDC mappings are provided for branded SPRYCEL (dasatinib) oral tablets with NDC package identifiers 0003-0855-22 and 0003-0528-11. The documents do not provide CPT drug-administration linkage, biosimilar mappings, multi-source generic mappings, or broader treatment sequencing mappings through 2026-09-21.
Which ALL therapies are billed under the pharmacy benefit versus the medical benefit?
The documents identify oral and intravenous ALL therapies, but they do not discuss United States claims adjudication under pharmacy versus medical benefit, dual-channel billing, or line-of-therapy routing ambiguities. SPRYCEL (dasatinib) for Philadelphia chromosome-positive acute lymphoblastic leukemia is described as an oral tablet therapy: "SPRYCEL TABLET ORAL" and "The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg administered orally once daily." KYMRIAH (tisagenlecleucel) for relapsed or refractory B-cell ALL is described as "suspension for intravenous infusion" and as a "CD19-directed genetically modified autologous T cell immunotherapy." The supplied documents do not state whether these products are adjudicated through pharmacy or medical benefits, nor do they describe benefit-routing ambiguities or dual-channel billing patterns affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and specify that they are administered intravenously, but they do not explicitly describe adjudication under pharmacy versus medical benefits, dual-channel billing, or claims-routing ambiguities. BLINCYTO (blinatumomab) is described as “for injection, for intravenous use,” and is indicated for multiple ALL settings including “relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).” Doxorubicin hydrochloride is also described as “injection, for intravenous use” and is indicated for “acute lymphoblastic leukemia,” including use “as a component of multi-agent adjuvant chemotherapy.” The documents do not provide information on oral therapies, pharmacy-benefit dispensing, medical-benefit adjudication practices, or how benefit-routing ambiguities affect line-of-therapy construction in U.S. claims data. The documents identify oral maintenance-regimen therapies for Acute Lymphoblastic Leukemia (ALL), specifically mercaptopurine oral suspension and methotrexate tablets, which implies pharmacy-dispensed oral agents rather than infused medical-benefit products. Mercaptopurine is described as "MERCAPTOPURINE oral suspension" with dosing "orally once daily as part of a combination chemotherapy maintenance regimen." Methotrexate is described as "METHOTREXATE tablets, for oral use" and is indicated for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen." The supplied documents do not discuss United States claims adjudication, pharmacy versus medical benefit routing rules, dual-channel billing, infused agents, or line-of-therapy construction ambiguities, so those aspects cannot be determined from the provided evidence. The supplied documents identify multiple Acute Lymphoblastic Leukemia therapies and regimen components through HCPCS injection or CAR-T procedure codes, which indicates adjudication in claims systems tied to HCPCS-coded administration. Documented HCPCS-coded agents include rituximab, blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel. The documents also show CAR-T products billed with HCPCS Q-codes that include administration-related language such as “including leukapheresis and dose preparation procedures, per infusion” and “per therapeutic dose.” The documents do not describe pharmacy-benefit therapies, oral agents, dual-channel billing, or routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and products that appear in HCPCS and FDA product listings, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), and obecabtagene autoleucel (Aucatzyl). The HCPCS entries for obecabtagene autoleucel describe administration-linked billing constructs such as “including leukapheresis and dose preparation procedures” and billing “per therapeutic dose” or “per infusion,” which indicates medical-claim routing through HCPCS-coded services. However, the supplied documents do not state which therapies are adjudicated under the pharmacy benefit versus the medical benefit, do not describe oral versus infused benefit routing, and do not discuss dual-channel billing patterns or line-of-therapy construction ambiguities. The supplied documents identify some Acute Lymphoblastic Leukemia therapies as oral tablet products, including imatinib mesylate and ponatinib (ICLUSIG). Imatinib mesylate is described as “tablets, for oral use” and includes indications for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” ICLUSIG is identified as “TABLET ORAL” in multiple strengths. However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not describe infused versus medically billed agents, and do not address dual-channel billing patterns, routing ambiguities, or line-of-therapy construction issues. The documents identify several Acute Lymphoblastic Leukemia (ALL) therapies as oral tablet products, which in claims practice could correspond to pharmacy-dispensed agents, but the documents do not explicitly discuss pharmacy versus medical benefit adjudication. The ALL-related oral agents named are methotrexate tablets, imatinib mesylate tablets, and dasatinib tablets. The documents also reference use "in combination with chemotherapy" or as part of a "combination chemotherapy maintenance regimen," indicating that oral agents may be combined with other chemotherapy components, but they do not specify whether those accompanying chemotherapy agents are infused, medically billed, dual-channeled, or associated with routing ambiguities affecting line-of-therapy construction. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and regimen components, but they do not describe United States claims adjudication under pharmacy versus medical benefits or line-of-therapy routing logic. The documents do show that Methotrexate for ALL is provided as an injectable therapy and may involve intramuscular, subcutaneous, intravenous, or intrathecal administration, while also noting that patients may switch between oral and injectable methotrexate formulations. The documents also describe TECARTUS (brexucabtagene autoleucel) as a "single dose" CAR-T cell therapy. No document discusses dual-channel billing, pharmacy-benefit claims, medical-benefit claims, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify both oral and intravenous ALL therapies, which are relevant to potential pharmacy-versus-medical benefit routing, but they do not directly describe United States claims adjudication practices, dual-channel billing, or line-of-therapy construction rules. IMKELDI is described as an "SOLUTION ORAL," while nelarabine/Arranon are described as "injection" products for "intravenous use," including dosing administered "intravenously over" specified time periods. The supplied documents do not state whether these products are typically processed under pharmacy or medical benefits, and they do not discuss routing ambiguities or dual-channel billing patterns. The supplied documents identify several Acute Lymphoblastic Leukemia therapies as intravenous injectable products, which implies administration in a clinical setting but does not explicitly discuss United States claims adjudication under pharmacy versus medical benefits. Clofarabine is repeatedly described as an "injection" administered "as an intravenous infusion," and ARRANON is listed as an "INJECTABLE INTRAVENOUS" product. The documents do not provide information about pharmacy-benefit therapies, dual-channel billing, oral-versus-infused routing distinctions in claims systems, or benefit-routing ambiguities affecting line-of-therapy construction. The documents identify several Acute Lymphoblastic Leukemia therapies and their coding or dosage-form characteristics, but they do not directly state whether they are adjudicated under the pharmacy benefit or medical benefit in U.S. claims data, nor do they describe line-of-therapy routing ambiguities. Imatinib appears in HCPCS coding as "HCPCS code S0088," while ponatinib (Iclusig) is described as an oral "TABLET, FILM COATED ORAL" product in FDA NDC records. The supplied documents do not discuss dual-channel billing patterns, infused versus physician-administered adjudication, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied document identifies therapies and regimen components used in Acute Lymphoblastic Leukemia treatment studies, including “BESPONSA,” “fludarabine + cytarabine + granulocyte colony-stimulating factor flag,” “mitoxantrone + cytarabine mxn/ara-c,” and “high dose cytarabine hidac.” The document also describes that patients received “treatment cycles” and compares “BESPONSA” with “Investigator’s choice of chemotherapy.” However, the document does not discuss United States claims adjudication, pharmacy versus medical benefit routing, oral versus infused benefit handling, dual-channel billing, or line-of-therapy construction ambiguities. The supplied documents identify Acute Lymphoblastic Leukemia therapies that are administered as intravenous injections or infusions, including clofarabine and nelarabine. Clofarabine is described as an “INJECTION INTRAVENOUS” product and its labeling states it is administered “as an intravenous infusion over 2 hours daily for 5 consecutive days.” Nelarabine (Arranon) is also described as an “INJECTION INTRAVENOUS” product. The documents do not provide information about adjudication under pharmacy versus medical benefits, dual-channel billing, oral versus infused benefit routing distinctions, or claims-based line-of-therapy ambiguities. The supplied documents identify doxorubicin as a therapy used for "acute lymphoblastic leukemia" and repeatedly describe it as being administered intravenously, including "given intravenously every 21 days," "administered as an intravenous bolus," and "Administration by Intravenous Injection." These documents therefore support that doxorubicin is an infused or injected regimen component rather than an oral agent. The documents identify several Acute Lymphoblastic Leukemia therapies through HCPCS billing codes that are associated with administered products typically appearing in medical claims. HCPCS code C9073 and HCPCS code Q2053 are both defined for "Brexucabtagene autoleucel" and include "leukapheresis and dose preparation procedures, per therapeutic dose," while HCPCS code J9039 is defined as "Injection, blinatumomab, 1 microgram." The supplied documents do not describe pharmacy-benefit adjudication, oral therapies, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet formulations, including "Product: Dasatinib (dasatinib) TABLET ORAL" and "Product: SPRYCEL (dasatinib) TABLET ORAL." However, the documents do not state whether these therapies are adjudicated under the pharmacy benefit or the medical benefit, and they do not describe dual-channel billing, infused agents, regimen-component routing, or line-of-therapy construction ambiguities. No information is provided about medical-benefit therapies, oral-versus-infused adjudication rules, or benefit-routing patterns in claims data. The documents identify certain Acute Lymphoblastic Leukemia therapies as HCPCS-coded injectable products, which are typically represented in medical claims data. Specifically, HCPCS code J9229 is defined as "Injection, inotuzumab ozogamicin, 0.1 mg," HCPCS code C9028 is also defined as "Injection, inotuzumab ozogamicin, 0.1 mg," and HCPCS code C9449 is defined as "Injection, blinatumomab, 1 mcg." The supplied documents do not discuss pharmacy-benefit adjudication, oral therapies, dual-channel billing, benefit-routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify dasatinib products as oral tablet therapies, which implies they are dispensed products rather than infused agents. The records state "Product: SPRYCEL (dasatinib) TABLET ORAL" and "Product: Dasatinib (dasatinib) TABLET, FILM COATED ORAL." However, the documents do not discuss United States claims adjudication under pharmacy versus medical benefits, do not identify medical-benefit therapies, and do not describe dual-channel billing patterns, routing ambiguities, or impacts on line-of-therapy construction. The supplied documents identify oral ALL-related therapies that would typically appear as pharmacy-dispensed products because they are described as oral tablets or oral solution products with NDC packaging. Ponatinib (Iclusig) is listed as a "TABLET, FILM COATED ORAL" product in bottle packaging, and imatinib (IMKELDI) is listed as a "SOLUTION ORAL" product. The documents do not describe any infused therapies, medical-benefit adjudication, dual-channel billing, or benefit-routing ambiguities affecting line-of-therapy construction. The supplied documents identify dasatinib/SPRYCEL as an oral tablet product, which is relevant to pharmacy-versus-medical benefit routing because the products are described as "TABLET ORAL." Specifically, the documents describe both branded SPRYCEL and generic dasatinib oral tablet formulations. However, the documents do not describe United States claims adjudication practices, pharmacy benefit versus medical benefit assignment, dual-channel billing, infused therapies, regimen components, or line-of-therapy routing ambiguities. The supplied documents identify dasatinib formulations that are "TABLET, FILM COATED ORAL," which indicates an oral therapy form relevant to Acute Lymphoblastic Leukemia treatment claims. However, the documents do not describe whether therapies are adjudicated under the pharmacy benefit or medical benefit, do not discuss infused agents, and do not provide information on dual-channel billing patterns, routing ambiguities, or line-of-therapy construction rules in United States claims data.
What supportive care agents should be excluded from ALL regimen identification?
The supplied documents identify some supportive or prophylactic agents associated with acute lymphoblastic leukemia care, but they do not provide a comprehensive exclusion list for regimen identification or line-of-therapy assignment in United States claims analyses. The documents mention prophylactic anticoagulation and supportive growth-factor use: in ALL, "Low-molecular-weight heparins (LMWH) at prophylactic doses are recommended as the first-line strategy" and "Direct oral anticoagulants (DOACs) may be considered" in selected situations; in leukemia supportive care, LEUKINE is described as "a leukocyte growth factor indicated" "To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections." The documents also reference transfusion support through measures such as "platelet (>20,000 cells/mm3) and RBC transfusion independence." No supplied document addresses anti-infective prophylaxis agents, antiemetics, rescue agents, tumor lysis management drugs, or explicit non-therapeutic exclusions for claims-based regimen construction. The supplied documents mention supportive care in acute lymphoblastic leukemia guidelines, but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor lysis, antiemetic, anti-infective, growth factor, or non-therapeutic agents that should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. One document states that the NCCN guidelines include “guidance on supportive care,” and another refers to “enhanced supportive care,” but neither provides the requested exclusion lists or agent names. The supplied document indicates that ALL guidelines include “supportive care considerations,” but it does not specify which supportive-care, prophylactic, rescue, adjunctive, or non-therapeutic agents should be excluded from regimen identification or line-of-therapy assignment in United States claims analyses. The document also does not provide lists covering anti-infective prophylaxis, growth factor support, antiemetics, tumor lysis management, transfusion support, or non-therapeutic exclusions. The supplied documents indicate that NCCN Acute Lymphoblastic Leukemia guidelines include “supportive care considerations,” but they do not enumerate specific supportive-care, prophylactic, rescue, adjunctive, transfusion, tumor-lysis, antiemetic, growth-factor, anti-infective, or non-therapeutic agents to exclude from regimen identification or line-of-therapy assignment in claims analyses. No document provides a list of medications or coding exclusions for treatment sequencing analyses.
What NDC identifiers and labelers correspond to the principal ALL agents, and where are biosimilars or multi-source generics involved?
The supplied documents identify methotrexate-containing therapies used in Acute Lymphoblastic Leukemia (ALL), including oral tablets, injectable products, and an oral solution, but they do not provide representative NDC identifiers, biosimilar relationships, or a complete exhaustive pull methodology. The Bryant Ranch Prepack labeling states that “Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” while the Hospira Drugs@FDA entry enumerates multiple injectable package presentations and strengths such as “METHOTREXATE SODIUM PRESERVATIVE FREE INJECTABLE INJECTION strength EQ 1GM BASE/40ML (EQ 25MG BASE/ML)” and “METHOTREXATE SODIUM INJECTABLE INJECTION strength EQ 50MG BASE/2ML (EQ 25MG BASE/ML).” Manufacturer or sponsor mapping is partially available because the sources are identified as “HOSPIRA,” “Bryant Ranch Prepack,” and “SHORLA ONCOLOGY,” and the IMKELDI entry states “Application: NDA219097 sponsored by SHORLA ONCOLOGY.” The documents also support multi-source generic considerations for methotrexate because multiple formulations and manufacturers are represented, including discontinued and prescription injectable products under the same active ingredient. The supplied documents identify some principal Acute Lymphoblastic Leukemia (ALL) therapies and classes used in treatment recommendations, but they do not provide the requested exhaustive United States claims-based drug identification universe elements such as NDC identifiers, manufacturer/labeler mappings, package presentations, biosimilar relationships, or multi-source generic logic. The NCCN guideline states that the ALL guidelines focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL,” while another document states that “Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” One FDA labeling document states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” However, none of the supplied documents contain representative NDCs, package presentations, manufacturer or labeler mappings, biosimilar relationships, or exhaustive pull methodologies for claims data extraction. The documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies and provide limited NDC, manufacturer/labeler, package, and coding details. The only explicit NDC/package/manufacturer mapping provided is for IMKELDI: "NDC 81927-201: IMKELDI" from "Shorla Oncology Inc." with packaging "140 mL in 1 BOTTLE (81927-201-01)" and active ingredient "IMATINIB MESYLATE 80 mg/mL." BLINCYTO is identified as "BLINCYTO (BLINATUMOMAB) KIT [AMGEN, INC]" and described as indicated for "B-cell precursor acute lymphoblastic leukemia (ALL)." CMS HCPCS release data additionally identify claims-relevant agents including blinatumomab, inotuzumab ozogamicin, rituximab, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, tisagenlecleucel, and brexucabtagene autoleucel, but the supplied documents do not provide exhaustive NDC universes, biosimilar relationships, or multi-source generic mappings through 2026-09-21. The documents identify dasatinib/SPRYCEL as a principal Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) therapy and provide manufacturer or labeler names plus dosage-form strengths, but they do not provide explicit NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. The branded product is "SPRYCEL" sponsored by "BRISTOL MYERS SQUIBB," with oral tablet strengths of "20MG," "50MG," "70MG," "80MG," "100MG," and "140MG." Generic labeling is also documented for "Dasatinib tablets" from "BluePoint Laboratories" and "Biocon Pharma Limited," and another SPRYCEL label references "Physicians Total Care, Inc." The supplied records support inclusion of branded and generic dasatinib products in a claims-based drug universe for Ph+ ALL, but the documents do not contain the exhaustive NDC-level inventory, package configurations, biosimilar mappings, or generic sourcing rules requested. The supplied documents identify representative NDCs, labelers/manufacturers, package presentations, and marketing categories for selected Acute Lymphoblastic Leukemia therapies, specifically Iclusig (ponatinib hydrochloride) and generic dasatinib products from Biocon Pharma Inc. Takeda Pharmaceuticals America, Inc. markets Iclusig under NDC 63020-535 with bottle presentations containing 30 or 60 film-coated tablets, while Biocon Pharma Inc. markets dasatinib ANDA products under NDCs 70377-083 and 70377-085 with 60-tablet bottle presentations at 20 mg and 70 mg strengths respectively. The documents support that dasatinib products are marketed under ANDA, which is relevant to multi-source generic considerations, whereas Iclusig is marketed under NDA. The documents do not provide biosimilar relationships, a complete ALL therapy universe, exhaustive pull methodology, or broader manufacturer-labeler mappings beyond the cited products. The supplied documents identify several Acute Lymphoblastic Leukemia-related therapies and their manufacturers or labelers, but they do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify “KYMRIAH (TISAGENLECLEUCEL) INJECTION, SUSPENSION novartis pharmaceuticals corporation”, “TECARTUS (BREXUCABTAGENE AUTOLEUCEL) SUSPENSION [KITE PHARMA, INC.]”, and “NELARABINE (NELARABINE)” from “Alembic Pharmaceuticals Limited”. The Nelarabine labeling specifically states that “Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)”. No supplied document contains representative NDCs, manufacturer-labeler crosswalks beyond the label names, package configurations, biosimilar mappings, or generic universe construction rules. The supplied documents identify imatinib mesylate as a therapy used for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)" and "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy." The documents also identify multiple labelers or sources for the same product labeling, including "Apotex Corp," "Sun Pharmaceutical Industries, Inc.," and "US Food and Drug Administration (FDA Drug Labeling (openFDA), tier 1)." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes through 2026-09-21. The supplied documents identify several principal Acute Lymphoblastic Leukemia therapies and certain biosimilar relationships from the FDA Purple Book, including Rituxan/rituximab, Blincyto/blinatumomab, Besponsa/inotuzumab ozogamicin, Kymriah/tisagenlecleucel, Tecartus/brexucabtagene autoleucel, Aucatzyl/obecabtagene autoleucel, and the rituximab biosimilars Truxima, Ruxience, and Riabni. The documents also provide representative NDC identifiers, package presentations, and manufacturer/labeler information for authorized generic dasatinib products from Prasco Laboratories, specifically NDCs 66993-233-60 and 66993-234-60. However, the documents do not provide an exhaustive ALL claims-identification universe through 2026-09-21, do not enumerate all manufacturers/labelers or package configurations for the listed therapies, and do not describe a complete pull methodology. The supplied documents identify representative Acute Lymphoblastic Leukemia therapy products and their NDC/package/manufacturer mappings, including Iclusig (ponatinib hydrochloride), Arranon (nelarabine), and SPRYCEL (dasatinib). lists Iclusig under NDC 63020-536 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (63020-536-30)"; Novartis Pharmaceuticals Corporation lists Arranon under NDC 0078-0683 with package presentation "50 mL in 1 VIAL (0078-0683-61)"; and E.R. Squibb & Sons, L.L.C. lists SPRYCEL under NDC 0003-0855 with package presentation "1 BOTTLE in 1 CARTON (0003-0855-22) / 30 TABLET in 1 BOTTLE." The documents do not provide biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology, and they do not establish a complete ALL therapy universe through 2026-09-21. The documents identify two Acute Lymphoblastic Leukemia therapies and their sponsors/labelers, but they do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive multi-source generic pull methodology. ICLUSIG is identified under "NDA203469 sponsored by TAKEDA PHARMS USA" with oral tablet products at strengths "EQ 10MG BASE," "EQ 45MG BASE," "EQ 30MG BASE," and "EQ 15MG BASE." Methotrexate Injection is identified from Hospira, Inc. labeling as indicated for "acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen" and described as "for intravenous, intramuscular, subcutaneous, or intrathecal use." The supplied documents do not state any NDC numbers, package sizes, biosimilar relationships, interchangeable products, or generic universe methodology. The supplied documents identify Biocon Pharma Inc. as the labeler/manufacturer source for several dasatinib oral tablet NDCs relevant to Acute Lymphoblastic Leukemia claims identification. Representative NDCs include 70377-084-11 for 50 mg tablets packaged as "60 TABLET, FILM COATED in 1 BOTTLE," 70377-086-11 for 80 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE," and 70377-087-11 for 100 mg tablets packaged as "30 TABLET, FILM COATED in 1 BOTTLE." All listed products are marketed under the "ANDA" category, which indicates generic approval status in the FDA NDC Directory entries. The documents do not provide exhaustive ALL therapy coverage, biosimilar relationships, broader manufacturer mappings, or a complete pull methodology for claims-universe construction. The supplied documents identify Acute Lymphoblastic Leukemia (ALL) therapies including methotrexate and imatinib, but they do not provide an exhaustive U.S. claims-data drug identification universe through 2026-09-21. The documents show that methotrexate tablets from multiple manufacturers are indicated for “acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” demonstrating a multi-source generic situation across at least Alembic Pharmaceuticals and Aurobindo Pharma. The HCPCS material also identifies imatinib under HCPCS code S0088 as “Imatinib 100 mg — Imatinib, 100 mg.” However, the documents do not provide representative NDC identifiers, package presentations, biosimilar relationships, or exhaustive pull methodology. The supplied documents identify representative NDCs for ALL-related kinase inhibitor therapies including Dasatinib and Iclusig/Ponatinib products. Biocon Pharma Inc. markets an ANDA dasatinib product under NDC 70377-088 with package presentation "30 TABLET, FILM COATED in 1 BOTTLE (70377-088-11)" and active ingredient strength "DASATINIB 140 mg/1." Takeda Pharmaceuticals America, Inc. markets Iclusig (ponatinib hydrochloride) NDA products under NDCs 63020-533 and 63020-534, each packaged as "30 TABLET, FILM COATED in 1 BOTTLE" with strengths "30 mg/1" and "45 mg/1" respectively. The documents do not provide biosimilar relationships, broader multi-source generic considerations, or an exhaustive pull methodology for claims-based drug identification universes. The supplied documents identify doxorubicin products used for Acute Lymphoblastic Leukemia treatment indications, including branded and generic presentations such as “Doxorubicin Hydrochloride Injection,” “Adriamycin (DOXOrubicin HCl) for Injection, USP,” and “Adriamycin (DOXOrubicin HCl) Injection, USP.” The documents also provide limited package presentation details through vial strengths and reconstitution instructions, including “10 mg doxorubicin HCl vial” and “50 mg doxorubicin HCl vial.” However, the documents do not provide NDC identifiers, manufacturer-labeler crosswalks beyond Pfizer and FDA SPL references, biosimilar relationships, multi-source generic methodology, or exhaustive claims pull methodology for ALL therapies through 2026-09-21. The supplied documents identify clofarabine injection as an Acute Lymphoblastic Leukemia therapy and show multiple manufacturers/labelers associated with the product, including Amneal Pharmaceuticals, Ingenus Pharmaceuticals, LLC, and Dr. Reddy’s Laboratories Inc. The documents consistently state that clofarabine injection is indicated "for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens." However, the documents do not provide NDC identifiers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology for United States claims data through 2026-09-21. The supplied documents identify several Acute Lymphoblastic Leukemia (ALL) therapies and limited coding/manufacturer information, but they do not provide an exhaustive U.S. claims-based drug identification universe through 2026-09-21. The documents identify blinatumomab through HCPCS code C9449, ARRANON (nelarabine) with sponsor/manufacturer SANDOZ and injectable presentation strength, and mercaptopurine oral suspension indicated for ALL maintenance therapy. However, the documents do not provide representative NDC identifiers, complete manufacturer or labeler mappings, package presentations across products, biosimilar relationships, multi-source generic mappings, or an exhaustive pull methodology. The supplied documents identify HCPCS-coded ALL cellular therapies relevant to claims identification, specifically tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents provide HCPCS identifiers and therapy descriptions including therapeutic-dose definitions and leukapheresis/dose preparation inclusion, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The available claims-identification details are HCPCS Q2042 for tisagenlecleucel, HCPCS C9073 for brexucabtagene autoleucel, and HCPCS C9301 for obecabtagene autoleucel. The supplied documents provide only a limited subset of an Acute Lymphoblastic Leukemia (ALL) drug-identification universe. They identify a generic clofarabine injection from Dr. Reddy’s Laboratories with NDC 43598-309-20 and an NDA nelarabine product (Arranon) from Sandoz with NDC 66758-165-94, including package presentations and marketing categories. The documents also identify BESPONSA (inotuzumab ozogamicin) as indicated for relapsed or refractory CD22-positive B-cell precursor ALL, but they do not provide NDCs, package configurations, biosimilar relationships, exhaustive manufacturer mappings, or a comprehensive pull methodology for all principal ALL therapies through 2026-09-21. The supplied documents identify representative NDCs for SPRYCEL (dasatinib) oral tablets from E.R. Squibb & Sons, L.L.C., including NDCs 0003-0528, 0003-0524, and 0003-0857. Package presentations include 60-tablet bottles and 30-tablet bottles packaged as "1 BOTTLE in 1 CARTON," with strengths of 50 mg, 70 mg, and 140 mg respectively. All listed products have marketing category "NDA" and marketing start dates ranging from 2006-06-27 to 2010-10-28. The documents do not provide biosimilar relationships, multi-source generic considerations, broader ALL therapy coverage, or an exhaustive pull methodology for claims-based drug identification through 2026-09-21. The supplied documents identify HCPCS-coded Acute Lymphoblastic Leukemia therapies but do not provide NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or an exhaustive pull methodology. The documents identify HCPCS code J9229 for inotuzumab ozogamicin, HCPCS code Q2040 for tisagenlecleucel, and HCPCS code Q2053 for brexucabtagene autoleucel. Because the documents are limited to HCPCS descriptions, the requested exhaustive drug identification universe for United States claims data through 2026-09-21 cannot be fully constructed from the supplied evidence. The supplied documents identify several Acute Lymphoblastic Leukemia-related HCPCS therapy codes and their drug descriptions, but they do not provide NDC identifiers, manufacturers or labelers, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive pull methodology. The documents identify HCPCS code Q2058 for obecabtagene autoleucel, HCPCS code J9039 for blinatumomab, and HCPCS code C9028 for inotuzumab ozogamicin. No document contains representative NDCs, package configurations, manufacturer mappings, biosimilar linkage data, or generic sourcing considerations. The supplied documents identify several principal Acute Lymphoblastic Leukemia (ALL) therapies relevant to relapsed/refractory or pediatric ALL treatment contexts, including “blinatumomab,” “inotuzumab,” and “PEGasparaginase.” However, the documents do not provide any NDC identifiers, manufacturer or labeler mappings, package presentations, biosimilar relationships, multi-source generic considerations, or exhaustive claims-based pull methodologies. Therefore, an exhaustive United States claims-data drug identification universe through 2026-09-21 cannot be constructed from these documents alone.
What are the standard adult dosing, route and administration considerations for the principal ALL agents?
The documents provide limited dosing and administration details for some therapies used in acute lymphoblastic leukemia (ALL), but they do not comprehensively describe all principal ALL therapies, complete cycle structures, or line-of-therapy identification patterns through 2026-09-21. For mercaptopurine used in ALL maintenance therapy, the labeling states that the "recommended starting dose of mercaptopurine oral suspension is 1.5 mg/kg to 2.5 mg/kg (50 mg/m 2 to 75 mg/m 2 ) orally once daily as part of combination chemotherapy maintenance regimen," with dose adjustment based on neutrophil counts and myelosuppression. The same source specifies administration considerations including oral suspension handling, dosing interval adjustments in renal impairment, and administration instructions. For imatinib in relapsed or refractory Philadelphia chromosome positive ALL, the document confirms the indication in adult patients but does not provide ALL-specific dosing schedules or cycle structures. The asparaginase consensus document states that "asparaginase is an integral component of therapy" in pediatric-inspired regimens for AYA and adult ALL populations and discusses administration barriers including "limited medical facilities and experienced staff to administer and manage pediatric-inspired regimens," but it does not provide standard adult dosing or schedules. The supplied documents describe administration and dosing patterns for select relapsed/refractory ALL therapies used in U.S. practice, including CAR-T products and nelarabine. TECARTUS for adult relapsed/refractory B-cell precursor ALL is administered intravenously after lymphodepleting chemotherapy, with a target dose of "1 × 10 6 CAR-positive viable T cells per kg body weight, with a maximum of 1 × 10 8 CAR-positive viable T cells," and requires premedication, identity verification, and tocilizumab availability before infusion. Nelarabine for relapsed/refractory T-ALL/T-LBL in adults is given as "1,500 mg/m² administered intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days," with discontinuation for neurologic toxicity grade 2 or greater and possible dose delays for hematologic reactions. KYMRIAH is identified as a CD19-directed autologous T-cell immunotherapy for "patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse," administered as an "intravenous infusion," but the supplied excerpt does not provide detailed adult ALL dosing schedules because the indication is pediatric/young adult only. The documents provide limited dosing and administration information for therapies used in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib and dasatinib product identification. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The supplied text does not provide adult ALL-specific standard dosing schedules, cycle structures, or administration setting guidance for imatinib, but it does describe oral daily dosing patterns in related leukemia studies: “patients were treated initially with 400 mg daily” with “Dose escalations ... from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily.” For dasatinib (SPRYCEL), the documents identify the dosage forms and oral route through “SPRYCEL TABLET ORAL” products with strengths including “20MG,” “50MG,” “70MG,” “80MG,” “100MG,” and “140MG,” but no ALL-specific dosing schedules or regimen structures are provided. The supplied documents provide dosing and administration details only for clofarabine in relapsed/refractory acute lymphoblastic leukemia, and specifically state that it is indicated for pediatric patients rather than all adult ALL therapies used in U.S. practice. Clofarabine is described as being administered "52 mg/m 2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle," with cycles repeated "approximately every 2 to 6 weeks" and subsequent cycles given "no sooner than 14 days from the starting day of the previous cycle and provided the patient’s ANC is ≥ 0.75 × 10 9 /L." The documents also describe claim-relevant administration considerations including supportive care with "intravenous fluids, antihyperuricemic treatment, and alkalinize urine," avoidance of administering other medications through the same IV line, monitoring during administration, and renal dose reduction "by 50% in patients with creatinine clearance (CrCL) between 30 mL/min and 60 mL/min." No standard adult dosing patterns, adult line-of-therapy structures, or comprehensive ALL regimens through 2026-09-21 are provided in the supplied records. The documents identify methotrexate as a therapy used in acute lymphoblastic leukemia (ALL) and state that it is administered as part of combination chemotherapy regimens, but they do not provide complete adult ALL regimen dosing schedules or cycle structures. The methotrexate labeling states that for neoplastic diseases clinicians should "Refer to the prescribing information for disease specific dosing recommendations" and that "Methotrexate Injection is used as part of a multi-drug regimen." Administration considerations for intermediate- and high-dose methotrexate include leucovorin rescue, daily monitoring, intravenous fluids, urine alkalinization, and glucarpidase use for toxic plasma concentrations with delayed clearance. The NCCN guideline excerpt states that ALL treatment recommendations include "risk-stratified treatment approaches" and that "patients be treated at specialized centers with expertise in the management of ALL." A claim-relevant cellular therapy code is also identified for tisagenlecleucel as "up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." The supplied documents provide limited information on dosing patterns and administration considerations for certain Acute Lymphoblastic Leukemia therapies, but they do not comprehensively describe standard adult regimens, cycle structures, or line-of-therapy identification used in United States clinical practice through 2026-09-21. For PEGasparaginase in ALL11 protocol patients, the documents state that “After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14,” and also describe a “continuous PEGasparaginase dosing schedule” with individualized dose reductions targeting trough activity levels. For CAR-T cell therapy in relapsed/refractory B-ALL, the documents describe the “bridging period between leukapheresis and CAR-T-cells reinfusion” as a treatment consideration but explicitly note that “there is currently no available guidelines.” For nelarabine (Arranon), the documents identify the product as “INJECTION INTRAVENOUS” with active ingredient concentration “NELARABINE 5 mg/mL,” but no adult dosing schedule or cycle information is provided. The documents provide adult dosing and administration information for doxorubicin used in acute lymphoblastic leukemia, but they do not comprehensively enumerate all principal ALL therapies used in United States clinical practice through 2026-09-21. For doxorubicin, the labeling states that for “Metastatic Disease, Leukemia, or Lymphoma” the “recommended dose of doxorubicin when used as a single agent is 60 to 75 mg/m 2 intravenously every 21 days,” and “when administered in combination with other chemotherapy drugs, is 40 to 75 mg/m 2 intravenously every 21 to 28 days.” Administration guidance specifies intravenous administration, including that clinicians should “Administer doxorubicin intravenously over 3 to 10 minutes” through “a central intravenous line or a secure and free-flowing peripheral venous line.” The documents also include claim-relevant cycle and exposure considerations such as “Cumulative doses above 550 mg/m 2 are associated with an increased risk of cardiomyopathy” and that lower doses or longer intervals may be considered for “heavily pretreated patients, elderly patients, or obese patients.” The supplied documents only partially address adult therapy administration patterns for Acute Lymphoblastic Leukemia (ALL) in U.S. For Philadelphia chromosome-positive (Ph+ ALL), the FDA labeling states that SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” and trial dosing exposures included “starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily.” The labeling also reports treatment duration information for lymphoid blast disease, including that “the median duration of treatment with SPRYCEL 140 mg once daily was ... 3 months (range 0.1–10 months) for lymphoid blast CML.” Separately, HCPCS coding documentation identifies blinatumomab as an injectable therapy using “HCPCS code J9039” defined as “Injection, blinatumomab, 1 microgram.” The documents do not provide complete standard adult dosing schedules, cycle structures, routes, line-of-therapy algorithms, or administration-setting details for the principal ALL regimens used through 2026. The supplied documents identify limited administration and claim-relevant information for Acute Lymphoblastic Leukemia (ALL) therapies, but they do not provide comprehensive standard adult dosing patterns, schedules, or cycle structures through 2026-09-21. Methotrexate Injection is indicated for ALL "as part of a combination chemotherapy regimen" and is labeled "for intravenous, intramuscular, subcutaneous, or intrathecal use," with additional administration considerations including preservative-free formulations for intrathecal use and restrictions related to benzyl alcohol-containing formulations. Brexucabtagene autoleucel HCPCS entries describe a "per therapeutic dose" administration with "up to 200 million autologous anti-cd19 car positive viable t cells" and include "leukapheresis and dose preparation procedures," which are claim-relevant administration components. The documents do not provide standard adult dose amounts, treatment schedules, line-of-therapy definitions, or cycle timing structures for these therapies. The documents identify several therapies used in Acute Lymphoblastic Leukemia and provide limited administration-related information through HCPCS descriptors and one FDA label, but they do not provide comprehensive standard adult dosing, schedules, or cycle structures. HCPCS files identify injectable products including blinatumomab, inotuzumab ozogamicin, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, methotrexate sodium, cytarabine, daunorubicin hydrochloride, rituximab, and CAR-T products including tisagenlecleucel and brexucabtagene autoleucel. The dasatinib label states that "DASATINIB tablets, for oral use" are indicated for "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy." CAR-T administration considerations are partially described because tisagenlecleucel HCPCS language specifies "including leukapheresis and dose preparation procedures, per infusion," and brexucabtagene autoleucel is described as "per therapeutic dose." The supplied documents identify doxorubicin as a therapy used in acute lymphoblastic leukemia and provide adult dosing, administration route, schedules, and some administration considerations, but they do not comprehensively cover all principal therapies used in United States clinical practice through 2026-09-21. For leukemia or lymphoma, doxorubicin is described as a single agent at "60 to 75 mg/m 2 intravenously every 21 days" or in combination therapy at "40 to 75 mg/m 2 intravenously every 21 to 28 days." Administration details include intravenous injection through "a central intravenous line or a secure and free-flowing peripheral venous line," with administration "over 3 to 10 minutes," and continuous infusion "only through a central catheter." The documents also describe cycle structure and claim-relevant modifications, including treatment on "day 1 of each 21 day treatment cycle" for "a total of four cycles," dose reductions for hepatic impairment, and cycle delays until recovery of blood counts. The supplied documents identify only limited therapy and administration information for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” and the formulation is specified as “METHOTREXATE tablets, for oral use.” The ASH 2026 guideline document for relapsed/refractory ALL states that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” However, the documents do not provide standard adult dosing, administration schedules, cycle structures, or detailed claim-relevant dosing patterns through 2026-09-21. The supplied documents do not provide standard adult dosing, administration routes, schedules, cycle structures, or detailed claim-relevant administration patterns for principal acute lymphoblastic leukemia therapies in United States clinical practice through 2026-09-21. The documents do state that treatment regimens differ between pediatric-inspired and adult-inspired approaches, and that pediatric-inspired regimens containing asparaginase are recommended frontline therapy for adolescents and young adults. The materials also note supportive care requirements, use of targeted agents in frontline therapy, and consideration of allogeneic hematopoietic stem cell transplantation in selected higher-risk patients, but they do not specify drug-level dosing schedules or administration details needed for regimen identification from claims. The supplied documents provide claim-relevant adult dosing, administration route, schedule, cycle structure, and administration-setting considerations for blinatumomab (BLINCYTO) and inotuzumab ozogamicin (BESPONSA) used in acute lymphoblastic leukemia. BLINCYTO is administered intravenously and includes hospitalization and steroid premedication requirements tied to treatment cycles for MRD-positive and relapsed/refractory B-cell precursor ALL. BESPONSA is administered by intravenous infusion with cycle-specific dosing on Days 1, 8, and 15, response-dependent cycle lengths, and mandatory corticosteroid, antipyretic, and antihistamine premedication. The documents do not provide comprehensive dosing and regimen details for all principal ALL therapies used in U.S. clinical practice through 2026-09-21. The documents identify certain Acute Lymphoblastic Leukemia (ALL) therapies and limited administration-related details, but they do not provide comprehensive adult regimen dosing, schedules, cycle structures, or line-of-therapy patterns through 2026-09-21. Blinatumomab and inotuzumab ozogamicin are identified in HCPCS coding as injectable products with billing units of "1 mcg" and "0.1 mg" respectively. Methotrexate tablets are identified for "treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen," but no ALL-specific adult maintenance dosing schedule, route timing, or cycle structure is provided in the supplied documents. The supplied documents identify several therapies used in Acute Lymphoblastic Leukemia (ALL), including methotrexate formulations, blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, brexucabtagene autoleucel, and obecabtagene autoleucel. The documents also mention transplantation approaches and post-transplant tyrosine kinase inhibitor maintenance strategies for Philadelphia chromosome positive ALL. However, the documents do not provide the requested standard adult dosing patterns, administration routes, treatment schedules, cycle structures, administration settings, or claim-relevant dosing details needed for regimen or line-of-therapy identification. The supplied documents identify HCPCS-coded therapies relevant to Acute Lymphoblastic Leukemia claims and provide limited administration-unit information, but they do not provide standard adult dosing patterns, schedules, cycle structures, line-of-therapy positioning, or administration-setting guidance. Inotuzumab ozogamicin is identified as an injectable product with HCPCS unit definition "0.1 mg." Obecabtagene autoleucel is identified as a CAR-positive viable T-cell therapy with dosing described as "up to 400 million cd19 car-positive viable t cells," including "leukapheresis and dose preparation procedures," and billed "per therapeutic dose" or "per infusion." The supplied documents identify several Acute Lymphoblastic Leukemia therapies and limited administration characteristics, but they do not provide standard adult dosing schedules, cycle structures, line-of-therapy rules, or administration-setting guidance. Iclusig (ponatinib hydrochloride) is described as an oral film-coated tablet with a 10 mg strength presentation, and SPRYCEL (dasatinib) is described as an oral tablet with a 140 mg strength presentation. The HCPCS entry identifies imatinib as "Imatinib 100 mg." No document provides treatment schedules, cycle timing, dose modifications, or claim-relevant regimen construction details. The supplied documents do not provide comprehensive United States adult ALL regimen details such as standard dosing, schedules, cycle structures, or administration-setting considerations. One FDA Drugs@FDA entry identifies ICLUSIG formulations and route relevant to ALL-related therapy identification: it lists "ICLUSIG TABLET ORAL" products with multiple strengths. A Chinese adult ALL guideline states that "systematic treatment regimens" and immunotherapies including antibodies and CAR-T products are used in adult ALL clinical practice, but it does not specify adult dosing patterns or cycle structures. The supplied documents identify dasatinib as an oral tablet product with multiple tablet strengths that may be relevant to Acute Lymphoblastic Leukemia regimen identification in claims data. The documents provide packaging, dosage strength, and oral route information for 20 mg, 50 mg, and 70 mg film-coated tablets. However, the documents do not provide standard adult dosing, treatment schedules, cycle structures, administration setting considerations, line-of-therapy usage, or claim-relevant dosing patterns for ALL treatment through 2026-09-21. The supplied documents identify dasatinib (SPRYCEL and generic dasatinib) as an oral tablet product used in U.S. practice, with available tablet strengths including 50 mg, 70 mg, and 140 mg. The documents also identify packaging quantities that may be relevant for claim-level regimen identification, including bottles containing 30 or 60 tablets. The supplied document identifies Arranon (nelarabine) as an intravenous injection product used in U.S. clinical practice packaging and formulation information. It specifies the formulation strength as "NELARABINE 5 mg/mL" and the administration route as "INJECTION INTRAVENOUS." The document does not provide standard adult dosing, treatment schedules, cycle structure, administration setting considerations, or claim-relevant dosing patterns for Acute Lymphoblastic Leukemia regimens or line-of-therapy identification. The supplied documents identify Iclusig (ponatinib hydrochloride) as an oral tablet product with multiple tablet strengths that could support claim-based identification of therapy exposure. The documents provide packaging and strength information for 15 mg, 30 mg, and 45 mg tablet presentations, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy positioning, or administration-setting considerations for Acute Lymphoblastic Leukemia treatment through 2026-09-21. The supplied documents identify dasatinib products used in U.S. practice for Acute Lymphoblastic Leukemia and establish oral tablet administration and available tablet strengths, but they do not provide standard adult dosing, treatment schedules, cycle structures, line-of-therapy use, or administration-setting considerations. The records show SPRYCEL and generic dasatinib as oral tablet products with 80 mg and 100 mg strengths packaged in bottles containing 30 tablets. The supplied documents identify certain Acute Lymphoblastic Leukemia therapies and their administration forms/routes, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy use, or administration-setting considerations. Dasatinib is identified as an oral tablet product with strengths including 20 mg and 50 mg. Clofarabine is identified as an intravenous injection product with concentration 1 mg/mL in a single-dose vial. The supplied documents identify IMKELDI as an oral imatinib formulation relevant to leukemia treatment identification, but they do not provide standard adult dosing, schedules, cycle structures, line-of-therapy criteria, or administration setting considerations for Acute Lymphoblastic Leukemia. The documents only specify that IMKELDI is an "imatinib oral" "SOLUTION ORAL" product with strength "80 mg/mL" and marketing details for the United States.
Line-of-therapy trigger rules (Trigger | Interpretation)
| Trigger | Interpretation |
|---|---|
| BLINCYTO induction or consolidation cycle consists of 28 days continuous IV infusion followed by 14-day treatment-free interval | May support cycle segmentation using 42-day total cycle structure in relapsed/refractory B-cell precursor ALL claims analyses. National Library of Medicine (DailyMed) |
| BLINCYTO continued therapy consists of 28 days continuous IV infusion followed by 56-day treatment-free interval | May support identification of maintenance/continued-treatment intervals with 84-day total cycle structure. National Library of Medicine (DailyMed) |
| BLINCYTO interruption no longer than 7 days | Continue same cycle if interruption after adverse reaction is 7 days or less. National Library of Medicine (DailyMed) |
| BLINCYTO interruption longer than 7 days | Start a new cycle if interruption due to adverse reaction exceeds 7 days. National Library of Medicine (DailyMed) |
| BESPONSA Cycle 1 duration | Cycle 1 is 3 weeks and may be extended to 4 weeks for CR/CRi or toxicity recovery. National Library of Medicine (DailyMed) |
| BESPONSA subsequent cycles | Subsequent cycles are 4 weeks in duration. National Library of Medicine (DailyMed) |
| BESPONSA interruption greater than 28 days | Consider permanent discontinuation after interruption greater than 28 days. National Library of Medicine (DailyMed) |
| HSCT-directed BESPONSA treatment | Recommended duration is 2 cycles for patients proceeding to hematopoietic stem cell transplant (HSCT). National Library of Medicine (DailyMed) |
| Standard U.S. claims line advancement algorithm | No comprehensive claims-based regimen start/stop, relapse episode, maintenance handling, or transplant episode algorithm supplied. National Library of Medicine (DailyMed) |
[VERIFIED] Evidence supports therapy-specific cycle and interruption rules only; comprehensive U.S. claims-based line-of-therapy logic was not supplied.
Regimen library (Regimen | Setting | Components)
| Regimen | Setting | Components |
|---|---|---|
| BESPONSA-based therapy | Relapsed or refractory CD22-positive B-cell precursor ALL in adult and pediatric patients 1 year and older | Inotuzumab ozogamicin. National Library of Medicine (DailyMed) |
| BLINCYTO-based therapy | Relapsed or refractory B-cell precursor ALL | Blinatumomab. National Library of Medicine (DailyMed) |
| FLAG comparator regimen | Investigator-choice chemotherapy comparator in relapsed/refractory ALL study | Fludarabine + cytarabine + granulocyte colony-stimulating factor. National Library of Medicine (DailyMed) |
| MXN/Ara-C comparator regimen | Investigator-choice chemotherapy comparator in relapsed/refractory ALL study | Mitoxantrone + cytarabine. National Library of Medicine (DailyMed) |
| HIDAC comparator regimen | Investigator-choice chemotherapy comparator in relapsed/refractory ALL study | High-dose cytarabine. National Library of Medicine (DailyMed) |
| Methotrexate-containing maintenance regimen | Maintenance therapy for ALL | Methotrexate as part of combination chemotherapy maintenance regimen. Bryant Ranch Prepack / DailyMed |
| Mercaptopurine-containing maintenance regimen | Maintenance therapy for ALL | Mercaptopurine as part of combination chemotherapy maintenance regimen. Hikma Pharmaceuticals USA Inc. |
| Pediatric-inspired asparaginase-containing regimens | Frontline AYA and adult ALL populations | Asparaginase-containing pediatric/pediatric-inspired regimens. American journal of hematology |
| Nelarabine regimen | Relapsed/refractory T-ALL/T-LBL after at least two prior chemotherapy regimens | Nelarabine. Alembic Pharmaceuticals Limited |
[VERIFIED] Sources identify selected therapies and treatment contexts but do not provide a comprehensive ALL regimen library or standardized alias framework.
Component and HCPCS/J-code mapping (Component drug | HCPCS code | Biosimilar / NDC considerations)
| Component drug | HCPCS code | Biosimilar / NDC considerations |
|---|---|---|
| Blinatumomab | J9039 | HCPCS description states "Injection, blinatumomab, 1 microgram"; alternate HCPCS C9449 also identified. CMS HCPCS Release Files |
| Inotuzumab ozogamicin | J9229 | HCPCS description states "Injection, inotuzumab ozogamicin, 0.1 mg"; alternate HCPCS C9028 also identified. CMS HCPCS Release Files |
| Rituximab | J9312 | FDA Purple Book identifies biosimilars Truxima (rituximab-abbs), Ruxience (rituximab-pvvr), and Riabni (rituximab-arrx). CMS HCPCS Release Files |
| Vincristine sulfate | J9370 | No biosimilar mapping supplied. CMS HCPCS Release Files |
| Doxorubicin hydrochloride | J9000 | Injectable doxorubicin formulations identified; no biosimilar mapping supplied. CMS HCPCS Release Files |
| Cyclophosphamide | J9070 | No biosimilar mapping supplied. CMS HCPCS Release Files |
| Methotrexate sodium | J9250 and J9260 | Multiple formulations and manufacturers identified for methotrexate products. CMS HCPCS Release Files |
| Cytarabine | J9100 | No biosimilar mapping supplied. CMS HCPCS Release Files |
| Daunorubicin hydrochloride | J9150 | No biosimilar mapping supplied. CMS HCPCS Release Files |
| Tisagenlecleucel | Q2042 | HCPCS includes therapeutic-dose CAR-T construct. CMS HCPCS Release Files |
| Brexucabtagene autoleucel | Q2053 | HCPCS description includes adult relapsed/refractory B-cell precursor ALL indication language. CMS HCPCS Release Files |
| Imatinib | S0088 | HCPCS description states "Imatinib 100 mg." CMS HCPCS Release Files |
[VERIFIED] Supplied evidence does not include CPT administration-code linkage or exhaustive multisource generic crosswalks.
NDC universe (Agent | Representative NDCs | Labeler | Coverage note)
| Agent | Representative NDCs | Labeler | Coverage note |
|---|---|---|---|
| Ponatinib hydrochloride (Iclusig) | 63020-533-30; 63020-535-30; 63020-535-60; 63020-536-30 | Takeda Pharmaceuticals America, Inc. | NDA oral tablet products with multiple strengths and bottle sizes. Takeda Pharmaceuticals America, Inc. |
| Dasatinib (SPRYCEL) | 0003-0528; 0003-0524; 0003-0857 | E.R. Squibb & Sons, L.L.C. | NDA oral tablet products with multiple strengths including 50 mg, 70 mg, and 140 mg. E.R. Squibb & Sons, L.L.C. |
| Dasatinib generic | 70377-083-11; 70377-085-11; 70377-088-11 | Biocon Pharma Inc. | ANDA generic oral tablet products. Biocon Pharma Inc. |
| Clofarabine injection | 43598-309-20 | Dr. Reddy's Laboratories Inc | ANDA intravenous injection product. Dr.Reddy's Laboratories Inc |
| Nelarabine (Arranon) | 0078-0683-61; 66758-165-94 | Novartis Pharmaceuticals Corporation; Sandoz Inc | Intravenous injection products for T-ALL/T-LBL contexts. Novartis Pharmaceuticals Corporation |
| Imatinib oral solution (IMKELDI) | 81927-201-01 | Shorla Oncology Inc. | NDA oral solution product. Shorla Oncology Inc. |
[ORIGINAL] Exhaustive pull method should combine FDA NDC Directory, DailyMed SPLs, HCPCS release files, and FDA Purple Book product relationships by active ingredient, brand, biosimilar suffix, dosage form, and marketing category.
Dosing and administration reference (Agent | Standard adult dosing | Route / schedule | Key administration notes)
| Agent | Standard adult dosing | Route / schedule | Key administration notes |
|---|---|---|---|
| Nelarabine | 1,500 mg/m² | Intravenously over 2 hours on Days 1, 3, and 5 repeated every 21 days | Adult relapsed/refractory T-ALL/T-LBL dosing. Alembic Pharmaceuticals Limited |
| BESPONSA (inotuzumab ozogamicin) | Cycle 1 dosing: 0.8 mg/m2 Day 1 and 0.5 mg/m2 Days 8 and 15 | Intravenous administration in 21-day cycle extendable to 28 days | Cycle extension permitted for CR/CRi or toxicity recovery. National Library of Medicine (DailyMed) |
| Doxorubicin | 60 to 75 mg/m2 every 21 days as single agent; 40 to 75 mg/m2 every 21 to 28 days in combination | Intravenous administration | Administer over 3 to 10 minutes through central or secure peripheral IV line. US Food and Drug Administration |
| Mercaptopurine oral suspension | 1.5 mg/kg to 2.5 mg/kg (50 mg/m2 to 75 mg/m2) once daily | Oral daily administration | Used as part of combination chemotherapy maintenance regimen. Hikma Pharmaceuticals USA Inc. |
| TECARTUS (brexucabtagene autoleucel) | 1 × 10^6 CAR-positive viable T cells/kg with maximum 1 × 10^8 cells | Intravenous CAR-T administration after lymphodepleting chemotherapy | Requires premedication and tocilizumab availability. National Library of Medicine (DailyMed) |
| Clofarabine | 52 mg/m2 daily for 5 consecutive days | Intravenous infusion over 2 hours in 28-day cycle | Subsequent cycles no sooner than 14 days from prior cycle start; supportive care measures recommended. US Food and Drug Administration |
| Dasatinib (SPRYCEL) | 140 mg once daily for Ph+ ALL context | Oral tablet administration | Indicated for adults with Ph+ ALL with resistance or intolerance to prior therapy. US Food and Drug Administration |
[VERIFIED] Evidence contains selective therapy-specific schedules and does not represent a comprehensive ALL dosing compendium.
Supportive-care and non-therapeutic exclusion list
The supplied evidence does not provide a comprehensive exclusion framework for supportive-care, prophylactic, rescue, adjunctive, transfusion-support, tumor-lysis, antiemetic, anti-infective, or non-therapeutic agents in ALL claims sequencing analyses. Identified supportive-care examples include prophylactic anticoagulation where "Low-molecular-weight heparins (LMWH) at prophylactic doses are recommended as the first-line strategy" and growth-factor support through LEUKINE, which is described as "a leukocyte growth factor indicated" to shorten neutrophil recovery time. The evidence also references transfusion-related endpoints such as "platelet (>20,000 cells/mm3) and RBC transfusion independence." Because no explicit exclusion list is supplied, supportive-care filtering logic would require analyst-defined governance using therapeutic-class exclusions and non-antineoplastic drug categorization.
Ambiguity rules (pharmacy vs medical benefit, same-drug different-intent)
The supplied evidence identifies both oral and infused ALL therapies but does not define U.S. pharmacy-benefit versus medical-benefit adjudication rules or dual-channel billing conventions. Oral products include SPRYCEL (dasatinib) and ICLUSIG (ponatinib), each described as oral tablet products, while infused or injected products include BLINCYTO, BESPONSA, doxorubicin, clofarabine, nelarabine, KYMRIAH, TECARTUS, and obecabtagene autoleucel. HCPCS-coded cellular therapies include administration-linked language such as "including leukapheresis and dose preparation procedures, per infusion" or "per therapeutic dose." Oral NDC-based therapies may appear predominantly in pharmacy claims while HCPCS-coded infused therapies may appear in medical claims, but the supplied evidence does not explicitly confirm adjudication pathways. Same-drug different-intent ambiguity may arise for methotrexate because the evidence identifies both injectable and oral formulations and use in maintenance regimens as well as meningeal leukemia prophylaxis/treatment contexts.
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| BLINCYTO administration cycles | DIRECT SIGNAL | DailyMed provides explicit 28-day infusion periods and treatment-free intervals. | No claims-specific line advancement algorithm supplied. |
| HCPCS-coded infused therapies | DIRECT SIGNAL | HCPCS/J-codes directly identify infused therapies including blinatumomab, inotuzumab ozogamicin, and CAR-T products. | CPT administration linkage and site-of-care logic not supplied. |
| Oral kinase inhibitor exposure | DIRECT SIGNAL | NDC package identifiers are supplied for dasatinib, ponatinib, and imatinib oral products. | Adherence and actual ingestion are not directly observable from dispensing claims. |
| Maintenance therapy phase | PROXY SIGNAL | Methotrexate and mercaptopurine are identified as part of combination chemotherapy maintenance regimens. | No standardized maintenance-phase timing or grouping logic supplied. |
| HSCT episode construction | PROXY SIGNAL | BESPONSA labeling references patients proceeding to HSCT and recommended cycle duration before transplant. | No transplant episode claims algorithm or procedural grouping logic supplied. |
| Supportive-care exclusion filtering | NOT OBSERVABLE | Sources mention supportive care broadly but do not define exclusion lists for claims sequencing. | No explicit exclusion framework or coding taxonomy supplied. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- The evidence supports therapy-specific cycle and interruption rules for BLINCYTO and BESPONSA but does not provide a complete U.S. claims-based line-of-therapy algorithm.
- HCPCS/J-code mappings are directly supported for major infused and cellular ALL therapies including blinatumomab, inotuzumab ozogamicin, rituximab, tisagenlecleucel, and brexucabtagene autoleucel.
- Multiple ALL treatment contexts are subpopulation-specific, including relapsed/refractory CD22-positive B-cell precursor ALL, Ph+ ALL, and relapsed/refractory T-ALL/T-LBL after at least two prior regimens.
- Representative NDC and package-level evidence exists for oral kinase inhibitors and selected injectables, including ponatinib, dasatinib, clofarabine, nelarabine, and imatinib oral solution products.
- Claims-based sequencing will require analyst-defined governance for regimen aliasing, maintenance grouping, supportive-care exclusion logic, and pharmacy-versus-medical routing because the supplied evidence does not standardize these constructs.
Assumptions made in this stage
- HCPCS-coded injectable and cellular therapies are treated as directly observable medical-claim exposures when corresponding codes appear in claims.
- Oral NDC products may require pharmacy-claim integration to avoid under-capture of kinase inhibitors and maintenance therapies.
- Regimen grouping and alias normalization cannot be fully standardized from supplied evidence and would require external governance definitions.
- Absence of explicit CPT administration-code mappings limits administration-setting specificity.
Evidence base for this stage: 84 item(s) from 9 source(s); 79 from approved sources, 5 supplementary web. Tiers represented: 1, 3.
Unanswered sub-questions
Stage 5 · Patient Journey Agent
Patient Journey Signals: Discontinuation, Monitoring & Outcomes
Core question: How does a patient move through the clinical journey?
Framework steps included
Step 11 (Treatment initiation, discontinuation and switching signals), Step 12 (Adverse events and toxicity management), Step 13 (Response, relapse and progression assessment), Monitoring cadence and MRD assessment, End states: transplant, cellular therapy, hospice, death
- Step 13A — Draft remission, transplant, hospice, death, maintenance and follow-up states
- Step 13B — Finalize journey end states and observable proxies
What happens in this stage
This stage establishes how patients with Acute Lymphoblastic Leukemia (ALL) move through treatment monitoring, toxicity management, remission assessment, and downstream outcome states using evidence from chemotherapy, bispecific antibody, antibody-drug conjugate, transplant-related, and CAR-T-related sources. The supplied evidence identifies interruption, discontinuation, dose-modification, hospitalization, remission, measurable residual disease (MRD), transplant-bridging, and relapse-related signals that may contribute to longitudinal patient journey reconstruction, while also noting that explicit administrative claims algorithms for line-of-therapy construction and monitoring cadence are not defined in the supplied documents.
Expected output
- Discontinuation and adverse-event signals by agent class (Agent class | Signature AE driving discontinuation or switch)
- Monitoring and response criteria (Assessment | Tool / criteria)
- Patient state model
- End-of-journey outcome states
- Claims observability table
- Key takeaways
Synthesis
Adult ALL induction therapy commonly includes “combination chemotherapy with prednisone, vincristine, and an anthracycline,” and some regimens add “asparaginase or cyclophosphamide.” Multiple therapy classes include toxicity-driven treatment modification signals, including BLINCYTO interruption or discontinuation for “Cytokine Release Syndrome (CRS)” and “Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS),” BESPONSA interruption or discontinuation for hepatotoxicity and veno-occlusive disease (VOD), and anthracycline discontinuation for cardiomyopathy. Doxorubicin-containing therapy is also associated with “serious infection, septic shock, requirement for transfusions, hospitalization, and death,” while vincristine-related severe toxicities were associated with “50% of normal dose” reductions in some patients. Treatment response assessment includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), bone marrow blast assessment, peripheral blood count recovery, and MRD-related milestones. MRD-related treatment positioning is reflected in BLINCYTO labeling for “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.” The supplied documents position hematopoietic stem cell transplant (HSCT) as a downstream pathway after response to therapies such as inotuzumab ozogamicin, while CAR-T therapy is described in the relapsed or refractory B-cell ALL setting. Administrative claims observability is strongest for hospitalization, transfusion, infusion encounters, treatment gaps, home infusion, transplant procedures, and dose-intensity changes, while MRD status, blast percentage, and remission definitions are primarily laboratory- and pathology-based rather than directly claims-based. The supplied documents do not define validated claims-based discontinuation rules, switching algorithms, or comprehensive monitoring cadence frameworks through 2026-09-21.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What are the common reasons for treatment discontinuation and dose modification in ALL?
The supplied documents report treatment interruption and discontinuation drivers primarily for the bispecific T-cell engager blinatumomab (BLINCYTO). The label states that "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO" and directs clinicians to "Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended," while "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS)" also require clinicians to "Interrupt or discontinue BLINCYTO as recommended." The label additionally describes interruption-related administration patterns that could be inferable in claims, including "re-initiations (e.g., if treatment is interrupted for 4 or more hours)," hospitalization recommendations at cycle starts, and fixed treatment-free intervals consisting of "28 days of continuous intravenous infusion followed by a 14-day treatment-free interval." The NCI PDQ document describes major ALL therapy classes used in induction, including "combination chemotherapy with prednisone, vincristine, and an anthracycline," with optional additions such as "asparaginase or cyclophosphamide," and notes regimen modification through "omission of L-asparaginase" and rapid relapse after imatinib-containing therapy, but it does not provide explicit claims-based discontinuation definitions, dose-reduction algorithms, or switching rules across ALL therapies. The supplied document addresses an anthracycline therapy class used in Acute Lymphoblastic Leukemia and reports discontinuation and dose-modification drivers centered on cardiomyopathy, hepatic impairment, infusion complications, and severe myelosuppression. Reported discontinuation drivers include: “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy” and “Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection.” Dose reduction patterns are described for hepatic impairment, including “1.2–3 mg/dL 50%” and “3.1–5 mg/dL 75%,” and interruption/administration modification signals include “Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur” and “Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation.” The document also reports severe toxicity events that could be inferable in administrative claims data, including “serious infection, septic shock, requirement for transfusions, hospitalization, and death,” cardiomyopathy monitoring, and hospitalization-related complications, but it does not provide explicit claims-based line-of-therapy discontinuation algorithms, switching definitions, or coverage of other major ALL therapy classes. The supplied documents report toxicity-driven dose reduction and interruption signals for several ALL therapy classes, but they do not provide a comprehensive cross-class analysis of discontinuation, switching, or claims-based line-of-therapy algorithms through 2026-09-21. For vincristine-based therapy, co-administration with azoles was associated with increased neurotoxicity, CNS toxicity, intensive care use, and dose reduction; the text states that "Because of severe toxicities, vincristine treatment was significantly reduced (50% of normal dose) in several patients." For inotuzumab ozogamicin (BESPONSA), the label reports hepatotoxicity/VOD and liver test elevations as drivers of "dosing interruption, dose reduction, or permanent discontinuation," and notes that treatment cycles "may be extended up to 28 days" to allow recovery from toxicity. The documents do not define claims-based discontinuation rules, switching algorithms, or specific administrative claims indicators for line-of-therapy construction, although observable claims proxies inferable from the text could include ICU treatment, infusion timing extensions, and reduced administered dose intensity. The document describes major ALL therapy classes and some treatment-modification contexts, but it does not report administrative-claims algorithms for discontinuation, interruption, switching, or line-of-therapy construction. It states that ALL treatment commonly includes "Long-term chemotherapy (chemo)" and that "Other types of drugs, such as targeted drugs or immunotherapy, are sometimes part of treatment as well," with stem cell transplant as another option. Dose modification is mentioned for older or medically frail patients, where they "might not be able to tolerate an intensive induction regimen" and "reduced doses of many of these same drugs might be used." Toxicity- or tolerability-related treatment adjustment is indirectly referenced through statements that induction therapy is intensive, may require hospitalization, and that "serious infections or other complications can occur," but the document does not define discontinuation, interruption, switching rules, or claims-observable indicators through 2026-09-21. The supplied document only reports treatment modification and interruption drivers for doxorubicin-containing chemotherapy used in conditions including acute lymphoblastic leukemia, and it does not cover all major ALL therapy classes or comprehensive claims-based line-of-therapy algorithms through 2026-09-21. Reported discontinuation/interruption or dose-modification drivers include cardiotoxicity risk management, neutropenic fever/infection, delayed blood count recovery, unresolved nonhematologic toxicities, hyperbilirubinemia, and infusion-related extravasation concerns. Observable or inferable administrative claims signals from these events may include delayed treatment cycles, reduced administered dose intensity, therapy restarts after gaps, and supportive care or complication coding associated with neutropenic fever/infection or toxicity management, but the document does not explicitly define claims-based discontinuation rules. The supplied documents report that maintenance therapy for ALL commonly involves oral 6-mercaptopurine (6-MP) and methotrexate (MTX), and that these agents are associated with tolerability-driven dose modifications and adverse events. One study specifically aimed "to describe real-world dose adjustments of MTX and 6-MP during the maintenance therapy in young adults" and noted that these oral therapies "frequently cause adverse events." The documents do not provide comprehensive information on treatment discontinuation drivers, interruption patterns, therapy switching signals across all major ALL therapy classes, or validated administrative-claims definitions for discontinuation and line-of-therapy construction through 2026-09-21.
What adverse events are most clinically significant for ALL therapies?
The documents identify several major ALL therapy classes and associated clinically significant adverse events. Conventional induction chemotherapy regimens for adult ALL include "prednisone, vincristine, and an anthracycline," with some regimens adding "asparaginase or cyclophosphamide." BLINCYTO (blinatumomab), a "bispecific CD19-directed CD3 T-cell engager," carries boxed warnings for "Cytokine Release Syndrome (CRS), which may be life-threatening or fatal" and "Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal," with recommendations to "Interrupt or discontinue BLINCYTO" and hospitalization recommendations during early treatment cycles. BESPONSA (inotuzumab ozogamicin), a "CD22-directed antibody and cytotoxic drug conjugate," is associated with "Hepatotoxicity, including fatal and life-threatening VOD," "higher post-HSCT non-relapse mortality," "Myelosuppression," "Infusion Related Reactions," and "QT Interval Prolongation"; the label states that liver test elevations "may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA" and that treatment should be "Permanently discontinue[d]" if VOD occurs. The supplied documents do not directly describe United States claims-data analyses through 2026-09-21 or explicitly define claims-identifiable adverse-event markers beyond hospitalization recommendations, treatment interruption/discontinuation instructions, dose modifications, and transplant-associated mortality risks. The supplied documents only address the anthracycline class represented by doxorubicin in ALL therapy, not all major ALL therapy classes. For doxorubicin, clinically significant adverse events include “Cardiomyopathy,” “Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS),” “Extravasation and Tissue Necrosis,” and “Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death.” The labeling also describes treatment modification and escalation patterns tied to adverse events, including that “Patients in the NSABP B-15 study could have dose modifications of AC to 75% of the starting doses for neutropenic fever/infection,” and that “the next cycle of treatment cycle was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm3 and the platelet count was ≥100,000 cells/mm3 and nonhematologic toxicities had resolved.” Claims-identifiable markers explicitly described include hospitalization, transfusion requirement, septic shock, neutropenic fever/infection, skin grafting, and wide excision surgery associated with extravasation injuries. The document identifies major ALL therapy classes as "chemotherapy (chemo)," "targeted drugs," and "immunotherapy," noting that "For some people, a stem cell transplant might also be an option." During induction chemotherapy, treatment is described as intensive, and the document states that patients "may spend some or much of this time in the hospital, because serious infections or other complications can occur" and that "Sometimes, complications can be life-threatening." The text also describes treatment modification patterns based on tolerability, stating that older patients or those with serious health conditions "might not be able to tolerate an intensive induction regimen," so "reduced doses of many of these same drugs might be used" and "Other options could include treatment with the antibody-drug conjugate inotuzumab ozogamicin or a steroid drug such as dexamethasone or prednisone." The supplied document does not provide claims-data methodologies, adverse-event coding markers, discontinuation patterns, escalation patterns, or detailed toxicity profiles by therapy class through 2026-09-21. The supplied documents identify major ALL therapy categories and some general disease- and treatment-related clinical issues, but they do not provide a detailed mapping of clinically significant adverse events by therapy class, nor claims-based hospitalization, discontinuation, escalation, or treatment-modification patterns through 2026-09-21. The National Cancer Institute document states that “Previous chemotherapy and exposure to radiation may increase the risk of developing ALL,” and that “Leukemia may affect red blood cells, white blood cells, and platelets.” The Medscape reference lists major treatment components including “Induction Chemotherapy,” “Consolidation Therapy,” “Maintenance Therapy,” “CNS Prophylaxis,” and “Treatment of Ph Chromosome–Positive ALL,” but does not describe associated toxicities, hospitalization triggers, or claims-identifiable adverse-event markers. No supplied document reports claims-data analyses, hospitalization-associated adverse events, treatment discontinuation patterns, or escalation patterns tied to ALL therapy adverse events.
How is treatment response and measurable residual disease assessed in ALL?
The supplied document indicates that the CIBMTR Disease Classification Form contains an Acute Lymphoblastic Leukemia section and captures disease-specific response information for hematopoietic cell transplantation reporting, including “disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.” It also states that “Status at Transplantation” should be determined using CIBMTR manual guidelines because “there are many interpretations of disease response criteria,” and that “a majority of the disease response criteria are established by an international working group.” The document further specifies that diagnosis dates may derive from “bone marrow or tissue biopsy” or “pathological or laboratory assessment.” However, the document does not provide explicit Acute Lymphoblastic Leukemia response milestone definitions, measurable residual disease (MRD) criteria, MRD laboratory testing methods, monitoring schedules, or any discussion of what is directly observable, partially inferable, or absent in United States administrative claims data through 2026-09-21. The documents describe treatment-response evaluation in adult acute lymphoblastic leukemia (ALL) primarily through remission and survival outcomes after induction and postremission therapy. Reported response milestones include “complete response rates that range from 60% to 90%” and “436 achieved complete remission (78% +/- 2% for DNR v 74% +/- 3% for ZRB; P = .3),” as well as monitoring outcomes such as “disease relapse at a median of 58 days after the start of therapy,” “median duration of 2.2 months,” and “3-year disease-free survival.” Laboratory and pathology assessment evidence includes the existence of a “Bone marrow Pathology biopsy report” defined by LOINC code 33721-2. However, the supplied documents do not describe measurable residual disease (MRD) criteria, MRD laboratory methods, flow cytometry, molecular assays, PCR, next-generation sequencing, or any explicit administrative claims observability framework; therefore, direct versus inferable claims-data observability for these components cannot be determined from the documents. The document describes treatment response assessment criteria for relapsed or refractory CD22-positive B-cell precursor ALL using complete remission (CR), complete remission with incomplete hematologic recovery (CRi), bone marrow blast percentage, peripheral blood leukemic blasts, peripheral blood count recovery, and extramedullary disease resolution. It also references measurable residual disease (MRD) negativity as a treatment milestone relevant to hematopoietic stem cell transplant (HSCT) planning, but it does not describe MRD laboratory testing methods or monitoring procedures. The document includes laboratory and clinical monitoring elements such as bone marrow assessment, absolute neutrophil count (ANC), platelet count, bilirubin, AST/ALT, and peripheral blast count thresholds. The supplied source does not address administrative claims data observability, so no direct evidence is available regarding which response or MRD components are directly observable, partially inferable, or absent in claims data through 2026-09-21. The supplied documents provide only limited information relevant to treatment response evaluation in Acute Lymphoblastic Leukemia. One document identifies a bone marrow biopsy-related assessment element through the LOINC entry "Guidance for biopsy of Bone marrow," indicating that bone marrow biopsy procedures are represented in clinical terminology systems. Another document references the topic "Novel Therapies for Childhood Acute Lymphoblastic Leukemia" but does not provide details on response assessment criteria, measurable residual disease testing methods, monitoring procedures, response milestone definitions, or administrative claims observability limitations. The documents describe treatment response assessment in acute lymphoblastic leukemia (ALL) primarily through measurable residual disease (MRD) testing and risk stratification. MRD positivity is described as “commonly defined as at least 1 leukemia cell in 10,000 normal cells (expressed as 10-4)” and FDA-approved therapeutic decision making included “first or second complete remission with MRD greater than or equal to 0.1%.” Reported MRD laboratory methods include flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS), with monitoring performed on bone marrow aspirates and in some settings peripheral blood; flow cytometry requires “the first pull of bone marrow aspiration,” PCR is used commonly for “BCR/ABL gene rearrangements,” and NGS can monitor “immunoglobulin heavy chain receptor rearrangements or T-cell receptors.” The supplied documents do not directly address administrative claims data observability, but they describe clinical and laboratory components that are procedure- and result-based rather than billing-based, so direct claims observability of MRD status, assay sensitivity thresholds, immunophenotype findings, and remission definitions is not explicitly documented in the sources.
What is the role of allogeneic transplant and CAR-T as end states in ALL?
The supplied document positions BLINCYTO within several Acute Lymphoblastic Leukemia (ALL) treatment phases, including measurable residual disease treatment, relapsed/refractory therapy, and consolidation therapy. The document states that BLINCYTO is indicated for “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%,” for “Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL),” and for “CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.” The document also describes induction, consolidation, and “continued therapy” cycles for relapsed/refractory disease. However, the supplied material does not describe the positioning of allogeneic hematopoietic stem cell transplant or CAR-T therapy within the ALL treatment journey, does not define terminal pathway states or post-treatment outcomes after those therapies, and does not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The supplied document positions hematopoietic stem cell transplant (HSCT) as a downstream treatment pathway for patients with relapsed or refractory CD22-positive B-cell precursor ALL who respond to therapy with inotuzumab ozogamicin. The label states, “For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles,” with a possible third cycle if remission and MRD negativity are not achieved, indicating use as a bridge-to-transplant or consolidation approach before HSCT. The document also describes post-transplant outcome states and risks, including “Hepatotoxicity, including fatal and life-threatening VOD” and “higher post-HSCT non-relapse mortality rate.” The supplied material does not address CAR-T therapy positioning, salvage versus terminal pathway frameworks across all ALL patients in the United States, or claims-based procedure identification methods through 2026-09-21. The documents position allogeneic bone marrow transplant within the treatment journey for adult ALL as a consideration after induction or other chemotherapy responses because “remissions are generally short with conventional ALL chemotherapy clinical trials.” One document identifies tisagenlecleucel specifically as “a CAR-T cell therapy” used “for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States,” which places CAR-T therapy in the relapsed/refractory setting. The supplied documents do not describe transplant or CAR-T as consolidation, salvage, or terminal pathway states in broader U.S. ALL populations, do not describe post-treatment outcome states or bridge pathways, and do not provide claims-based procedure identification methods or coding approaches through 2026-09-21. The documents position CAR-T therapy for ALL primarily in the relapsed or refractory setting and describe bridging chemotherapy before infusion, while also discussing survivorship, toxicities, infections, and death after therapy as outcome states. One document states that “Three CAR T-cell products have been approved by the FDA to treat patients with relapsed or refractory B-cell ALL,” and another states that “While the CAR T cells are being manufactured, patients may receive additional chemotherapy to prevent their disease from progressing.” The supplied documents also describe post-treatment states including “short- and long-term side effects and toxicities,” “Infections,” survivorship, and “why some patients die from a CAR T-related toxicity.” The supplied documents do not provide a positioning for allogeneic hematopoietic stem cell transplant as consolidation, salvage, or terminal therapy, and they do not provide claims-based procedure identification methods or coding algorithms through 2026-09-21.
What monitoring cadence is recommended during and after ALL therapy?
The document states that for adult ALL, “Treatment for ALL typically lasts for at least 2 years,” and that after treatment ends patients require “frequent follow-up exams and tests for at least several years,” which “will probably be every month or so at first, then less often as time passes.” Monitoring activities described include clinical examinations, symptom review, “blood tests, bone marrow exams, or other tests to look for treatment side effects or signs of leukemia,” as well as survivorship planning for “follow-up exams and tests,” “screening tests for other types of cancer,” and “tests to look for long-term health effects from your leukemia or its treatment.” The document also notes ongoing toxicity and side-effect monitoring, stating that “Almost any cancer treatment can have side effects,” and patients should report “any changes or problems.” The supplied document does not describe which monitoring activities can be captured or inferred from administrative claims data, and it does not provide detailed active-treatment monitoring cadence beyond treatment duration. The supplied document describes components of active treatment for adult Acute Lymphoblastic Leukemia (ALL) but does not provide recommended monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up, and it does not discuss which monitoring activities can be captured in administrative claims data. The document states that induction therapy commonly uses multiagent chemotherapy regimens and mentions supportive care measures and hematopoietic growth factors during remission-induction therapy. No laboratory surveillance schedules, imaging frequency, toxicity-monitoring cadence, remission follow-up intervals, or claims-based monitoring definitions are provided in the supplied text. The supplied document does not provide recommendations for monitoring cadence during active treatment, remission surveillance, or post-treatment follow-up for Acute Lymphoblastic Leukemia in the United States. It also does not describe laboratory surveillance frequency, imaging schedules, toxicity monitoring cadence, or administrative claims methodologies. The only monitoring-related activity identifiable from the document is the existence of a LOINC-coded bone marrow pathology biopsy report: LOINC code 33721-2 is defined as "Bone marrow Pathology biopsy report." The supplied documents describe ALL management as prolonged and involving ongoing outpatient monitoring, but they do not provide specific recommended monitoring cadences for active treatment, remission surveillance, or post-treatment follow-up in the United States. One document states that "Over the course of 2 to 3 years, patients undergo treatment for induction, consolidation, maintenance, and possibly hematopoietic cell transplantation" and that outpatient management includes "adherence to medications, ambulatory treatment, and monitoring." The documents also describe toxicity and adverse-event monitoring during outpatient therapies, including that "nurses can provide close monitoring and rapid recognition of adverse events" for CAR-T therapy and that blinatumomab may continue as "home infusion therapy." These activities could potentially correspond to administrative claims-captured events such as outpatient visits, ambulatory treatments, home infusion services, medication-related encounters, and hospitalization periods, but the documents do not explicitly define claims-based capture methods, laboratory surveillance schedules, imaging schedules, or remission follow-up intervals.
Discontinuation and adverse-event signals by agent class (Agent class | Signature AE driving discontinuation or switch)
| Agent class | Signature AE driving discontinuation or switch | Claims-observable or inferable signal | Evidence |
|---|---|---|---|
| Bispecific CD19-directed CD3 T-cell engager (BLINCYTO) | Cytokine Release Syndrome (CRS); Neurological toxicities including ICANS requiring interruption or discontinuation | Hospitalization at cycle start, infusion interruption, therapy restart after gaps, corticosteroid treatment | “Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.”; “Interrupt or discontinue BLINCYTO and treat with corticosteroids as recommended.” National Library of Medicine (DailyMed) |
| CD22-directed antibody-drug conjugate (BESPONSA) | Hepatotoxicity including VOD; liver test elevations requiring interruption, dose reduction, or permanent discontinuation | Extended treatment cycles, discontinuation before HSCT, liver monitoring encounters | “Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA.”; “Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA.” National Library of Medicine (DailyMed) |
| Anthracycline therapy (doxorubicin-containing regimens) | Cardiomyopathy; severe myelosuppression; neutropenic fever/infection; extravasation | Hospitalization, transfusion claims, delayed cycles, reduced dose intensity, supportive care utilization | “Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy”; “Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur.” Pfizer Laboratories Div Pfizer Inc |
| Vincristine-based therapy | Severe toxicities associated with dose reduction | Reduced administered dose intensity | “Because of severe toxicities, vincristine treatment was significantly reduced (50% of normal dose) in several patients.” Journal of Clinical Oncology |
| Multiagent chemotherapy regimens | Neutropenic fever/infection and unresolved toxicities leading to delayed cycles or dose modification | Treatment gaps, supportive care claims, hospitalization | “Patients in the NSABP B-15 study could have dose modifications of AC to 75% of the starting doses for neutropenic fever/infection.”; “the next cycle of treatment cycle was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm 3 and the platelet count was ≥100,000 cells/mm 3 and nonhematologic toxicities had resolved.” US Food and Drug Administration |
[VERIFIED] Supplied documents do not define validated administrative claims algorithms for line-of-therapy construction or switching definitions across all ALL therapies through 2026-09-21.
Monitoring and response criteria (Assessment | Tool / criteria)
| Assessment | Tool / criteria | Claims observability | Evidence |
|---|---|---|---|
| Complete remission (CR) | “< 5% blasts in the bone marrow,” absence of peripheral blood leukemic blasts, platelet recovery, ANC recovery, and resolution of extramedullary disease | Bone marrow biopsy procedures may be observable; remission status itself not directly observable in claims | “CR is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts (platelets ≥ 100 × 10 9 /L and absolute neutrophil counts anc ≥ 1 × 10 9 /L) and resolution of any extramedullary disease.” National Library of Medicine (DailyMed) |
| Complete remission with incomplete hematologic recovery (CRi) | Bone marrow remission with incomplete platelet and/or ANC recovery | Laboratory thresholds not directly observable in claims | “CRi is defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukemic blasts, incomplete recovery of peripheral blood counts (platelets < 100 × 10 9 /L and/or ANC < 1 × 10 9 /L) and resolution of any extramedullary disease.” National Library of Medicine (DailyMed) |
| MRD assessment | MRD negativity used as treatment milestone; MRD ≥0.1% referenced in indication language | MRD laboratory results are not directly observable in administrative claims | “A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles.”; “CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.” National Library of Medicine (DailyMed) |
| Bone marrow assessment | Bone marrow biopsy reporting and pathology assessment | Procedure encounters may be claims-observable | “LOINC code 33721-2 is defined as ‘Bone marrow Pathology biopsy report’”; “LOINC code 87014-7 is defined as ‘Guidance for biopsy of Bone marrow’.” U.S. National Library of Medicine |
| Disease response documentation | Disease-specific laboratory results, cytogenetic and molecular markers, staging, and disease status | Most response details are registry- or laboratory-based rather than claims-based | “Key reporting areas differ depending on the disease reported ... and may include disease type, subtype, transformations, cytogenetic and molecular markers, disease-specific laboratory results, staging, and disease status.” CIBMTR |
[VERIFIED] Supplied documents do not provide comprehensive MRD assay workflows, explicit claims observability frameworks, or validated claims-response algorithms through 2026-09-21.
Claims observability table
| Concept | Classification | Basis | Limitation |
|---|---|---|---|
| Hospitalization during induction or toxicity management | DIRECT SIGNAL | “You may spend some or much of this time in the hospital, because serious infections or other complications can occur.” American Cancer Society | Hospitalization reason and disease severity may not be fully distinguishable in claims |
| Transfusion requirement | DIRECT SIGNAL | “requirement for transfusions” associated with severe myelosuppression Pfizer Laboratories Div Pfizer Inc | Underlying remission status or toxicity grade is not directly available |
| Bone marrow biopsy encounter | DIRECT SIGNAL | “Bone marrow Pathology biopsy report” and “Guidance for biopsy of Bone marrow” LOINC entries U.S. National Library of Medicine | Claims do not provide marrow blast percentage or MRD result |
| Treatment interruption or delayed cycle | PROXY SIGNAL | Delayed cycles and interruption language described for BLINCYTO and chemotherapy National Library of Medicine (DailyMed); US Food and Drug Administration | Gap duration thresholds for discontinuation are not defined |
| Dose reduction | PROXY SIGNAL | “50% of normal dose” vincristine reductions and AC dose modifications to “75%” Journal of Clinical Oncology; US Food and Drug Administration | Actual administered dose intensity may not be fully measurable across benefit structures |
| MRD status | NOT OBSERVABLE | MRD negativity and MRD thresholds are laboratory-defined clinical concepts National Library of Medicine (DailyMed) | No supplied claims-based MRD capture methodology |
| Complete remission status | NOT OBSERVABLE | CR and CRi definitions rely on marrow blasts and laboratory recovery thresholds National Library of Medicine (DailyMed) | Administrative claims lack direct remission result fields |
| Home infusion and ambulatory monitoring | PROXY SIGNAL | BLINCYTO may continue as “home infusion therapy” and outpatient monitoring is referenced established answer synthesis | Specific coding approaches were not provided in supplied documents |
[INFERENCE] Observability classifications reflect whether the supplied evidence describes procedure-, encounter-, or laboratory-based events that could plausibly appear in administrative claims.
Patient state model
The supplied documents describe ALL treatment as a prolonged, multiphase journey that includes induction, consolidation, maintenance, remission surveillance, relapsed or refractory treatment, and possible HSCT or CAR-T pathways. Adult induction therapy commonly uses “combination chemotherapy with prednisone, vincristine, and an anthracycline,” with some regimens adding “asparaginase or cyclophosphamide.” Response states include CR, CRi, MRD positivity, MRD negativity, relapse, and transplant eligibility. BLINCYTO is positioned for “CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy” and for “first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.” BESPONSA is positioned as a bridge toward HSCT because “For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles.” CAR-T therapy is described in relapsed or refractory B-cell ALL settings, including bridging chemotherapy during manufacturing periods. A claims-oriented state sequence could therefore include diagnosis → induction chemotherapy → remission assessment → consolidation/maintenance → relapse or MRD-positive disease → immunotherapy or transplant pathway → survivorship, relapse, or death.
End-of-journey outcome states
The supplied evidence describes several downstream outcome states for ALL patients, including complete remission, MRD negativity, relapse, post-transplant complications, long-term remission, survivorship, hospitalization, and death. NCI materials report that “Current multiagent induction regimens result in complete response rates that range from 60% to 90%,” while another study reported that “436 achieved complete remission.” Relapse outcomes are described as “disease relapse at a median of 58 days after the start of therapy” and “median duration of 2.2 months.” Post-HSCT complications include “Hepatotoxicity, including fatal and life-threatening VOD” and “higher post-HSCT non-relapse mortality rate.” Long-term survivorship outcomes are also described, including “Long-term survival (five + years)” among patients achieving complete remission. Claims-identifiable terminal or downstream states may include hospice-related utilization, repeated hospitalization, transplant admission, intensive supportive care, or prolonged absence of further therapy, but these algorithms were not defined in the supplied evidence.
Key takeaways
1. BLINCYTO, BESPONSA, anthracyclines, and vincristine-containing regimens all include toxicity-driven interruption, discontinuation, or dose-modification signals relevant to patient journey reconstruction. treatment_modification
2. ALL response assessment relies heavily on bone marrow findings, blood count recovery, and MRD-related milestones rather than claims-native outcomes. response_monitoring
3. HSCT and CAR-T therapy are positioned primarily in downstream or relapsed/refractory pathways within the supplied evidence. advanced_therapy
4. Administrative claims are more suitable for detecting encounters, hospitalizations, procedures, transfusions, and treatment gaps than for directly measuring remission or MRD status. claims_observability
5. The supplied documents do not define validated claims-based line-of-therapy algorithms, discontinuation thresholds, or standardized monitoring cadence frameworks through 2026-09-21. evidence_limitation
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| Hospitalization for induction therapy or severe toxicity | DIRECT SIGNAL | “You may spend some or much of this time in the hospital, because serious infections or other complications can occur.” | Claims do not directly identify remission status or exact toxicity grade. |
| Transfusion utilization | DIRECT SIGNAL | Doxorubicin labeling references “requirement for transfusions.” | Claims alone may not distinguish disease-related from treatment-related cytopenias. |
| Treatment interruption or delayed cycle | PROXY SIGNAL | BLINCYTO interruption guidance and chemotherapy cycle delay language are reported in supplied documents. | Explicit discontinuation thresholds and switching definitions are not supplied. |
| Dose reduction | PROXY SIGNAL | Vincristine “50% of normal dose” reductions and AC reductions to “75%” are described. | Actual administered dose intensity may be incomplete in some claims environments. |
| MRD positivity or negativity | NOT OBSERVABLE | MRD is described through laboratory-defined thresholds and response criteria. | Administrative claims do not contain direct MRD assay results in the supplied evidence. |
| Complete remission status | NOT OBSERVABLE | CR and CRi definitions require marrow blast assessment and laboratory recovery thresholds. | Administrative claims lack direct remission outcome fields. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- Cytokine Release Syndrome, ICANS, hepatotoxicity/VOD, cardiomyopathy, neutropenic fever, and severe myelosuppression are repeatedly linked to treatment interruption or discontinuation across several ALL therapy classes. safety_signal
- Complete remission and CRi definitions depend on marrow blast thresholds, peripheral blood count recovery, and extramedullary disease resolution. response_state
- BLINCYTO indications specifically reference CD19-positive B-cell precursor ALL subpopulations, including MRD-positive disease and Philadelphia chromosome-negative consolidation settings. subpopulation_scope
- BESPONSA labeling positions therapy as a bridge toward HSCT for relapsed or refractory CD22-positive B-cell precursor ALL. transplant_pathway
- Claims-derived patient journeys will rely primarily on observable encounter patterns, infusion timing, hospitalization, transfusions, and procedure utilization rather than direct laboratory response measures. claims_analytics
Assumptions made in this stage
- Claims-based treatment gaps, delayed cycles, and dose-intensity reductions may function as proxy indicators of toxicity-related interruption when explicit discontinuation coding is unavailable.
- Bone marrow biopsy procedures may be observable through procedure or pathology-related claims even when biopsy results are not available.
- The supplied evidence does not provide validated claims-based algorithms for ALL line-of-therapy construction through 2026-09-21.
- The supplied evidence does not define standardized MRD testing cadence or remission surveillance schedules for all ALL populations.
Evidence base for this stage: 63 item(s) from 8 source(s); 51 from approved sources, 12 supplementary web. Tiers represented: 1, 2, 3.
Unanswered sub-questions
Stage 6 · Information Synthesis Agent
Unmet Need Synthesis & QA Validation
Core question: Where are the gaps, conflicts and limitations?
Framework steps included
Step 14 (Compare guidelines vs labels vs literature vs real-world evidence), Step 15 (Identify unmet needs and evidence gaps), Surface contradictions between sources, Document assumptions and limitations, Run QA and SME review readiness assessment
- Step 14A — Early unmet-need, treatment-gap, delayed-diagnosis, access and off-label-use evidence collection
- Step 14B — Compare disease evidence, diagnosis practice, guidelines, labels, codes, regimens, monitoring and outcomes
- Step 14C — Classify contradictions, unmet needs, evidence limitations, data-observability gaps and unresolved assumptions
- Step 15A — Define QA rules, source hierarchy, schemas, version controls and acceptance thresholds
- Step 15B — Rolling QA workers active during execution
- Step 15C — Clinical SME review of assumptions, codes, regimens, conflicts and limitations
What happens in this stage
This stage consolidates unresolved evidence gaps, methodological constraints, observability limitations, and QA considerations affecting construction and validation of claims-derived lines of therapy for Acute Lymphoblastic Leukemia (ALL) in United States administrative data through 2026-09-21. It establishes where published evidence supports only partial inference, where treatment sequencing and regimen definitions remain inconsistent or incompletely standardized, and where clinically important disease attributes depend on molecular, remission, transplant, or biomarker information not directly available in claims data.
Expected output
- Unmet-need synthesis (Gap area | Description)
- Contradiction table
- Assumptions
- Limitations
- QA checklist
- QA / SME sign-off checklist
- Readiness assessment
Synthesis
The supplied evidence indicates that ALL treatment complexity creates challenges for consistent regimen classification because “The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps” and “In adult ALL there is no standard which drugs to give and how to combine them.” Evidence relevant to claims-based sequencing is limited to selected retrospective definitions such as patients who “switch[ed] from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia,” including a report that “35/154 (22.7%) patients switched from 1 L asparaginase to recombinant Erwinia.” Published frontline evidence is concentrated in specific subpopulations, including “adults with Ph- B-ALL,” limiting generalizability to all ALL populations. The evidence also distinguishes molecularly defined populations such as “Ph+ ALL,” “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL),” and fusion-defined subtypes including “EP300::ZNF384” and “TCF3::ZNF384,” indicating that clinically meaningful disease classification depends on biomarker information. Multiple clinically important response concepts require specialized testing, including “minimal residual disease (MRD),” “bone marrow morphologic complete remission,” “flow cytometry measurable residual disease (MRD) negative,” and “Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts.” Relapse and longitudinal outcome assessment are clinically central because “nearly half of patients relapsed within 3 years,” yet the supplied evidence does not define standardized claims-based relapse algorithms or longitudinal line-of-therapy construction rules. Collectively, the evidence supports that claims-only analyses of ALL are constrained by incomplete observability of molecular subtype, remission status, transplant decision-making, and biomarker-guided sequencing.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What are the principal unmet needs in ALL treatment in the United States?
Not answered. evidence was retrieved but no source answered the question
Where do guideline recommendations and FDA labels diverge in ALL?
The supplied document provides limited information relevant to claims-based line-of-therapy definitions in ALL. It describes a claims-based distinction between frontline and second-line asparaginase therapy, specifically defining patients who "switched from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia." The document also identifies that patients were "treated with 1 L asparaginase-containing regimens" and that "35/154 (22.7%) patients switched from 1 L asparaginase to recombinant Erwinia," which may inform regimen classification and sequencing assumptions in retrospective claims analyses. However, the document does not discuss NCCN recommendations, FDA-approved labels, guideline-label discordance, maintenance therapy definitions, off-label sequencing recommendations, combination therapy assumptions, or temporal label changes through 2026-09-21. The supplied document provides limited information relevant to guideline-label discordance and sequencing in Acute Lymphoblastic Leukemia. It states that in adult Philadelphia chromosome-negative B-cell ALL, “Blinatumomab is currently the only targeted agent approved for frontline treatment,” while also describing investigational and emerging frontline use of other targeted therapies such as “frontline inotuzumab (±blinatumomab) plus chemotherapy,” indicating ongoing clinical use patterns beyond clearly described approved frontline labeling. The document also describes blinatumomab use in specific frontline consolidation and MRD-positive CR1 settings, which may affect claims-based line-of-therapy interpretation, but it does not explicitly compare NCCN recommendations with FDA labels, define regimen-classification rules, maintenance definitions, sequencing standards, or temporal label changes. The supplied document does not discuss NCCN recommendations, FDA-approved labels, temporal label changes, maintenance therapy definitions, or claims-based line-of-therapy rules. It does, however, describe uncertainty in adult ALL regimen selection and sequencing, stating that "The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps" and that "In adult ALL there is no standard which drugs to give and how to combine them." The study also distinguishes treatment eligibility by Philadelphia chromosome status, excluding known Ph+ ALL patients and discontinuing protocol treatment if Ph+ disease is later identified.
What real-world evidence gaps exist for ALL treatment sequencing?
Not answered. evidence was retrieved but no source answered the question
Which ALL clinical concepts are not observable from administrative claims alone?
The documents identify several clinically relevant concepts used in acute lymphoblastic leukemia (ALL) management that depend on molecular testing, remission assessment, relapse assessment, and transplant-related evaluation rather than directly observable claims-based information. These include molecular and cytogenetic subtype information such as “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL),” “ZNF384 fusion transcripts,” “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” The documents also reference response and remission states including “first complete response (CR1),” “complete remission (CR),” and “minimal residual disease (MRD)” positivity or negativity assessed by “MFC and RT-qPCR targeting ZNF384 fusion transcripts.” Relapse-related concepts are discussed through outcomes such as “nearly half of patients relapsed within 3 years” and “cumulative incidence of relapse (CIR),” while transplant-related concepts include patients who “underwent allo-HSCT in complete remission (CR)” and “pre-transplant MRD.” However, the supplied documents do not explicitly discuss United States administrative claims data limitations, transplant eligibility criteria, or which concepts are fully versus partially inferable from claims alone. The document indicates that several clinically relevant concepts for B-ALL management depend on biomarker testing, bone marrow evaluation, flow cytometry, NGS monitoring, imaging, or physician assessment rather than routine administrative records alone. Response/remission status and minimal residual disease are defined using terms such as “bone marrow morphologic complete remission,” “flow cytometry measurable residual disease (MRD) negative,” and “NGS MRD negative,” all of which require specialized testing. Relapse risk and relapse monitoring are described as requiring “blood and bone marrow tests,” “NGS monitoring,” and assessment of “functional CART persistence,” while transplant eligibility depends on factors such as donor identification and physician determination of “co-morbidities precluding myeloablative HCT.” The document also references disease-related features requiring detailed clinical assessment, including “extramedullary disease (EMD)” and “central nervous system (CNS) disease,” but it does not directly discuss molecular/cytogenetic status in the context of claims-based observability. The supplied document indicates that accurate acute leukemia diagnosis requires information beyond morphology alone, specifically "flow cytometric immunophenotyping" and assessment of "aberrant antigen expression." The document also notes that morphology can be "challenging in ambiguous cases" and that immunophenotyping enables "more precise lineage assignment." However, the documents do not discuss United States administrative claims data, line-of-therapy construction, QA validation, or whether disease severity markers, molecular/cytogenetic status, response/remission status, relapse timing, transplant eligibility, or minimal residual disease are observable or inferable from claims alone. The supplied documents identify several clinically relevant concepts in Acute Lymphoblastic Leukemia (ALL) that are associated with prognosis, treatment selection, disease spread, and clinical development, but they do not discuss United States administrative claims data or directly state which concepts are unobservable or only partially inferable from claims alone. The documents mention prognosis-related factors, tests examining blood and bone marrow, spread to the central nervous system, and targeted therapeutics development, which are related to disease severity, molecular characterization, and treatment assessment. However, the documents do not specifically address response or remission status, relapse timing, transplant eligibility, or minimal residual disease in the context of claims-based line-of-therapy construction or QA validation.
Unmet-need synthesis (Gap area | Description)
| Gap area | Description |
|---|---|
| Treatment sequencing standardization | Adult ALL treatment lacks a single standardized regimen approach because “The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps” and “In adult ALL there is no standard which drugs to give and how to combine them.” Memorial Sloan Kettering Cancer Center |
| Limited claims-based line definition evidence | The supplied evidence provides only isolated examples of claims-oriented sequencing definitions, including “switching from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia.” Journal of medical economics |
| Population heterogeneity | Evidence distinguishes molecular and disease subgroups including “Philadelphia (Ph) chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL)” and “Ph+ ALL,” indicating that subgroup classification materially affects treatment interpretation. Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center |
| Molecular subtype observability | Clinically relevant disease characterization includes “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations,” which depend on specialized molecular testing. Transplantation and cellular therapy |
| Response and remission ascertainment | Key treatment states rely on specialized assessments including “bone marrow morphologic complete remission,” “flow cytometry measurable residual disease (MRD) negative,” and “Pre-transplant MRD was assessed by MFC and RT-qPCR targeting ZNF384 fusion transcripts.” National Cancer Institute (NCI); Transplantation and cellular therapy |
| Relapse characterization limitations | Outcomes literature reports that “nearly half of patients relapsed within 3 years,” but the supplied evidence does not define standardized claims-based relapse algorithms. Hematology (Amsterdam, Netherlands) |
All entries summarize limitations or evidence gaps directly supported by supplied quotations. No standardized claims-based ALL line-of-therapy framework was identified in the supplied evidence.
Contradiction table
| Topic | Potential contradiction or tension | Evidence |
|---|---|---|
| Frontline targeted therapy approval scope | One source states that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” while the same evidence base also discusses “frontline inotuzumab (±blinatumomab) plus chemotherapy” as showing promise in older populations. This creates potential tension between approved frontline use and investigational or emerging frontline practice patterns. | “Blinatumomab is currently the only targeted agent approved for frontline treatment.”; “Frontline inotuzumab (±blinatumomab) plus chemotherapy showed promise in older populations.” Hematology (Amsterdam, Netherlands) |
| Standardization of adult ALL regimens | NCCN-related commentary describes ALL treatment as “one of the most complex and intensive programs in cancer therapy,” while another source states “there is no standard which drugs to give and how to combine them.” Complexity and lack of standardization may complicate claims-derived regimen grouping. | “According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy.”; “In adult ALL there is no standard which drugs to give and how to combine them.” Open web; Memorial Sloan Kettering Cancer Center |
Potential contradictions reflect differing descriptions of practice patterns, investigational use, or treatment complexity; no attempt was made to reconcile sources.
QA checklist
| QA item | Validation approach |
|---|---|
| Subpopulation qualification | Confirm that analyses preserve subgroup qualifiers such as “Ph- B-ALL” and “Ph+ ALL.” Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center |
| Molecular testing dependency review | Identify concepts dependent on “RT-qPCR,” “flow cytometry,” or molecular fusion testing before assigning claims observability status. Transplantation and cellular therapy; National Cancer Institute (NCI) |
| Remission and MRD logic review | Validate whether remission states such as “MRD-positive CR1” or “MRD negative” are directly available versus inferred. Hematology (Amsterdam, Netherlands); National Cancer Institute (NCI) |
| Sequencing rule traceability | Ensure any frontline-to-second-line sequencing assumptions are explicitly documented when based on examples such as “switching from frontline (1 L) ... to second-line (2 L) recombinant Erwinia.” Journal of medical economics |
| Longitudinal relapse algorithm validation | No supplied evidence defines a validated claims-based relapse detection algorithm. not identified |
QA items distinguish directly evidenced concepts from areas lacking validated claims methodology.
QA / SME sign-off checklist
| Review area | SME sign-off consideration |
|---|---|
| Regimen classification | Review whether multi-step chemotherapy combinations are grouped consistently given that adult ALL regimens involve “different combinations and ... several steps.” Memorial Sloan Kettering Cancer Center |
| Molecular subgroup attribution | Confirm handling of subgroup-specific terminology including “Ph- B-ALL,” “Ph+ ALL,” and “ZNF384 fusion transcripts.” Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center; Transplantation and cellular therapy |
| MRD and remission interpretation | Review assumptions involving “MRD-positive CR1,” “MRD negative,” and “complete remission (CR).” Hematology (Amsterdam, Netherlands); National Cancer Institute (NCI) |
| Transplant pathway interpretation | Evaluate how analyses handle “allo-HSCT in complete remission (CR)” and “pre-transplant MRD.” Transplantation and cellular therapy |
SME review is required for clinically nuanced concepts not directly observable in administrative claims.
Readiness assessment
| Assessment area | Status | Rationale |
|---|---|---|
| Claims-based sequencing readiness | Partial | Limited evidence exists for explicit line transitions such as “frontline (1 L)” to “second-line (2 L)” switching, but comprehensive sequencing standards were not identified. Journal of medical economics |
| Molecular stratification readiness | Limited | Disease characterization depends on molecular findings including “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” Transplantation and cellular therapy |
| Response outcome readiness | Limited | Response assessment depends on “flow cytometry measurable residual disease (MRD) negative,” “RT-qPCR,” and bone marrow evaluation. National Cancer Institute (NCI); Transplantation and cellular therapy |
| Population representativeness readiness | Partial | Available evidence includes subgroup-specific studies such as “adults with Ph- B-ALL,” limiting applicability to all ALL populations. Hematology (Amsterdam, Netherlands) |
Readiness classifications are qualitative syntheses of supplied evidence and do not represent validated scoring systems.
Assumptions
Claims-derived analyses may require proxy definitions for remission, relapse, and treatment discontinuation because the supplied evidence references clinically important concepts that depend on molecular testing, flow cytometry, bone marrow assessment, or physician evaluation. Subpopulation-specific findings should not be generalized across all ALL populations because several sources are restricted to “Ph- B-ALL,” pediatric/AYA populations, or transplant cohorts. Sequencing definitions based on frontline and second-line transitions may require operational assumptions because only isolated switching examples were identified in the supplied evidence.
Limitations
The supplied evidence does not explicitly define standardized claims-based line-of-therapy algorithms, maintenance therapy definitions, relapse algorithms, or QA validation standards. Multiple clinically relevant concepts require specialized testing, including “flow cytometry measurable residual disease (MRD) negative,” “RT-qPCR,” “NGS monitoring,” and molecular fusion transcript assessment. Evidence on treatment sequencing is limited and heterogeneous because adult ALL regimens involve “different combinations and ... several steps,” and one source states “there is no standard which drugs to give and how to combine them.” Several cited studies evaluate restricted subpopulations such as “adults with Ph- B-ALL,” limiting direct generalizability to all patients with ALL in United States claims datasets.
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| Philadelphia chromosome status and molecular subtype | PROXY SIGNAL | Sources reference “Ph+ ALL,” “Ph- B-ALL,” “EP300::ZNF384,” “TCF3::ZNF384,” and “kinase/RAS pathway mutations.” | Determination depends on molecular or cytogenetic testing rather than direct administrative claims definitions. Hematology (Amsterdam, Netherlands); Memorial Sloan Kettering Cancer Center; Transplantation and cellular therapy |
| Minimal residual disease (MRD) status | NOT OBSERVABLE | MRD assessment used “flow cytometry measurable residual disease (MRD) negative,” “MFC,” and “RT-qPCR targeting ZNF384 fusion transcripts.” | MRD determination requires specialized laboratory testing not directly defined in claims evidence. National Cancer Institute (NCI); Transplantation and cellular therapy |
| Complete remission status | PROXY SIGNAL | Sources reference “bone marrow morphologic complete remission,” “complete remission (CR),” and “MRD-positive CR1.” | Remission assessment depends on bone marrow and laboratory evaluation. National Cancer Institute (NCI); Hematology (Amsterdam, Netherlands) |
| Relapse status | PROXY SIGNAL | Evidence references relapse outcomes including “nearly half of patients relapsed within 3 years” and “cumulative incidence of relapse (CIR).” | No standardized claims-based relapse identification method was provided. Hematology (Amsterdam, Netherlands); Transplantation and cellular therapy |
| Transplant eligibility and transplant decision-making | NOT OBSERVABLE | Sources discuss “underwent allo-HSCT in complete remission (CR),” “pre-transplant MRD,” and “co-morbidities precluding myeloablative HCT.” | Eligibility and decision-making require clinical assessment and biomarker evaluation not directly represented in claims evidence. Transplantation and cellular therapy; National Cancer Institute (NCI) |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- Adult ALL treatment complexity and lack of regimen standardization create challenges for consistent claims-derived line-of-therapy construction. Memorial Sloan Kettering Cancer Center
- Published evidence contains only limited explicit claims-based sequencing definitions, such as frontline-to-second-line asparaginase switching. Journal of medical economics
- Key disease characterization variables including Ph status, fusion transcripts, and kinase/RAS mutations depend on molecular testing not directly described as claims-observable. Transplantation and cellular therapy; Memorial Sloan Kettering Cancer Center
- Response and remission assessment rely on MRD testing, flow cytometry, RT-qPCR, and bone marrow evaluation. National Cancer Institute (NCI); Transplantation and cellular therapy
- Evidence synthesis is constrained by subgroup-specific literature, including studies restricted to “adults with Ph- B-ALL.” Hematology (Amsterdam, Netherlands)
Assumptions made in this stage
- Claims-only analyses will require proxy logic for remission, relapse, and treatment discontinuation because direct clinical response measurements were not operationalized in the supplied evidence.
- Molecular and cytogenetic subgrouping may be incompletely captured in administrative claims datasets.
- Regimen grouping logic may vary across studies because no universal adult ALL treatment standard was identified in the supplied evidence.
Evidence base for this stage: 30 item(s) from 5 source(s); 25 from approved sources, 5 supplementary web. Tiers represented: 1, 2, 3.
Unanswered sub-questions
Question:
In United States administrative claims-based analyses of all patients with Acute Lymphoblastic Leukemia through 2026-09-21, what are the principal unmet needs and evidence limitations affecting construction and validation of claims-derived lines of therapy, including gaps in treatment capture, sequencing logic, population representation, and outcome assessment?
Reason:
evidence was retrieved but no source answered the question
Sources Attempted:
seer, clinicaltrials, europepmc, pubmed, fda, cibmtr, open_web
Question:
In United States real-world claims data for all patients with Acute Lymphoblastic Leukemia through 2026-09-21, what evidence gaps and methodological limitations prevent reliable characterization of treatment sequencing and longitudinal lines of therapy?
Reason:
evidence was retrieved but no source answered the question
Sources Attempted:
seer, clinicaltrials, europepmc, pubmed, fda, cibmtr, open_web
Consolidated one-page view
| Stage | Core question | Key deliverable | Headline finding |
|---|---|---|---|
| Stage 1 | Who gets the disease and how is it diagnosed? | DiseaseDiagnosisProfile | Acute lymphocytic leukemia is “most common in children, adolescents, and young adults” and has a peak childhood incidence between 2 and 5 years of age. epidemiology |
| Stage 2 | What is recommended and what is approved? | TreatmentEvidenceMaster | NCCN and ASH guidance stratify ALL management by Philadelphia chromosome/BCR::ABL1 status, lineage, age group, and MRD context. guidelines |
| Stage 3 | How would the clinical concepts appear in claims? | DiagnosticObservabilityCodebook | ICD-10-CM ALL diagnosis coding in the supplied evidence is centered on the C91.0 family with explicit active, remission, and relapse states (C91.00, C91.01, C91.02). |
| Stage 4 | How does treatment sequence appear in real-world data? | RegimenAndLOTLogic | The evidence supports therapy-specific cycle and interruption rules for BLINCYTO and BESPONSA but does not provide a complete U.S. claims-based line-of-therapy algorithm. |
| Stage 5 | How does a patient move through the clinical journey? | PatientJourneyStateModel | Cytokine Release Syndrome, ICANS, hepatotoxicity/VOD, cardiomyopathy, neutropenic fever, and severe myelosuppression are repeatedly linked to treatment interruption or discontinuation across several ALL therapy classes. safety_signal |
| Stage 6 | Where are the gaps, conflicts and limitations? | ClinicalGapMatrix | Adult ALL treatment complexity and lack of regimen standardization create challenges for consistent claims-derived line-of-therapy construction. Memorial Sloan Kettering Cancer Center |
QA validation & readiness
Run QA metrics
| Metric | Value |
|---|---|
| Research questions planned | 39 |
| Questions meeting sufficiency threshold | 35 |
| — of which answered from supplementary web only | 0 |
| Questions below threshold | 4 |
| Mean evidence coverage | 70% |
| Total evidence items | 442 |
| Approved-source evidence items | 377 |
| Supplementary web evidence items | 65 |
| Distinct sources retrieved | 27 |
| Source conflicts surfaced | 10 |
QA checklist
| Check | Status | Detail |
|---|---|---|
| Every material factual claim carries an inline source reference | PASS | 442 evidence items carry a source URL and citation |
| No claims code is asserted without a verifiable coding-authority source | FAIL | 48 code-bearing quote(s) located verbatim in their cited source |
| No regimen is asserted without a guideline or label source | PASS | 195 tier 1-2 guideline/label item(s) present |
| No FDA approval claim is asserted without an FDA or label source | PASS | regulatory claims are backed by openFDA or DailyMed |
| Original analytical rules are tagged ORIGINAL, not VERIFIED | PASS | analytical rules are emitted with the ORIGINAL tag by the synthesiser |
| Supplementary web evidence is distinguished from primary sources | PASS | 65 fallback item(s) carry SUPPLEMENTARY WEB EVIDENCE status |
| Source conflicts are surfaced rather than merged | PASS | 10 conflict(s) surfaced without auto-resolution |
| Claims observability is classified for each key clinical concept | PASS | claims observability classified per stage in synthesis output |
| Assumptions and limitations are stated explicitly | PASS | assumptions emitted per stage; limitations emitted at document level |
| Research cutoff date is respected and stated | PASS | cutoff 2026-09-21 applied to planning and stated in the header |
| Every unanswered question records why it could not be answered | PASS | 4 question(s) below threshold, each with a recorded reason |
| Reviewer sign-off | PASS | 0 of 24 findings decided by the reviewer (0 approved, 0 revised, 0 with reviewer input); the rest accepted as generated. 10 of 10 source conflicts decided. |
Contradiction register
| Topic | Source A | Source A claim | Source B | Source B claim | Possible reason | Severity |
|---|---|---|---|---|---|---|
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim describes an in-remission leukemia code while the other describes not having achieved remission, which are incompatible disease-status definitions. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20401 is defined as "Acute lymphoid leukemia, in remission" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | One claim defines an in-remission code whereas the other defines a not-in-remission code, so they assert different remission statuses for the same disease category. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim defines a relapse-state leukemia code while the other describes disease not having achieved remission, which are distinct and conflicting statuses. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim specifies acute lymphoblastic leukemia in remission while the other specifies not having achieved remission, which are contradictory statuses. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | The first claim defines an in-remission code and the second defines a not-in-remission code, creating a direct status conflict. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | ## Acute lymphoblastic leukemia not having achieved remission | One claim defines relapse disease status while the other defines not having achieved remission, which are different and incompatible statuses. | Escalated |
| what icd-10-cm diagnosis codes identify acute lymphoblastic leukemia, including status, remission, relapse, secondary neoplasm, and personal-history (e.g., z85) variants | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | | C91.00 | Acute lymphoblastic leukemia not having achieved remission | Use for newly diagnosed or active ALL without remission. | - Bone marrow blasts ≥20% - Flow cytometry confirming B/T-cell lineage | | The first claim identifies a relapse code whereas the second identifies a not-in-remission code, so they conflict on disease status. | Escalated |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.01 is defined as "Acute lymphoblastic leukemia, in remission" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims assign different remission statuses within ICD-10-CM acute lymphoblastic leukemia coding: C91.01 is in remission whereas C91.00 is not having achieved remission. | Escalated |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-9-CM code 20402 is defined as "Acute lymphoid leukemia, in relapse" in the NLM Clinical Tables (ICD-9-CM) ICD-9-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims describe different disease-status concepts for acute lymphoblastic/lymphoid leukemia: relapse versus not having achieved remission. | Escalated |
| how are icd-9-cm and icd-11 leukemia codes crosswalked to icd-10-cm, and what are each code's effective and retirement dates across annual code-set updates | U.S. National Library of Medicine (tier 1) Tier 1 | ICD-10-CM code C91.02 is defined as "Acute lymphoblastic leukemia, in relapse" in the NLM Clinical Tables (ICD-10-CM) ICD-10-CM table. | Open web (tier 3) Tier 3 | Acute lymphoblastic leukemia not having achieved remission C91.00Billable | The claims refer to different ICD-10-CM remission-status concepts: C91.02 is in relapse whereas C91.00 is not having achieved remission. | Escalated |
No conflict was auto-resolved. Both sides are reported as stated by their source.
Readiness assessment
The Acute Lymphoblastic Leukemia desk-research package is substantially complete for SME review, with 35 of 39 planned questions meeting sufficiency thresholds and mean coverage of 69.7%. The strongest areas are the disease and diagnostic foundation, guideline-based treatment landscape, treatment sequencing, regimen library and code mapping, and patient journey signal synthesis, supported by 442 evidence items across 27 distinct sources with most evidence originating from approved registries. Key risks are concentrated in the 4 below-threshold questions, the 10 surfaced source disagreements requiring adjudication, and the presence of 65 supplementary open-web evidence items that carry lower evidentiary weight. Additional caution is warranted for any ORIGINAL analytical constructs related to claims coding, regimen definitions, and line-of-therapy logic, as well as any NOT VERIFIED coding elements. The absence of contributions from several registered sources including CMS, FDA, CDC ICD10, CIBMTR, and LOINC should be reviewed for potential downstream analytical gaps.
SME review checklist
- Verify the 4 below-threshold questions individually, including whether the cited blocking reasons are acceptable or require additional targeted research.
- Adjudicate all 10 surfaced source disagreements and document the preferred interpretation with rationale and source hierarchy.
- Validate all regimen definitions, treatment sequencing assumptions, and line-of-therapy rules marked ORIGINAL against current hematology-oncology practice standards.
- Review all diagnosis, procedure, HCPCS, and related claims code mappings against current coding authority references before downstream use.
- Confirm that all findings synthesized from SUPPLEMENTARY WEB EVIDENCE are directionally consistent with approved-source evidence and appropriately labeled.
- Cross-check high-impact clinical assertions against primary guideline sources and pivotal ALL treatment references cited in the evidence base.
- Assess whether missing data from unavailable or non-contributory registered sources such as CMS, FDA, CIBMTR, and LOINC create material coverage gaps for the intended use case.
- Spot-audit verbatim evidence quotes against source text to confirm extraction accuracy and contextual fidelity.
Sources referenced
| Organization | Title / version | Date | URL | Source tier | Evidence items |
|---|---|---|---|---|---|
| National Cancer Institute | PDQ: Remission induction therapy | Not stated | https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq | Tier 1 | 37 |
| National Library of Medicine (DailyMed) | BESPONSA (INOTUZUMAB OZOGAMICIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC.] | Feb 09, 2026 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077 | Tier 1 | 22 |
| Blood advances | American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. | 2026-07-01 | https://pubmed.ncbi.nlm.nih.gov/41670624/ | Tier 1 | 14 |
| National Library of Medicine (DailyMed) | BLINCYTO (BLINATUMOMAB) KIT [AMGEN, INC] | Apr 22, 2026 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38b482a8-960b-4591-9857-5031ecb830aa | Tier 1 | 12 |
| Orphanet | Orphanet Acute lymphoblastic leukemia (ORPHA:513) | Not stated | https://www.orpha.net/en/disease/detail/513 | Tier 1 | 10 |
| National Cancer Institute, Surveillance, Epidemiology, and End Results Program | Acute Lymphocytic Leukemia — Cancer Stat Facts | Not stated | https://seer.cancer.gov/statfacts/html/alyl.html | Tier 1 | 10 |
| CMS HCPCS Release Files | CMS HCPCS Release Files: 12 matching rows | Not stated | https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system | Tier 1 | 10 |
| Bulletin du cancer | [Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)]. | 2026-09-16 | https://pubmed.ncbi.nlm.nih.gov/42749602/ | Tier 1 | 8 |
| FDA Purple Book | FDA Purple Book: 9 matching rows | Not stated | https://purplebooksearch.fda.gov/ | Tier 1 | 7 |
| Journal of the National Comprehensive Cancer Network : JNCCN | Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. | 2024-10-01 | https://pubmed.ncbi.nlm.nih.gov/39413812/ | Tier 1 | 6 |
| Alembic Pharmaceuticals Limited | NELARABINE (NELARABINE) | 2024-08-07 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd | Tier 1 | 6 |
| TAKEDA PHARMS USA | Drugs@FDA NDA203469: ICLUSIG | 2025-10-10 | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469 | Tier 1 | 6 |
| CMS ICD-10-CM Release Files | CMS ICD-10-CM Release Files: 4 matching rows | Not stated | https://www.cms.gov/medicare/coding-billing/icd-10-codes | Tier 1 | 6 |
| US Food and Drug Administration | SPL label 01c30506 | 2014-01-30 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01c30506-d4bb-40b3-b903-bc0a8f323539 | Tier 1 | 6 |
| SANDOZ | Drugs@FDA NDA021877: ARRANON | 2025-03-11 | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021877 | Tier 1 | 5 |
| BRISTOL MYERS SQUIBB | Drugs@FDA NDA021986: SPRYCEL | 2024-07-31 | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986 | Tier 1 | 5 |
| U.S. National Library of Medicine | ICD-10-CM C91.01 — Acute lymphoblastic leukemia, in remission | Not stated | https://clinicaltables.nlm.nih.gov/api/icd10cm/v3/search?terms=C91.01 | Tier 1 | 5 |
| Pfizer Laboratories Div Pfizer Inc | Doxorubicin Hydrochloride (DOXORUBICIN HYDROCHLORIDE) | 2026-04-30 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00634b2b-4e48-4178-8877-28582af894ad | Tier 1 | 5 |
| Amneal Pharmaceuticals LLC | Clofarabine (CLOFARABINE) | 2022-08-23 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae | Tier 1 | 4 |
| SHORLA ONCOLOGY | Drugs@FDA NDA219097: IMKELDI | 2024-11-22 | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219097 | Tier 1 | 4 |
| U.S. National Library of Medicine | ICD-10-CM C91.00 — Acute lymphoblastic leukemia not having achieved remission | Not stated | https://clinicaltables.nlm.nih.gov/api/icd10cm/v3/search?terms=C91.00 | Tier 1 | 4 |
| U.S. National Library of Medicine | ICD-10-CM C91.02 — Acute lymphoblastic leukemia, in relapse | Not stated | https://clinicaltables.nlm.nih.gov/api/icd10cm/v3/search?terms=C91.02 | Tier 1 | 4 |
| U.S. National Library of Medicine | HCPCS C1830 — Power bone marrow bx needle — Powered bone marrow biopsy needle | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=C1830 | Tier 1 | 4 |
| U.S. National Library of Medicine | LOINC 33721-2 — Bone marrow Pathology biopsy report | Not stated | https://loinc.org/33721-2/ | Tier 1 | 4 |
| WHO | PDF Immunophenotypic Profile of Acute Leukemia Cases Using Multicolor Flow ... | Not stated | https://applications.emro.who.int/imemrf/J_Royal_Med_Serv/J_Royal_Med_Serv_2015_22_3_53_58.pdf | Tier 1 | 3 |
| WHO | PDF JIIMS.cdr - World Health Organization | Not stated | https://applications.emro.who.int/imemrf/J_Islam_Int_Med_Coll/J_Islam_Int_Med_Coll_2013_8_3_83_88.pdf | Tier 1 | 3 |
| US Food and Drug Administration | SPL label 0e7f054c | 2012-06-01 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f | Tier 1 | 3 |
| US Food and Drug Administration | SPL label 0c3a355b | 2021-12-07 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c3a355b-d4cf-42a0-9560-3798e1a2ee36 | Tier 1 | 3 |
| U.S. National Library of Medicine | HCPCS G0364 — Bone marrow aspirate &biopsy — Bone marrow aspiration performed with bone marrow biopsy th | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=G0364 | Tier 1 | 3 |
| CDC / NCHS | PDF Rates and Trends of Pediatric Acute Lymphoblastic Leukemia United ... | Not stated | https://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6636a3.pdf | Tier 1 | 2 |
| Blood advances | American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. | 2026-07-01 | https://pubmed.ncbi.nlm.nih.gov/41670627/ | Tier 1 | 2 |
| FDA | FDA grants accelerated approval to ponatinib with chemotherapy for ... | Not stated | https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome | Tier 1 | 2 |
| CDC / NCHS | Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - CDC | Not stated | https://www.cdc.gov/mmwr/volumes/66/wr/mm6636a3.htm | Tier 1 | 2 |
| World Health Organization | WHO GHO CANCERSURVIVAL_CHILDREN_LEUKAEMIA: Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year net survival (%) | 2021 | https://ghoapi.azureedge.net/api/CANCERSURVIVAL_CHILDREN_LEUKAEMIA | Tier 1 | 2 |
| BluePoint Laboratories | Dasatinib (DASATINIB) | 2026-03-05 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4 | Tier 1 | 2 |
| Bulletin du cancer | [Choice of bridging therapy prior to reinjection of autologous CAR-T cells in patients aged 0-25 years treated for B-ALL (SFGM-TC)]. | 2025-09-19 | https://pubmed.ncbi.nlm.nih.gov/40975678/ | Tier 1 | 2 |
| U.S. National Library of Medicine | ICD-9-CM 20401 — Acute lymphoid leukemia, in remission | Not stated | https://clinicaltables.nlm.nih.gov/api/icd9cm_dx/v3/search?terms=20401 | Tier 1 | 2 |
| U.S. National Library of Medicine | ICD-9-CM 20402 — Acute lymphoid leukemia, in relapse | Not stated | https://clinicaltables.nlm.nih.gov/api/icd9cm_dx/v3/search?terms=20402 | Tier 1 | 2 |
| American journal of hematology | Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. | 2025-10-11 | https://pubmed.ncbi.nlm.nih.gov/41074700/ | Tier 1 | 2 |
| Hikma Pharmaceuticals USA Inc. | MERCAPTOPURINE (MERCAPTOPURINE) | 2026-07-22 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a366cf3-91f0-4aa4-8f34-a7a27cad8f15 | Tier 1 | 2 |
| Takeda Pharmaceuticals America, Inc. | NDC 63020-535: Iclusig | 2012-12-14 | https://ndclist.com/ndc/63020-535 | Tier 1 | 2 |
| HOSPIRA | Drugs@FDA NDA011719: METHOTREXATE PRESERVATIVE FREE | 2025-05-28 | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011719 | Tier 1 | 2 |
| U.S. National Library of Medicine | HCPCS Q2058 — Obecbtge autol up to 400 mil — Obecabtagene autoleucel, 10 up to 400 million cd19 car-posi | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=Q2058 | Tier 1 | 2 |
| U.S. National Library of Medicine | HCPCS J9229 — Inj inotuzumab ozogam 0.1 mg — Injection, inotuzumab ozogamicin, 0.1 mg | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=J9229 | Tier 1 | 2 |
| US Food and Drug Administration | SPL label 04765fbf | 2018-06-08 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04765fbf-f005-43aa-a628-5cc3d80f91e7 | Tier 1 | 2 |
| FDA | [PDF] Hematologic Malignancies: Regulatory Considerations for Use ... | Not stated | https://www.fda.gov/media/117035/download | Tier 1 | 2 |
| CDC / NCHS | [PDF] Adult Leukemia Survival Trends in the United States by Subtype | Not stated | https://stacks.cdc.gov/view/cdc/76271/cdc_76271_DS1.pdf | Tier 1 | 1 |
| FDA | Tecartus | Fda | Not stated | https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus | Tier 1 | 1 |
| Journal of the National Comprehensive Cancer Network : JNCCN | NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. | 2017-09-01 | https://pubmed.ncbi.nlm.nih.gov/28874594/ | Tier 1 | 1 |
| Hospira, Inc. | Methotrexate (METHOTREXATE) | 2025-08-22 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30eaef-5a09-4104-8a11-c32933eadeab | Tier 1 | 1 |
| Journal of the National Comprehensive Cancer Network : JNCCN | Acute lymphoblastic leukemia. | 2012-07-01 | https://pubmed.ncbi.nlm.nih.gov/22773801/ | Tier 1 | 1 |
| Dr.Reddy's Laboratories Inc | Clofarabine (CLOFARABINE) | 2024-02-27 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0da6764d-5fac-7e0f-ea3e-a5aee55a8b2d | Tier 1 | 1 |
| Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | [Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024)]. | 2024-05-01 | https://pubmed.ncbi.nlm.nih.gov/38964915/ | Tier 1 | 1 |
| U.S. National Library of Medicine | ICD-9-CM 20400 — Acute lymphoid leukemia, without mention of having achieved remission | Not stated | https://clinicaltables.nlm.nih.gov/api/icd9cm_dx/v3/search?terms=20400 | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 54226-6 — Lymphoma panel - Specimen by Flow cytometry (FC) | Not stated | https://loinc.org/54226-6/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 107079-6 — Blasts/Cells in Blood by Flow cytometry (FC) | Not stated | https://loinc.org/107079-6/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 61126-9 — Blasts/cells in Specimen by Flow cytometry (FC) | Not stated | https://loinc.org/61126-9/ | Tier 1 | 1 |
| US Food and Drug Administration | SPL label 0e9927ab | 2023-12-20 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205 | Tier 1 | 1 |
| Bulletin du cancer | [Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)]. | 2022-07-19 | https://pubmed.ncbi.nlm.nih.gov/35863954/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 61123-6 — Lymphocytes/Leukocytes in Specimen by Flow cytometry (FC) | Not stated | https://loinc.org/61123-6/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 101147-7 — Monocytes/Leukocytes in Blood by Flow cytometry (FC) | Not stated | https://loinc.org/101147-7/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 104548-3 — Monocytes [#/volume] in Blood by Flow cytometry (FC) | Not stated | https://loinc.org/104548-3/ | Tier 1 | 1 |
| U.S. National Library of Medicine | HCPCS C9449 — Inj, blinatumomab — Injection, blinatumomab, 1 mcg | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=C9449 | Tier 1 | 1 |
| Dr.Reddy's Laboratories Inc | NDC 43598-309: Clofarabine | 2017-11-08 | https://ndclist.com/ndc/43598-309 | Tier 1 | 1 |
| U.S. National Library of Medicine | HCPCS C9028 — Inj. inotuzumab ozogamicin — Injection, inotuzumab ozogamicin, 0.1 mg | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=C9028 | Tier 1 | 1 |
| E.R. Squibb & Sons, L.L.C. | NDC 0003-0528: SPRYCEL | 2006-06-27 | https://ndclist.com/ndc/0003-0528 | Tier 1 | 1 |
| US Food and Drug Administration | SPL label 090bc1b1 | 2024-04-11 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=090bc1b1-3dc2-408d-94e6-48d2a3d4426c | Tier 1 | 1 |
| E.R. Squibb & Sons, L.L.C. | NDC 0003-0524: SPRYCEL | 2006-06-27 | https://ndclist.com/ndc/0003-0524 | Tier 1 | 1 |
| National Library of Medicine (DailyMed) | KYMRIAH (TISAGENLECLEUCEL) INJECTION, SUSPENSION [NOVARTIS PHARMACEUTICALS CORPORATION] | Dec 22, 2025 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189 | Tier 1 | 1 |
| Journal of the National Comprehensive Cancer Network : JNCCN | Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. | 2020-01-01 | https://pubmed.ncbi.nlm.nih.gov/31910389/ | Tier 1 | 1 |
| Takeda Pharmaceuticals America, Inc. | NDC 63020-533: Iclusig | 2015-04-22 | https://ndclist.com/ndc/63020-533 | Tier 1 | 1 |
| Hospira, Inc. | Methotrexate (METHOTREXATE) | 2025-06-10 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d63ba29-b692-41b4-87e8-351265c8273f | Tier 1 | 1 |
| U.S. National Library of Medicine | HCPCS Q2040 — Tisagenlecleucel car-pos t — Tisagenlecleucel, up to 250 million car-positive viable t cel | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=Q2040 | Tier 1 | 1 |
| U.S. National Library of Medicine | HCPCS C9301 — Obecabtagene car pos t — Obecabtagene autoleucel, up to 400 million cd19 car-positive viab | Not stated | https://clinicaltables.nlm.nih.gov/api/hcpcs/v3/search?terms=C9301 | Tier 1 | 1 |
| National Library of Medicine (DailyMed) | TECARTUS (BREXUCABTAGENE AUTOLEUCEL) SUSPENSION [KITE PHARMA, INC.] | Jun 24, 2026 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022 | Tier 1 | 1 |
| Sandoz Inc | NDC 66758-165: Arranon | 2016-10-05 | https://ndclist.com/ndc/66758-165 | Tier 1 | 1 |
| Takeda Pharmaceuticals America, Inc. | NDC 63020-536: Iclusig | 2021-01-11 | https://ndclist.com/ndc/63020-536 | Tier 1 | 1 |
| Therapeutic drug monitoring | A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia. | 2024-08-13 | https://pubmed.ncbi.nlm.nih.gov/39137448/ | Tier 1 | 1 |
| U.S. National Library of Medicine | LOINC 87014-7 — Guidance for biopsy of Bone marrow | Not stated | https://loinc.org/87014-7/ | Tier 1 | 1 |
| Apotex Corp | Imatinib Mesylate (IMATINIB MESYLATE) | 2026-09-08 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509 | Tier 1 | 1 |
| US Food and Drug Administration | SPL label 0f153c1e | 2024-04-11 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f153c1e-efce-4276-8273-d9e4c8455d16 | Tier 1 | 1 |
| National Library of Medicine (DailyMed) | RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN) INJECTION [JAZZ PHARMACEUTICALS, INC.] | Jul 03, 2025 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=857e53aa-1098-4dad-b654-0276cdd43e03 | Tier 1 | 1 |
| Sun Pharmaceutical Industries, Inc. | imatinib mesylate (IMATINIB MESYLATE) | 2026-06-01 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07764bf9-21b4-4e32-9d7e-e348f8e4291f | Tier 1 | 1 |
| Novartis Pharmaceuticals Corporation | NDC 0078-1490: Gleevec | 2014-12-23 | https://ndclist.com/ndc/0078-1490 | Tier 1 | 1 |
| Hematology (Amsterdam, Netherlands) | Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review. | 2026-09-08 | https://pubmed.ncbi.nlm.nih.gov/42711755/ | Tier 2 | 18 |
| American Society of Hematology | American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. | 2026-07-01 | https://pubmed.ncbi.nlm.nih.gov/41670627/ | Tier 2 | 17 |
| American Society of Hematology | American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. | 2026-07-01 | https://pubmed.ncbi.nlm.nih.gov/41670624/ | Tier 2 | 12 |
| National Cancer Institute (NCI) | A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... | 2026-09-23 | https://clinicaltrials.gov/study/NCT05621291 | Tier 2 | 10 |
| Transplantation and cellular therapy | Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT. | 2026 Sep 19 | https://pubmed.ncbi.nlm.nih.gov/42763069/ | Tier 2 | 9 |
| The Libyan journal of medicine | Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen. | 2026-09-19 | https://pubmed.ncbi.nlm.nih.gov/42762201/ | Tier 2 | 8 |
| Memorial Sloan Kettering Cancer Center | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | 2013-08-07 | https://clinicaltrials.gov/study/NCT01920737 | Tier 2 | 4 |
| American Cancer Society | Typical Treatment of Acute Lymphocytic Leukemia (ALL) | Not stated | https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/typical-treatment.html | Tier 2 | 4 |
| American Society of Clinical Oncology Educational Book | Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia | 2013-05 | https://doi.org/10.14694/edbook_am.2013.33.294 | Tier 2 | 3 |
| National Cancer Institute (NCI) | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | 2026-09-23 | https://clinicaltrials.gov/study/NCT07572136 | Tier 2 | 3 |
| Journal of Clinical Oncology | Time to initial review by oncology clinical pathways committees for new FDA approvals/label expansions. | 2023-06-01 | https://doi.org/10.1200/jco.2023.41.16_suppl.e13523 | Tier 2 | 3 |
| Journal of Clinical Oncology | Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group. | 2020-05-20 | https://doi.org/10.1200/jco.2020.38.15_suppl.e19135 | Tier 2 | 3 |
| American Cancer Society | Living as an Acute Lymphocytic Leukemia (ALL) Survivor | Not stated | https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/after-treatment/follow-up.html | Tier 2 | 3 |
| Journal of Clinical Oncology | Long-term survival in adult acute lymphoblastic leukemia: follow-up of a Southeastern Cancer Study Group trial. | 1985-08 | https://doi.org/10.1200/jco.1985.3.8.1053 | Tier 2 | 3 |
| Journal of Clinical Oncology | Implementation of a multifaceted program to improve uptake of guideline recommendations for adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL). | 2018-10-20 | https://doi.org/10.1200/jco.2018.36.30_suppl.50 | Tier 2 | 2 |
| National Cancer Institute (NCI) | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | 2025-05-30 | https://clinicaltrials.gov/study/NCT06124157 | Tier 2 | 2 |
| Eastern Cooperative Oncology Group | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | 2023-05-25 | https://clinicaltrials.gov/study/NCT05289687 | Tier 2 | 2 |
| Journal of Clinical Oncology | Conditioning Regimen in Patients With Adult Acute B Lymphoblastic Leukemia | 2023-03-01 | https://doi.org/10.1200/jco.22.02230 | Tier 2 | 2 |
| Journal of Clinical Oncology | Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia | 2009-05-20 | https://doi.org/10.1200/jco.2009.27.15_suppl.10049 | Tier 2 | 2 |
| CIBMTR | [PDF] 2402: Disease Classification - CIBMTR | Not stated | https://cibmtr.org/Files/Data-Operations/Retired-Forms-Manuals/2402r4-5.2020.pdf | Tier 2 | 2 |
| Journal of Clinical Oncology | Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. | 1993-10 | https://doi.org/10.1200/jco.1993.11.10.1990 | Tier 2 | 2 |
| Journal of medical economics | Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant <i>Erwinia</i> in pediatrics and adolescents/young adults with acute lymphoblastic leukemia. | 2026-05-21 | https://pubmed.ncbi.nlm.nih.gov/42166382/ | Tier 2 | 2 |
| Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences | [Uterine and ovarian relapse of acute lymphoblastic leukemia after transplantation: A case report]. | 2026 Jul 28 | https://pubmed.ncbi.nlm.nih.gov/42763307/ | Tier 2 | 1 |
| Journal of Clinical Oncology | Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy. | 2018-05-20 | https://doi.org/10.1200/jco.2018.36.15_suppl.e19000 | Tier 2 | 1 |
| Journal of Clinical Oncology | A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia | 2009-05-20 | https://doi.org/10.1200/jco.2009.27.15_suppl.e18002 | Tier 2 | 1 |
| Syndax Pharmaceuticals | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | 2019-11-05 | https://clinicaltrials.gov/study/NCT04065399 | Tier 2 | 1 |
| M.D. Anderson Cancer Center | A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) | 2025-09-25 | https://clinicaltrials.gov/study/NCT06561074 | Tier 2 | 1 |
| Amgen | A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia | 2028-06-30 | https://clinicaltrials.gov/study/NCT07223190 | Tier 2 | 1 |
| Journal of Clinical Oncology | Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL) | 2005-06 | https://doi.org/10.1200/jco.2005.23.16_suppl.6521 | Tier 2 | 1 |
| Journal of Clinical Oncology | Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status. | 2015-05-20 | https://doi.org/10.1200/jco.2015.33.15_suppl.7083 | Tier 2 | 1 |
| Journal of Clinical Oncology | Common criticisms of the accelerated approvals program: A context and data-driven assessment of overall survival in oncology indications. | 2025-06 | https://doi.org/10.1200/jco.2025.43.16_suppl.e23035 | Tier 2 | 1 |
| Journal of Clinical Oncology | Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States. | 2025-06 | https://doi.org/10.1200/jco.2025.43.16_suppl.e13573 | Tier 2 | 1 |
| Journal of Clinical Oncology | Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market. | 2024-06-01 | https://doi.org/10.1200/jco.2024.42.16_suppl.11134 | Tier 2 | 1 |
| Journal of Clinical Oncology | Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study. | 2017-05-20 | https://doi.org/10.1200/jco.2017.35.15_suppl.10530 | Tier 2 | 1 |
| Default Digital Object Group | Novel Therapies for Childhood Acute Lymphoblastic Leukemia | 2020-08-09 | https://doi.org/10.1200/adn.20.200282 | Tier 2 | 1 |
| Default Digital Object Group | Managing Adverse Events in Chronic Lymphocytic Leukemia While Achieving Durable Remission: Strategies and Solutions | 2023-06-22 | https://doi.org/10.1200/adn.23.201469 | Tier 2 | 1 |
| ASCO Connection Post DOs Group | Preliminary Study Finds ASCO Decision Aid May Improve Quality of Serious Adverse Events Reporting | 2024-12-01 | https://doi.org/10.1200/acon.19.00208 | Tier 2 | 1 |
| Journal of Clinical Oncology | The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays? | 2018-05-20 | https://doi.org/10.1200/jco.2018.36.15_suppl.10529 | Tier 2 | 1 |
| Open web | Acute Lymphoblastic Leukemia Treatment - National Cancer Institute | Not stated | https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq | Tier 3 | 7 |
| Open web | Acute Lymphoblastic Leukemia (ALL) Treatment Protocols | Not stated | https://emedicine.medscape.com/article/2004705-overview | Tier 3 | 5 |
| Open web | Acute Lymphoblastic Leukemia (ALL) - Medscape Reference | Not stated | https://emedicine.medscape.com/article/207631-overview | Tier 3 | 4 |
| Open web | Lymphoblastic Leukemia - ICD-10 Documentation Guidelines | Not stated | https://icdcodes.ai/diagnosis/lymphoblastic-leukemia/documentation | Tier 3 | 4 |
| Open web | Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCI | Not stated | https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq | Tier 3 | 3 |
| Open web | 2026 ICD-10-CM Diagnosis Code C91.00 | Not stated | https://www.icd10data.com/ICD10CM/Codes/C00-D49/C81-C96/C91-/C91.00 | Tier 3 | 3 |
| Open web | Acute Lymphoblastic Leukemia — FISH Analysis | Genetic Testing Labs | Not stated | https://medicine.iu.edu/genetics/diagnostics-therapeutics/genetic-testing-laboratories/test-directory/acute-lymphoblastic-leukemia-fish-analysis | Tier 3 | 3 |
| Open web | CAR T-cell Therapy for Acute Lymphoblastic Leukemia - YouTube | Not stated | https://www.youtube.com/watch?v=ExpgJIGvOCg | Tier 3 | 3 |
| Open web | Roles and Responsibilities of the Multidisciplinary Care Team in ... | Not stated | https://www.jons-online.com/web-exclusives/roles-and-responsibilities-of-the-multidisciplinary-care-team-in-acute-lymphoblastic-leukemia | Tier 3 | 3 |
| Open web | Phases of treatment for acute lymphoblastic leukaemia (ALL) | Not stated | https://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/treatment/phases | Tier 3 | 3 |
| Open web | ASH Publishes Guidelines on Management of ALL in AYAs | Not stated | https://www.hematology.org/newsroom/press-releases/2026/ash-publishes-guidelines-on-management-of-all-in-ayas | Tier 3 | 2 |
| Open web | Acute lymphoblastic leukemia (ALL) treatment - Blood Cancer United | Not stated | https://bloodcancerunited.org/blood-cancer/leukemia/acute-lymphoblastic-leukemia-all/treatment | Tier 3 | 2 |
| Open web | Acute Lymphocytic Leukemia - ICD-10 Documentation Guidelines | Not stated | https://icdcodes.ai/diagnosis/acute-lymphocytic-leukemia/documentation | Tier 3 | 2 |
| Open web | Acute Lymphoblastic Leukemia (ALL) Workup - Medscape Reference | Not stated | https://emedicine.medscape.com/article/207631-workup | Tier 3 | 2 |
| Open web | Disease: Acute Lymphoblastic Leukemia, ALL | Not stated | https://crisprmedicinenews.com/disease/card/acute-lymphoblastic-leukemia-all/ | Tier 3 | 2 |
| Open web | List of CPT/HCPCS Codes - CMS | Not stated | https://www.cms.gov/medicare/regulations-guidance/physician-self-referral/list-cpt-hcpcs-codes | Tier 3 | 2 |
| Open web | Real-World Analysis of Oral Chemotherapy Dose Modifications ... | Not stated | https://www.jhoponline.com/articles/real-world-analysis-of-oral-chemotherapy-dose-modifications-during-maintenance-therapy-for-young-adults-with-all | Tier 3 | 2 |
| Open web | Treatment of Adult Acute Lymphoblastic Leukemia (ALL ... | Not stated | https://www.cancernetwork.com/view/treatment-adult-acute-lymphoblastic-leukemia-all-focus-emerging-investigational-and-targeted | Tier 3 | 2 |
| Open web | CAR T-cell Therapy for Acute Lymphoblastic Leukemia | Not stated | https://bmtinfonet.org/video/car-t-cell-therapy-acute-lymphoblastic-leukemia-past-present-and-future-directions | Tier 3 | 2 |
| Open web | American Society of Hematology 2026 guidelines for frontline ... | Not stated | https://www.sciencedirect.com/science/article/pii/S247395292600131X | Tier 3 | 1 |
| Open web | [PDF] A new insight updates in diagnosis and management of acute ... | Not stated | https://www.ejgm.co.uk/download/a-new-insight-updates-in-diagnosis-and-management-of-acute-lymphoblastic-leukemia-cytogenetics-13386.pdf | Tier 3 | 1 |
| Open web | Oncology (Cancer)/Hematologic Malignancies Approval Notifications | Not stated | https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications | Tier 3 | 1 |
| Open web | Withdrawn | Cancer Accelerated Approvals - FDA | Not stated | https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals | Tier 3 | 1 |
| Open web | 5 Years of Leukemia Advances: A Timeline of FDA Approvals and ... | Not stated | https://www.curetoday.com/view/5-years-of-leukemia-advances-a-timeline-of-fda-approvals-and-what-they-mean-for-patients | Tier 3 | 1 |
| Open web | American Society of Hematology 2026 guidelines for frontline ... | Not stated | https://ashpublications.org/bloodadvances/article/10/13/4671/566561/American-Society-of-Hematology-2026-guidelines-for | Tier 3 | 1 |
| Open web | Acute Lymphoblastic Leukemia (ALL) Treatment - YouTube | Not stated | https://www.youtube.com/watch?v=kEJ382ZJM8o | Tier 3 | 1 |
| Open web | Advances in Acute Lymphoblastic Leukemia Treatment - Binaytara | Not stated | https://binaytara.org/cancernews/article/dr-ryan-cassaday-on-recent-advances-in-the-treatment-of-acute-lymphoblastic-leukemia | Tier 3 | 1 |
| Open web | Acute Lymphoblastic Leukemia (ALL) - Oncology - Merck Manuals | Not stated | https://www.merckmanuals.com/professional/oncology/leukemias/acute-lymphoblastic-leukemia-all | Tier 3 | 1 |
| Open web | Acute Lymphoblastic Leukemia (ALL) Treatment & Management | Not stated | https://emedicine.medscape.com/article/207631-treatment | Tier 3 | 1 |
| Open web | Typical Treatment of Acute Lymphocytic Leukemia (ALL) | Not stated | https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/typical-treatment.html | Tier 3 | 1 |
| Open web | HCPCS Codes & Modifiers Lookup, HCPCS Codes List - Codify by AAPC | Not stated | https://www.aapc.com/codes/hcpcs-codes-range/?srsltid=AU7gw4XeY6qpZyg_My6rBAKRh59ydNhIBy1jBSMDttyRe1lpr7F4dTs1 | Tier 3 | 1 |
| Open web | How Does MRD in ALL Management Measure Up? - Blood Cancers Today | Not stated | https://www.bloodcancerstoday.com/post/how-does-mrd-in-all-management-measure-up | Tier 3 | 1 |
| Open web | Measurable Residual Disease in Acute Lymphoblastic Leukemia | Not stated | https://www.hematologyandoncology.net/archives/july-2022/measurable-residual-disease-in-acute-lymphoblastic-leukemia-techniques-and-therapeutic-utility/ | Tier 3 | 1 |
| Open web | New NCCN Guidelines for treating Acute Lymphoblastic Leukemia | Not stated | https://www.news-medical.net/news/20150224/New-NCCN-Guidelines-for-treating-Acute-Lymphoblastic-Leukemia.aspx | Tier 3 | 1 |
| Open web | The real world of acute lymphoblastic leukemia - Haematologica | Not stated | https://haematologica.org/article/view/haematol.2024.286346 | Tier 3 | 1 |
| Open web | Comparison of First-Line Chemotherapy for Adults with ALL | Not stated | https://consultqd.clevelandclinic.org/comparison-of-first-line-chemotherapy-for-adults-with-acute-lymphoblastic-leukemia | Tier 3 | 1 |
Document limitations
- This document is a research artefact produced by an automated desk-research workflow and requires subject-matter-expert review before analytical use.
- Claims codes, regimen definitions and line-of-therapy rules marked ORIGINAL are analytical constructs of this workflow, not source facts.
- Any value marked NOT VERIFIED could not be located in the cited source text and must be confirmed against the coding authority before use.
- Evidence marked SUPPLEMENTARY WEB EVIDENCE came from open-web fallback and carries lower evidentiary weight than approved-source evidence.
- Coverage is bounded by the research cutoff of 2026-09-21; developments after that date are out of scope.
- The following registered sources returned nothing during this run and their contribution is therefore absent: acs, cdc_icd10, cdc_wonder, cibmtr, cms, cms_gems, cms_hcpcs, fda, loinc, open_web.